{"trajectories": [{"actions": ["Southern blot", "Enzyme assay", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "After ruling out **HTT gene expansion** with a normal Southern blot result, the remaining possibilities are G6PD deficiency mutation, MTHFR mutation, and DMD mutation. To narrow these down efficiently, the **Enzyme assay** is the most strategic next step. If the enzyme activity falls within 75-100%, it would conclusively exclude **G6PD deficiency mutation**, leaving only two possibilities. This assay directly tests for a functional deficiency linked to G6PD and provides actionable results in a single step. \n\n<ANSWER> Enzyme assay </ANSWER>", "After ruling out **G6PD deficiency mutation** with the enzyme assay result (activity = 82.05, which falls within 75-100%), the remaining possibilities are **MTHFR mutation** and **DMD mutation**. To resolve this efficiently, **Western blot** is the optimal next step. If the Western blot detects a protein of expected size, it rules out **DMD mutation**, leaving **MTHFR mutation** as the only plausible answer. Conversely, if the protein is absent or truncated, it confirms **DMD mutation**. This assay directly tests for dystrophin (the protein affected in DMD) and provides a definitive answer in one step. \n\n<ANSWER> Western blot </ANSWER>", "The Western blot result showing **\"Protein absent or truncated\"** directly implicates the **DMD mutation**, as this mutation disrupts dystrophin production. Since the remaining options after prior eliminations (MTHFR and DMD) are mutually exclusive, and MTHFR mutation does not affect dystrophin, the observed result conclusively identifies **DMD mutation** as the cause. No further assays are necessary. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 23801, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 82.0459461099926}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Southern blot", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "After performing the Enzyme assay and observing an activity level of 82 (which rules out **G6PD deficiency mutation**), the remaining possibilities are HTT gene expansion, MTHFR mutation, and DMD mutation. To narrow further, **Southern blot** is the most strategic next assay. If the Southern blot detects a normal-sized fragment, HTT gene expansion is excluded, leaving MTHFR and DMD. If an expanded fragment is detected, HTT gene expansion is confirmed. This choice efficiently reduces possibilities based on a single assay result. \n\n<ANSWER> Southern blot </ANSWER>", "After ruling out G6PD deficiency and HTT gene expansion, the remaining mutations are **MTHFR mutation** and **DMD mutation**. To distinguish between these, **Western blot** is the most efficient next step. If the Western blot detects a protein of expected size, it rules out DMD mutation (confirming MTHFR mutation). If the protein is absent/truncated, DMD mutation is confirmed. This assay directly tests for the presence of dystrophin, the protein affected in DMD, providing a definitive answer in one step. \n\n<ANSWER> Western blot </ANSWER>", "After performing the Western blot and observing \"Protein absent or truncated,\" the remaining mutations are **MTHFR mutation** and **DMD mutation**. However, MTHFR mutation does not affect dystrophin (the protein analyzed by the Western blot). Since the result aligns with DMD mutation (which disrupts dystrophin production), and no other remaining mutation explains this outcome, the **DMD mutation** is conclusively identified. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 24814, "observations": [null, {"action": "Enzyme assay", "observation": 82.0459461099926}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "Western blot", "High-resolution melt analysis (HRM)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "The Southern blot result ruled out HTT gene expansion. The remaining mutations are G6PD deficiency, MTHFR mutation, and DMD mutation. To narrow down efficiently, the next step is to perform the **Enzyme assay**. If enzyme activity is between 75-100, G6PD deficiency is excluded. If activity is low (0-25), G6PD remains a possibility. This assay directly targets one of the remaining mutations and provides clear exclusion criteria, making it the most strategic next step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result (82.05 activity) rules out **G6PD deficiency mutation**, leaving **MTHFR mutation** and **DMD mutation** as possibilities. To distinguish between these, the most efficient next step is **Western blot**. If the protein is detected at the expected size, DMD mutation is excluded, leaving MTHFR as the answer. If the protein is absent/truncated, DMD mutation is confirmed. This assay directly targets DMD and provides clear exclusion criteria, resolving the remaining options in one step. \n\n<ANSWER> Western blot </ANSWER>", "The Western blot result (\"Protein absent or truncated\") does not directly rule out DMD mutation but aligns with its possibility. The remaining mutations are **MTHFR mutation** and **DMD mutation**. To differentiate conclusively, **High-resolution melt analysis (HRM)** is the optimal next step. If HRM shows **no melting curve abnormalities**, MTHFR mutation is excluded, leaving DMD mutation as the answer. If **abnormal melting curves** are detected, MTHFR mutation is confirmed. This assay directly targets MTHFR and provides unambiguous exclusion criteria, resolving the final two possibilities in one step. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "The HRM result (\"No melting curve abnormalities\") rules out **MTHFR mutation**, leaving **DMD mutation** as the only remaining possibility. All other mutations (HTT, G6PD, MTHFR) have been systematically excluded via prior assays. No further testing is required. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 26879, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 82.0459461099926}, {"action": "Western blot", "observation": "Protein absent or truncated"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "The Southern blot result ruled out HTT gene expansion. Next, using the Enzyme assay can determine if G6PD deficiency is present. If enzyme activity is normal (75-100), G6PD deficiency is excluded, leaving MTHFR and DMD mutations. This step efficiently narrows down the remaining candidates. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result (82.045) falls within the 75-100 range, ruling out G6PD deficiency mutation. Now, only **MTHFR mutation** and **DMD mutation** remain. To distinguish between them, **Western blot** is the most efficient next step. If the Western blot detects a protein of expected size, DMD mutation is excluded, leaving MTHFR as the answer. If the protein is absent/truncated, DMD mutation is confirmed. This step resolves the remaining ambiguity in one move. \n\n<ANSWER> Western blot </ANSWER>", "The Western blot result (\"Protein absent or truncated\") directly supports **DMD mutation**, as this mutation leads to absent or truncated dystrophin protein. Since all other mutations (HTT, G6PD, and MTHFR) have already been ruled out by prior assays, this result conclusively identifies **DMD mutation** as the cause. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 17870, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 82.0459461099926}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "High-resolution melt analysis (HRM)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "After ruling out HTT gene expansion with a normal Southern blot result, the next step is to eliminate another mutation efficiently. The Enzyme assay can directly assess G6PD deficiency: a normal enzyme activity (75-100) would exclude G6PD deficiency, narrowing the remaining candidates to MTHFR and DMD mutations. If the result is abnormal (0-25), G6PD deficiency remains possible, but this assay provides actionable information to guide further testing. This approach minimizes steps by targeting a mutation-specific functional assay. \n\n<ANSWER> Enzyme assay </ANSWER>", "After ruling out HTT and G6PD deficiency, the remaining candidates are **MTHFR** and **DMD mutations**. The **High-resolution melt analysis (HRM)** directly targets the MTHFR mutation: a **normal melting curve** would exclude MTHFR, leaving DMD as the answer. If the curve is abnormal, MTHFR remains possible, requiring further testing. This step minimizes remaining candidates efficiently by targeting MTHFR specifically. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out **HTT gene expansion** (Southern blot normal), **G6PD deficiency** (Enzyme assay activity 82), and **MTHFR mutation** (HRM normal), the only remaining candidate is **DMD mutation**. Since all other mutations have been excluded via assay results, no further testing is required. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 17882, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 82.0459461099926}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}], "seed": 0, "average_actions": 5.2, "average_tokens": 22249.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.2, "average_successful_tokens": 22249.2}
{"trajectories": [{"actions": ["Western blot", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "After performing the Western blot, the result ruled out **DMD mutation** and **COL1A1 mutation**, leaving **APC gene mutation** and **CFTR mutation** as possibilities. To distinguish between these two, the **Protein truncation test** is the most strategic next step. If the test detects truncated proteins, it confirms APC gene mutation (since APC mutations often cause truncated proteins). If no truncations are found, APC is ruled out, leaving CFTR mutation as the answer. This test directly addresses the remaining candidates efficiently. \n\n<ANSWER> Protein truncation test </ANSWER>", "The **Protein truncation test** result (\"No truncated proteins detected\") rules out **APC gene mutation**, leaving **CFTR mutation** as the only remaining possibility. Since all other mutations have been systematically excluded through prior assays, no further testing is required. The logical conclusion is **CFTR mutation**.\n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 10299, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "High-resolution melt analysis (HRM)", "Splice-site analysis", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein Truncation Test result (\"No truncated proteins detected\") rules out **DMD mutation** and **APC gene mutation**, leaving **COL1A1 mutation** and **CFTR mutation**. To distinguish between these, **High-resolution melt analysis (HRM)** is optimal:  \n- If HRM shows **no melting curve abnormalities**, CFTR mutation is excluded, leaving COL1A1.  \n- If HRM detects **abnormal melting**, CFTR mutation is confirmed.  \n\nThis step efficiently narrows the options.  \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "The High-Resolution Melt Analysis (HRM) detected abnormal melting curves, which does **not** rule out **CFTR mutation** (since HRM only rules out CFTR when results are normal). This leaves **CFTR mutation** and **COL1A1 mutation** as possibilities. To distinguish between them, **Splice-site analysis** is the most efficient next step:  \n- If **splicing abnormalities are detected**, CFTR mutation is confirmed.  \n- If **no splicing abnormalities**, CFTR is ruled out, leaving COL1A1 mutation.  \n\nThis directly targets CFTR\u2019s splicing defects, minimizing steps.  \n\n<ANSWER> Splice-site analysis </ANSWER>", "The **Splice-site analysis** detected splicing abnormalities, which confirms the **CFTR mutation** (as per the guidebook: \"No splicing abnormalities detected\" would rule out CFTR, but abnormalities here confirm it). Since all other mutations (DMD, APC) were previously ruled out, and COL1A1 is excluded by the absence of splicing issues in CFTR\u2019s case, **CFTR mutation** is the only remaining option.  \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 19583, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Splice-site analysis", "observation": "Splicing abnormalities detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "High-resolution melt analysis (HRM)", "Splice-site analysis", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "To determine the remaining mutation between COL1A1 and CFTR, the **Splice-site analysis** directly assesses CFTR mutations by checking for splicing abnormalities. If splicing issues are detected, CFTR is confirmed; otherwise, COL1A1 is the answer. This test efficiently narrows down the options in one step. \n\n<ANSWER> Splice-site analysis </ANSWER>", "The splice-site analysis detected abnormalities, which confirms the CFTR mutation as the remaining possibility (COL1A1 was ruled out by HRM's abnormal result, and APC/DMD were already eliminated). \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 25004, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Splice-site analysis", "observation": "Splicing abnormalities detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "High-resolution melt analysis (HRM)", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "After performing the **Protein truncation test**, the result \"No truncated proteins detected\" rules out **DMD mutation** and **APC gene mutation**. This leaves **COL1A1 mutation** and **CFTR mutation** as possibilities. To distinguish between these, the **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows **no melting curve abnormalities**, it would rule out **CFTR mutation**, leaving **COL1A1 mutation** as the answer. Conversely, if HRM detects abnormalities, **CFTR mutation** would be confirmed. This assay directly targets one of the remaining candidates, minimizing steps.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After the **High-resolution melt analysis (HRM)** showed **abnormal melting curves**, this indicates a DNA sequence variation in the CFTR gene (since HRM specifically rules out CFTR mutation only if no abnormalities are detected). With **COL1A1 mutation** and **CFTR mutation** as the remaining candidates, the HRM result confirms **CFTR mutation** as the cause. No further assays are required. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 16209, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "High-resolution melt analysis (HRM)", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein truncation test result ruled out APC and DMD mutations, leaving COL1A1 and CFTR. To differentiate, **High-resolution melt analysis (HRM)** can check for CFTR mutations. If HRM shows no abnormalities, CFTR is excluded (leaving COL1A1). If abnormalities are detected, CFTR is confirmed. This step efficiently narrows the options to one mutation.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After performing the Protein truncation test and High-resolution melt analysis (HRM), the results narrowed the possibilities to **CFTR mutation** and **COL1A1 mutation**. The HRM assay detected abnormal melting curves, which does not rule out CFTR (only a normal HRM result would exclude CFTR). Since HRM abnormalities are specifically linked to CFTR mutations in the guidebook (with no mention of COL1A1), this strongly supports CFTR as the remaining candidate. No further assays are needed to differentiate between the two. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 21865, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}], "successful": true, "parse_error": false}], "seed": 1, "average_actions": 4.4, "average_tokens": 18592.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.4, "average_successful_tokens": 18592.0}
{"trajectories": [{"actions": ["Protein truncation test", "Enzyme assay", "ELISA", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "<ANSWER> ELISA </ANSWER>", "The Protein truncation test detected truncated proteins, which is associated with APC gene mutations. PAH and LEP mutations were ruled out by the Enzyme assay and ELISA results. Although MTHFR mutation remains a possibility, the presence of truncated proteins strongly implicates APC gene mutation. No further assays are needed as all other mutations have been eliminated. \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 27692, "observations": [null, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "Enzyme assay", "observation": 99.99296989863173}, {"action": "ELISA", "observation": 15.961783452617343}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "ELISA", "High-resolution melt analysis (HRM)", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein truncation test detected truncated proteins, which does not exclude any mutations according to the guide. To narrow down the possibilities efficiently, the next logical step is to use **ELISA** to check leptin levels. If the result is low (0-25), it would rule out the LEP mutation, leaving MTHFR, APC, and PAH. This allows systematic elimination of mutations stepwise. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of 15.96 falls within the 0-25 range, which **rules out the LEP mutation** according to the guide. This leaves three possible mutations: MTHFR, APC, and PAH. To proceed efficiently, the next logical step is to use **High-resolution melt analysis (HRM)**. If HRM shows no melting curve abnormalities, it will rule out the MTHFR mutation, narrowing the options to APC and PAH. This approach minimizes steps by targeting MTHFR first (using HRM) before addressing PAH (via Enzyme assay if needed). \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "The HRM result showing no abnormalities **rules out the MTHFR mutation**, leaving **APC gene mutation** and **PAH mutation** as possibilities. To differentiate between these, perform the **Enzyme assay** next. If enzyme activity is in the 75-100 range, it rules out PAH mutation (confirming APC). If activity is low (0-25), PAH mutation is confirmed. This is the most direct next step to resolve the remaining candidates.\n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 99.99 falls within the 75-100 range, which **rules out the PAH mutation** per the guide. The only remaining mutation is **APC gene mutation**, as all others (LEP, MTHFR, PAH) have been excluded by prior assay results. No further assays are needed.\n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 27347, "observations": [null, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "ELISA", "observation": 15.961783452617343}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "Enzyme assay", "observation": 99.99296989863173}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "ELISA", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "After the Protein truncation test detected truncated proteins, the APC gene mutation remains a candidate. To efficiently narrow down the remaining possibilities (MTHFR, APC, LEP, PAH), the next logical step is to perform **ELISA**. If the result is (0, 25), LEP mutation is ruled out, leaving MTHFR, APC, and PAH. If the result is (75, 100), LEP remains possible, but this assay provides critical information to eliminate one mutation if possible. This approach systematically eliminates candidates step-by-step.\n\n<ANSWER> ELISA </ANSWER>", "After performing the ELISA with a result of 15.96 (falling in the 0\u201325 range), the **LEP mutation** is ruled out. The remaining candidates are **MTHFR mutation**, **APC gene mutation**, and **PAH mutation**. To proceed efficiently, the **Enzyme assay** is the optimal next step. If the Enzyme assay result is in the **75\u2013100 range**, it will rule out the **PAH mutation**, narrowing the options to MTHFR and APC. If the result is **0\u201325**, PAH remains a candidate, and further testing (e.g., HRM or DNA sequencing) would be needed. The Enzyme assay directly addresses PAH, making it the most strategic choice to eliminate one mutation definitively.\n\n<ANSWER> Enzyme assay </ANSWER>", "After the Enzyme assay result (99.99 in the 75\u2013100 range), the **PAH mutation** is ruled out. The remaining candidates are **MTHFR mutation** and **APC gene mutation**. However, the **Protein truncation test** previously detected truncated proteins, which directly implicates the **APC gene mutation** (as APC mutations cause truncated proteins, and no other remaining mutation in the list explains this result). Since MTHFR mutations do not affect protein length or structure in a way detectable by the Protein truncation test, the only plausible remaining mutation is **APC gene mutation**.\n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 29539, "observations": [null, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "ELISA", "observation": 15.961783452617343}, {"action": "Enzyme assay", "observation": 99.99296989863173}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Protein truncation test", "ELISA", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing result ruled out MTHFR mutation. The remaining possibilities are APC, LEP, and PAH. The Protein Truncation Test can eliminate APC if no truncated proteins are detected. This reduces the remaining candidates to LEP and PAH, streamlining subsequent steps. \n\n<ANSWER> Protein truncation test </ANSWER>", "The Protein Truncation Test detected truncated proteins, which does not rule out APC gene mutation. The remaining candidates are APC, LEP, and PAH. The ELISA assay can directly rule out LEP if the result is low (0\u201325). If ELISA excludes LEP, the next step would be to use the Enzyme assay to differentiate between APC and PAH. Choosing ELISA now efficiently narrows the possibilities.  \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of 15.96 falls within the (0, 25) range, which rules out **LEP mutation**. The remaining candidates are **APC gene mutation** and **PAH mutation**. To distinguish between these, the **Enzyme assay** is critical: a result in the (75, 100) range would rule out PAH mutation, leaving APC as the answer. If the enzyme activity is low (0, 25), PAH mutation remains plausible. This assay efficiently resolves the final ambiguity.  \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 99.99 falls within the (75, 100) range, which **rules out PAH mutation**. After sequentially eliminating MTHFR (via DNA sequencing), LEP (via ELISA), and PAH (via Enzyme assay), the only remaining possibility is **APC gene mutation**. No further assays are needed.  \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 24485, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "ELISA", "observation": 15.961783452617343}, {"action": "Enzyme assay", "observation": 99.99296989863173}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 12751, "observations": [null, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}], "successful": true, "parse_error": false}], "seed": 2, "average_actions": 5.0, "average_tokens": 24362.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 24362.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "ELISA", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "The previous assays ruled out HBB and COL1A1 mutations via NGS (no variants detected). The Enzyme assay result (11.75, within 0\u201325) does **not** rule out PAH mutation (low activity aligns with PAH mutation). The remaining candidates are **LEP mutation** and **PAH mutation**. \n\nThe next optimal assay is **ELISA**:  \n- If ELISA results are **0\u201325**, LEP mutation is ruled out, leaving PAH mutation as the answer.  \n- If ELISA results are **75\u2013100**, LEP mutation remains plausible.  \n\nUsing ELISA here directly distinguishes between the two remaining candidates.  \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of **24.89** (within 0\u201325) rules out the **LEP mutation**, leaving only **PAH mutation** as the plausible candidate. All other mutations have been excluded by prior assays. No further testing is required.  \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 8381, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 11.756587688061199}, {"action": "ELISA", "observation": 24.89112088776157}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "ELISA", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "After NGS ruled out HBB and COL1A1, the remaining possibilities are LEP and PAH. The enzyme assay result (11.76) supports PAH mutation (low activity aligns with PAH dysfunction) but does not confirm it. To differentiate, perform **ELISA**: if leptin levels are low (0\u201325), LEP mutation is ruled out, leaving PAH. If levels are high (75\u2013100), LEP mutation is confirmed. This step efficiently narrows the options to one mutation.\n\n<ANSWER> ELISA </ANSWER>", "After performing NGS (ruled out HBB and COL1A1), enzyme assay (low PAH activity supports PAH mutation), and ELISA (result 24.89 in 0\u201325 range, ruling out LEP mutation), **PAH mutation** is the only remaining possibility. All other mutations are excluded by assay outcomes. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 11656, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 11.756587688061199}, {"action": "ELISA", "observation": 24.89112088776157}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "ELISA", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations, leaving LEP and PAH as possibilities. To distinguish between these, **ELISA** is the most efficient next step. If ELISA returns a result of 0\u201325, LEP is ruled out (leaving PAH), while a result of 75\u2013100 keeps LEP as a candidate. This approach minimizes further steps compared to other assays. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of 24.89 (within 0\u201325) rules out the **LEP mutation**, leaving **PAH mutation** as the only remaining possibility. No further assays are needed. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 9498, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "ELISA", "observation": 24.89112088776157}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "ELISA", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations, leaving LEP and PAH. To distinguish between these, **ELISA** directly tests for LEP mutation. If ELISA results are 0\u201325, LEP is excluded, leaving PAH. If 75\u2013100, PAH would require further testing. Choosing ELISA efficiently narrows down the options. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of 24.89 falls in the 0\u201325 range, which rules out the **LEP mutation**. Since NGS previously excluded HBB and COL1A1, the only remaining mutation is **PAH mutation**. No further testing is required. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 9287, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "ELISA", "observation": 24.89112088776157}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "ELISA", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> ELISA </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations. The ELISA result (24.89) falls in the 0-25 range, ruling out LEP mutation. The only remaining option is **PAH mutation**. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 5752, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "ELISA", "observation": 24.89112088776157}], "successful": true, "parse_error": false}], "seed": 3, "average_actions": 4.4, "average_tokens": 8914.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.4, "average_successful_tokens": 8914.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result \"No variants detected\" rules out HBB, GJB2, and CFTR mutations, leaving only HTT gene expansion. Since HTT expansions are detected via Southern blot, but no further assays are needed once all other options are eliminated. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 6194, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB, GJB2, and CFTR mutations, leaving only HTT gene expansion. Southern blot could confirm HTT expansion, but since it's the only remaining mutation, it can be directly identified. <ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 10754, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 10960, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB, CFTR, and GJB2 mutations. Only HTT gene expansion remains possible. <ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 8697, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "Since the NGS result showed \"No variants detected,\" the HBB, GJB2, and CFTR mutations are ruled out according to the guidebook. The only remaining mutation is **HTT gene expansion**, which involves repeat expansions not typically detected by standard NGS. No further assays are needed. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 7771, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}], "seed": 4, "average_actions": 3.0, "average_tokens": 8875.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.0, "average_successful_tokens": 8875.2}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "Western blot", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "The Enzyme Assay result of 86.7 falls within the 75\u2013100 range, ruling out the PAH mutation. The MLPA result already excluded PMP22 duplication. Remaining possibilities are **DMD mutation** and **BRCA2 mutation**. \n\nTo differentiate between these, **Western blot** directly tests for dystrophin protein (expected size rules out DMD mutation). If the Western blot detects the protein, BRCA2 mutation remains; if not, DMD is confirmed. This assay efficiently narrows down the options in one step.\n\n<ANSWER> Western blot </ANSWER>", "The Western blot detected the protein of expected size, ruling out the **DMD mutation**. With **PAH mutation**, **PMP22 duplication**, and **DMD mutation** already eliminated, the only remaining possibility is **BRCA2 mutation**. No further assays are required. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 14678, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 86.72672619455409}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "Sanger sequencing", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The MLPA assay ruled out PMP22 duplication by showing a normal copy number. The remaining mutations are DMD, PAH, and BRCA2. To efficiently eliminate another mutation, the **Enzyme assay** can test for PAH enzyme activity. If the result is within the normal range (75-100), PAH mutation is excluded, narrowing the options to DMD and BRCA2. If the activity is low, PAH mutation is confirmed. This approach minimizes steps by targeting a specific mutation directly. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 86.7 (within the normal range) rules out the PAH mutation. The remaining candidates are **DMD mutation** and **BRCA2 mutation**. To distinguish between them, **Sanger sequencing** directly tests for BRCA2 mutations. If no mutations are found, BRCA2 is excluded, leaving DMD as the answer. If mutations are detected, BRCA2 is confirmed. This assay resolves the remaining ambiguity in one step. \n\n<ANSWER> Sanger sequencing </ANSWER>", "The **Sanger sequencing** detected mutations, confirming the **BRCA2 mutation** as per the guidebook. All other mutations have been ruled out through previous assays. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 14468, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 86.72672619455409}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "Sanger sequencing", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The MLPA assay showed a normal copy number, ruling out PMP22 duplication. The remaining mutations are DMD, PAH, and BRCA2. To proceed efficiently, the next assay should target a mutation that can be definitively ruled out or confirmed. The **Enzyme assay** directly assesses PAH activity: if normal (75-100), PAH mutation is excluded, narrowing it to DMD or BRCA2. If abnormal, PAH is confirmed. This step minimizes further testing by addressing a mutation with a unique assay. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 86.73 falls within the normal activity range (75-100), ruling out the **PAH mutation**. This leaves **DMD mutation** and **BRCA2 mutation** as possible candidates. To differentiate between these, **Sanger sequencing** directly evaluates the BRCA2 gene for mutations. If no mutations are detected, BRCA2 is excluded, leaving DMD as the answer. If a mutation is found, BRCA2 is confirmed. This step resolves the remaining ambiguity in one move. \n\n<ANSWER> Sanger sequencing </ANSWER>", "The Sanger sequencing detected mutations, confirming a **BRCA2 mutation** as per the guidebook (Sanger sequencing detects BRCA2 mutations). All other possibilities have been ruled out through previous assays. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 19974, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 86.72672619455409}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "Western blot", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The MLPA result ruled out PMP22 duplication. Now, the remaining possibilities are DMD, PAH, and BRCA2 mutations. The next step should be an assay that can eliminate one of these. The Enzyme Assay can directly assess PAH mutation: if enzyme activity is normal (75-100), PAH is ruled out, narrowing it to DMD or BRCA2. If activity is low, PAH is confirmed. This test provides a decisive outcome for one mutation, making it efficient for elimination. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme Assay result of 86.73 falls within the normal range (75-100), ruling out the PAH mutation. Now, only **DMD mutation** and **BRCA2 mutation** remain. To distinguish between these, the **Western blot** is the most efficient next step. If the Western blot detects a protein of the expected size (normal dystrophin), the DMD mutation is ruled out, leaving BRCA2 as the answer. If the protein is absent or truncated, DMD mutation is confirmed. This assay directly addresses one of the remaining mutations with a definitive outcome.\n\n<ANSWER> Western blot </ANSWER>", "The Western blot detected the protein of expected size, ruling out the **DMD mutation**. Only **BRCA2 mutation** remains. No further assays are needed, as all other possibilities have been eliminated. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 19530, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 86.72672619455409}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "Sanger sequencing", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "After ruling out PAH and PMP22 mutations, the remaining possibilities are DMD and BRCA2. The **Sanger sequencing** assay directly checks for BRCA2 mutations. If no mutations are detected, BRCA2 is ruled out, leaving DMD as the answer. If mutations are found, BRCA2 is confirmed. This step efficiently narrows the options to one mutation in a single test.\n\n<ANSWER> Sanger sequencing </ANSWER>", "The Sanger sequencing detected mutations, confirming BRCA2 mutation. All other possibilities have been ruled out. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 19634, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 86.72672619455409}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}], "seed": 5, "average_actions": 5.0, "average_tokens": 17656.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 17656.8}
{"trajectories": [{"actions": ["Protein truncation test", "Southern blot", "Enzyme assay", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "<ANSWER> Southern blot </ANSWER>", "After performing the **Protein Truncation Test** (ruled out APC and DMD mutations) and **Southern blot** (did not rule out FMR1 due to an expanded fragment), the remaining candidates are **FMR1 gene expansion** and **SERPINA1 mutation**. \n\nThe **Enzyme assay** directly addresses SERPINA1:  \n- If enzyme activity is **75\u2013100 units**, SERPINA1 is ruled out, leaving **FMR1** as the answer.  \n- If activity is **0\u201325 units**, SERPINA1 remains possible, requiring further testing.  \n\nThis is the most efficient next step to resolve the remaining ambiguity.  \n\n<ANSWER> Enzyme assay </ANSWER>", "The **Enzyme assay** result of **87.22 units** (falling within 75\u2013100 units) rules out the **SERPINA1 mutation**. With **APC** and **DMD** already eliminated earlier, the only remaining mutation is **FMR1 gene expansion**. No further testing is required.  \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 10624, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Southern blot", "observation": "Expanded fragment detected"}, {"action": "Enzyme assay", "observation": 87.22103178536808}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein Truncation Test ruled out **DMD mutation** and **APC gene mutation**, leaving **FMR1 gene expansion** and **SERPINA1 mutation** as possibilities. To distinguish between these, **Southern blot** directly checks for FMR1 expansions. If the result shows a normal-sized fragment, FMR1 is eliminated (confirming SERPINA1). If an expanded fragment is observed, FMR1 is confirmed. This assay resolves the remaining options in one step. \n\n<ANSWER> Southern blot </ANSWER>", "The Southern blot detected an expanded fragment, which confirms **FMR1 gene expansion** (since a normal fragment would have ruled it out). This eliminates SERPINA1 mutation as the remaining possibility. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 10006, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein truncation test ruled out APC and DMD mutations, leaving FMR1 and SERPINA1. To distinguish between these, **Southern blot** directly checks for FMR1 gene expansion. A normal result would eliminate FMR1, leaving SERPINA1 as the answer, while an expanded fragment confirms FMR1. This is the most efficient next step. \n\n<ANSWER> Southern blot </ANSWER>", "The Southern blot detected an expanded fragment, which is specific to **FMR1 gene expansion** (characteristic of Fragile X Syndrome). Since the remaining options were FMR1 and SERPINA1 after the Protein truncation test, and SERPINA1 (Alpha-1 Antitrypsin Deficiency) does not involve repeat expansions detectable by Southern blot, the expanded fragment conclusively identifies FMR1 as the mutation. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 15221, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Enzyme assay", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "The Protein truncation test result ruled out DMD and APC mutations. Remaining possibilities are FMR1 gene expansion and SERPINA1 mutation. The **Enzyme assay** directly assesses SERPINA1: if enzyme activity is 75-100 units, SERPINA1 is eliminated (leaving FMR1). If activity is low (0-25), no elimination occurs, but this would suggest SERPINA1 remains possible. This assay provides a clear path to rule out one mutation in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result (87.22 units) rules out the **SERPINA1 mutation** (as activity \u226575 units eliminates it). Only **FMR1 gene expansion** remains after eliminating APC, DMD, and SERPINA1. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 7791, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Enzyme assay", "observation": 87.22103178536808}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Southern blot", "Enzyme assay", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Protein truncation test </ANSWER>", "After the Protein Truncation Test ruled out **APC gene mutation** and **DMD mutation**, the remaining candidates are **FMR1 gene expansion** and **SERPINA1 mutation**. To distinguish between these, **Southern blot** is the most efficient next step. If the Southern blot shows a **normal-sized fragment**, FMR1 gene expansion is ruled out, leaving SERPINA1 mutation as the answer. If an **expanded fragment** is observed, FMR1 gene expansion is confirmed. This assay directly targets one of the two remaining mutations, ensuring resolution in one step. \n\n<ANSWER> Southern blot </ANSWER>", "After the Southern blot detected an expanded fragment, **FMR1 gene expansion** remains a candidate, as the expanded fragment does not eliminate it (per the guidebook rules). However, **SERPINA1 mutation** is still possible. To differentiate conclusively:  \n- **Enzyme assay** directly checks for SERPINA1 mutation.  \n  - If enzyme activity is **75\u2013100 units**, SERPINA1 is ruled out, confirming **FMR1 gene expansion**.  \n  - If activity is **0\u201325 units**, SERPINA1 mutation is confirmed.  \n\nThis assay efficiently resolves the remaining ambiguity in one step.  \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of **87.22 units** (within the 75\u2013100 range) rules out the **SERPINA1 mutation**, leaving **FMR1 gene expansion** as the only remaining candidate. All other mutations were previously eliminated by prior assays. No further testing is required.  \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 13384, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Southern blot", "observation": "Expanded fragment detected"}, {"action": "Enzyme assay", "observation": 87.22103178536808}], "successful": true, "parse_error": false}], "seed": 6, "average_actions": 4.4, "average_tokens": 11405.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.4, "average_successful_tokens": 11405.2}
{"trajectories": [{"actions": ["Fluorescence in situ hybridization (FISH)", "PCR amplification", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After performing FISH and detecting a deletion, SMN1 deletion remains a candidate. To confirm this, the next logical step is **PCR amplification**. If the fragment fails to amplify, SMN1 deletion is confirmed. If it amplifies, SMN1 deletion is ruled out, narrowing the possibilities to COL1A1, HTT, or MTHFR mutations. This approach minimizes steps by directly testing the most likely mutation first. \n\n<ANSWER> PCR amplification </ANSWER>", "The PCR amplification result of \"No amplification\" confirms **SMN1 deletion** as the mutation, as per the guidebook. No further assays are needed since the deletion was already indicated by FISH and confirmed by PCR. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 13082, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "The FISH assay detected a deletion. According to the guide, this does not explicitly rule out any mutations. However, among the four possible mutations, **SMN1 deletion** is the only one involving a deletion. The other mutations (COL1A1 mutation, HTT expansion, MTHFR mutation) are not associated with deletions but instead involve point mutations, repeat expansions, or SNPs. Since FISH detected a deletion, the only plausible remaining mutation is **SMN1 deletion**. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 11282, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Western blot", "High-resolution melt analysis (HRM)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["<ANSWER> Tandem repeat PCR </ANSWER>", "After performing the Tandem repeat PCR, the observed repeat size (2.578) falls within the 0\u201330 range, which **rules out HTT gene expansion**. The remaining possible mutations are **SMN1 deletion**, **COL1A1 mutation**, and **MTHFR mutation**. To narrow down further, the **Western blot** assay is the most strategic choice. If the Western blot detects a protein of the expected size, it would **rule out COL1A1 mutation**, leaving SMN1 deletion and MTHFR mutation. If the result shows an abnormal or truncated protein, COL1A1 remains possible, but the assay does not directly confirm it. This step efficiently targets COL1A1, which is critical for reducing the remaining options. \n\n<ANSWER> Western blot </ANSWER>", "After performing the Tandem repeat PCR and Western blot, **HTT gene expansion** and **COL1A1 mutation** have been ruled out. The remaining possibilities are **SMN1 deletion** and **MTHFR mutation**. To differentiate between these, the **High-resolution melt analysis (HRM)** assay is the most efficient next step. If HRM shows **no melting curve abnormalities**, it will **rule out MTHFR mutation**, leaving **SMN1 deletion** as the only remaining mutation. If abnormal curves are detected, further testing (e.g., FISH or PCR) would still be required, but HRM offers the quickest path to resolving the remaining ambiguity. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out **HTT gene expansion**, **COL1A1 mutation**, and **MTHFR mutation**, the only remaining possibility is **SMN1 deletion**. No further assays are needed since all other mutations have been eliminated through systematic testing. The observed results align conclusively with **SMN1 deletion**. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 26796, "observations": [null, {"action": "Tandem repeat PCR", "observation": 2.5784170106751505}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After performing FISH and detecting a deletion, the result does not explicitly rule out any mutations according to the guidebook. However, SMN1 deletion is the only mutation among the options that involves a deletion, making it the most plausible candidate. FISH is specifically used to detect deletions, and since the other mutations (COL1A1 mutation, HTT expansion, MTHFR mutation) are not deletions, the detected deletion strongly implicates SMN1. While the guidebook states that a deletion detected by FISH does not \"rule out\" others, logical deduction based on mutation types and assay specificity allows confident identification of SMN1 deletion as the responsible mutation.\n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 15273, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Western blot", "Southern blot", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After performing FISH and detecting a deletion, the next logical step is to use **Western blot** to check for COL1A1 mutation. If the Western blot result shows a protein of expected size, COL1A1 mutation is ruled out, narrowing the possibilities further. This approach systematically eliminates one of the remaining mutations efficiently.\n\n<ANSWER> Western blot </ANSWER>", "After ruling out COL1A1 mutation via Western blot, the remaining possibilities are **SMN1 deletion**, **HTT gene expansion**, and **MTHFR mutation**. The goal is to eliminate one of these efficiently. \n\n**Southern blot** directly targets HTT gene expansion. If the result shows a **normal-sized fragment**, HTT is ruled out, leaving SMN1 and MTHFR. If the fragment is expanded, HTT remains possible. This assay narrows down the options effectively, enabling subsequent steps (e.g., HRM for MTHFR) to resolve the remaining mutations quickly. \n\n<ANSWER> Southern blot </ANSWER>", "After performing **Southern blot** and observing a **normal-sized fragment**, **HTT gene expansion** is ruled out. The remaining possibilities are **SMN1 deletion** and **MTHFR mutation**.  \n\nThe **FISH assay** previously detected a deletion, which aligns with **SMN1 deletion** (a deletion mutation). Since **MTHFR mutation** is a point mutation unrelated to deletions, the FISH result strongly supports **SMN1 deletion** as the correct answer. No further assays are needed to distinguish between the two remaining mutations.  \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 31191, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}], "seed": 7, "average_actions": 4.0, "average_tokens": 19524.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 19524.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Southern blot", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations. The remaining candidates are **PAH mutation** and **HTT gene expansion**. To distinguish between them, **Southern blot** is optimal: it detects DNA fragment size changes caused by HTT expansions. A normal fragment would eliminate HTT, leaving PAH as the answer. An expanded fragment confirms HTT. \n\n<ANSWER> Southern blot </ANSWER>", "The Southern blot result showing a normal-sized fragment rules out **HTT gene expansion**. With **HBB mutation** and **COL1A1 mutation** already excluded by the NGS result, the only remaining candidate is **PAH mutation**. No further assays are needed. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 10910, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "After NGS ruled out HBB and COL1A1 mutations, the remaining candidates are **PAH mutation** and **HTT gene expansion**. To differentiate these, **Southern blot** is ideal for detecting HTT expansions. A normal fragment size would eliminate HTT, leaving PAH as the answer. Conversely, an expanded fragment confirms HTT. This assay directly addresses the remaining possibilities efficiently.\n\n<ANSWER> Southern blot </ANSWER>", "After performing **Southern blot** and observing a **normal-sized fragment**, the **HTT gene expansion** is ruled out. With **HBB** and **COL1A1 mutations** already excluded by the prior NGS result, the only remaining mutation is **PAH mutation**. No further assays are necessary as all other candidates have been eliminated. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 11413, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> Southern blot </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations. The Southern blot's normal-sized fragment excluded HTT gene expansion. Only PAH mutation remains plausible. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 10800, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Next-generation sequencing (NGS)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "The Southern blot result ruled out **HTT gene expansion**, leaving **HBB, PAH, and COL1A1 mutations**. To narrow further, **Next-generation sequencing (NGS)** is optimal. If NGS detects no variants, it eliminates **HBB** and **COL1A1**, leaving **PAH mutation** as the only possibility. If variants are detected, follow-up assays can target the remaining options. This minimizes steps by potentially resolving the case in one action.\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The Southern blot ruled out **HTT gene expansion**, and the subsequent NGS result (\"No variants detected\") excluded **HBB** and **COL1A1 mutations** based on the guidebook. This leaves **PAH mutation** as the only remaining option. Since no further assays are needed to confirm this conclusion, the final answer is the **PAH mutation**.\n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 12608, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The NGS result ruled out HBB and COL1A1 mutations, leaving PAH mutation and HTT gene expansion. To distinguish between these, **Southern blot** can detect HTT gene expansions. If the Southern blot shows a normal fragment size, HTT expansion is excluded, leaving PAH mutation as the answer. If an expanded fragment is observed, HTT is confirmed. Thus, Southern blot is the most efficient next step.\n\n<ANSWER> Southern blot </ANSWER>", "The Southern blot result showing a normal-sized fragment rules out **HTT gene expansion** (as HTT expansions would show an expanded fragment). With HBB and COL1A1 mutations already excluded by the NGS result, **PAH mutation** is the only remaining possibility. No further assays are needed.  \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 12998, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}], "seed": 8, "average_actions": 4.0, "average_tokens": 11745.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 11745.8}
{"trajectories": [{"actions": ["Western blot", "Enzyme assay", "RNA sequencing", "MECP2 mutation", {"predicted_truth": "MECP2 mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "The Western blot result ruled out DMD and COL1A1 mutations. The remaining candidates are **MECP2 mutation** and **PAH mutation**. To differentiate between them, the **Enzyme assay** directly tests PAH enzyme activity. If activity is 75\u2013100%, PAH is excluded (confirming MECP2). If 0\u201325%, PAH is confirmed. This assay efficiently resolves the remaining ambiguity in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 18.2% (0\u201325%) does **not** rule out any mutations, leaving **MECP2** and **PAH** as candidates. To resolve this, **RNA sequencing** is optimal:  \n- **Normal transcript levels** would rule out MECP2 (confirming PAH).  \n- **Abnormal transcript levels** would confirm MECP2.  \nThis assay provides definitive exclusion of one mutation based on transcript data.  \n\n<ANSWER> RNA sequencing </ANSWER>", "The RNA sequencing result showing **abnormal transcript levels** aligns with **MECP2 mutation**, which disrupts transcript regulation. Since PAH mutations typically involve enzyme dysfunction (detected via enzyme assay) but do not inherently alter RNA transcript levels, the abnormal RNA result strongly implicates MECP2. No further assays are needed to exclude PAH, as the RNA data already differentiates the two. The remaining mutation is **MECP2 mutation**.\n\n<ANSWER> MECP2 mutation </ANSWER>"], "consumed_tokens": 18907, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Enzyme assay", "observation": 18.204805884327666}, {"action": "RNA sequencing", "observation": "Abnormal transcript levels"}], "successful": false, "parse_error": false}, {"actions": ["Western blot", "Enzyme assay", "Methylation-specific PCR", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "The Western blot result ruled out DMD and COL1A1 mutations (since protein size was normal), leaving **MECP2** and **PAH** as possibilities. To distinguish between these, the **Enzyme assay** directly tests PAH enzyme activity: a result of 75\u2013100% activity would rule out PAH, leaving MECP2 as the answer, while low activity (0\u201325%) would confirm PAH. This assay provides the fastest resolution between the remaining candidates. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 18.2% (within 0\u201325%) does **not** rule out PAH mutation, as per the guidebook. Since only PAH and MECP2 remain, **Methylation-specific PCR** is the next logical step: a normal methylation pattern would exclude MECP2, leaving PAH as the answer. Conversely, abnormal methylation would confirm MECP2. This assay directly tests MECP2\u2019s epigenetic signature, resolving the remaining ambiguity efficiently. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The **normal methylation pattern** from Methylation-specific PCR rules out **MECP2 mutation** (as per the guidebook). Only **PAH mutation** remains. No further assays are needed\u2014**PAH mutation** is conclusively identified. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 10222, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Enzyme assay", "observation": 18.204805884327666}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Western blot", "Enzyme assay", "Methylation-specific PCR", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "After performing the Western blot and Enzyme assay, DMD and COL1A1 mutations are ruled out (Western blot showed normal protein size). The Enzyme assay result (18.2) falls in the 0\u201325 range, which does **not** exclude PAH mutations (as low enzyme activity aligns with PAH mutations). This leaves MECP2 and PAH as possible candidates. To differentiate, **Methylation-specific PCR** is the most efficient next step: a normal methylation pattern would exclude MECP2, leaving PAH as the only remaining mutation. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After ruling out DMD and COL1A1 (via Western blot) and MECP2 (via Methylation-specific PCR), the only remaining mutation is **PAH mutation**. No further assays are needed. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 10369, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Enzyme assay", "observation": 18.204805884327666}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Western blot", "Enzyme assay", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "The Western blot result ruled out DMD and COL1A1 mutations, leaving MECP2 and PAH. The **Enzyme assay** directly tests PAH enzyme activity: if activity is 75\u2013100%, PAH is excluded (confirming MECP2). If activity is 0\u201325%, PAH is confirmed. This assay resolves the remaining options in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result (18.2% activity) falls in the 0\u201325% range, which does **not** rule out PAH mutation according to the guidebook. However, since PAH mutations impair enzyme function, this strongly suggests PAH mutation. Confirming this requires one more assay to exclude MECP2. **Methylation-specific PCR** is optimal: a normal methylation pattern would rule out MECP2, leaving PAH as the answer. If abnormal, MECP2 is confirmed. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 9806, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Enzyme assay", "observation": 18.204805884327666}], "successful": true, "parse_error": false}, {"actions": ["Western blot", "Methylation-specific PCR", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["<ANSWER> Western blot </ANSWER>", "After the Western blot result ruled out DMD and COL1A1 mutations, the remaining candidates are **MECP2** and **PAH**. To differentiate between them, **Methylation-specific PCR** is the most efficient next step. If the methylation pattern is **normal**, MECP2 is excluded (leaving PAH). If **abnormal**, MECP2 is confirmed. This assay resolves the remaining ambiguity in one step, avoiding potential inconclusive results from other tests (e.g., low enzyme activity in an enzyme assay would not definitively rule out PAH). \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After the Methylation-specific PCR result showed a normal methylation pattern, MECP2 mutation is ruled out. Only **PAH mutation** remains from the original list. No further assays are required. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 10161, "observations": [null, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}], "seed": 9, "average_actions": 4.6, "average_tokens": 11893.0, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 4.5, "average_successful_tokens": 10139.5}
{"trajectories": [{"actions": ["Enzyme assay", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 76.9 (75-100 range) excludes **G6PD deficiency mutation** and **SERPINA1 mutation**, leaving **FMR1 gene expansion** and **MTHFR mutation** as possibilities. To distinguish between these, the most efficient assay is **DNA sequencing**. If no mutations are detected, MTHFR is excluded, confirming FMR1. If mutations are detected, MTHFR is confirmed. This assay directly targets MTHFR and resolves the remaining options in one step. \n\n<ANSWER> DNA sequencing </ANSWER>", "The Enzyme assay excluded G6PD and SERPINA1 mutations. DNA sequencing detected mutations, which **does not exclude MTHFR mutation** (as \"mutations detected\" provides no exclusions). However, FMR1 gene expansion is caused by **CGG repeat expansions**, which are **not reliably detected by standard DNA sequencing** (they require Tandem Repeat PCR or similar methods). Since DNA sequencing detected mutations (likely point mutations or SNPs), this aligns with **MTHFR mutation**, as MTHFR is typically caused by small sequence variants (e.g., C677T, A1298C) that DNA sequencing can identify. No further assays are needed\u2014**MTHFR mutation** is confirmed. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 15346, "observations": [null, {"action": "Enzyme assay", "observation": 76.9022336695337}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["Enzyme assay", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 76.9 falls within the 75-100 range, excluding **SERPINA1 mutation** and **G6PD deficiency mutation**. This leaves **FMR1 gene expansion** and **MTHFR mutation** as possibilities. To differentiate between these, **DNA sequencing** is the most direct assay: if no mutations are detected, MTHFR is excluded, leaving FMR1 as the answer. If mutations are found, MTHFR is confirmed. This assay provides a definitive result in one step. \n\n<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing result detected mutations, which does not exclude the MTHFR mutation. Since FMR1 gene expansions (trinucleotide repeats) are not typically identified by standard DNA sequencing, the detected mutation likely corresponds to the MTHFR mutation. This leaves MTHFR as the only plausible remaining option. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 11136, "observations": [null, {"action": "Enzyme assay", "observation": 76.9022336695337}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["Enzyme assay", "Tandem repeat PCR", "RNA sequencing", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result (76.9) excluded **SERPINA1 mutation** and **G6PD deficiency mutation**, leaving **FMR1 gene expansion** and **MTHFR mutation**. To narrow down further, **Tandem repeat PCR** directly tests for FMR1's CGG repeat expansion. If the repeat size is 0-30, FMR1 is excluded, leaving MTHFR as the answer. If the repeat size is 30-200, FMR1 remains possible. This assay offers a clear exclusion step for FMR1, optimizing efficiency. \n\n<ANSWER> Tandem repeat PCR </ANSWER>", "The Tandem repeat PCR result of 191.9 falls within the 30-200 range, which does **not** exclude **FMR1 gene expansion** (per the guidebook). The remaining candidates are **FMR1 gene expansion** and **MTHFR mutation**. To differentiate:  \n- **RNA sequencing** can exclude FMR1 if transcript levels are normal (abnormal levels confirm FMR1).  \n- **DNA sequencing** can exclude MTHFR if no mutation is found.  \n\n**RNA sequencing** is optimal here because FMR1 expansions often silence the gene, leading to abnormal RNA levels. If RNA levels are normal, FMR1 is ruled out, leaving MTHFR as the answer. If abnormal, FMR1 is confirmed. This step resolves the ambiguity efficiently.  \n\n<ANSWER> RNA sequencing </ANSWER>", "The **RNA sequencing** result (\"Abnormal transcript levels\") aligns with **FMR1 gene expansion**, as this mutation silences the gene, leading to abnormal RNA levels. MTHFR mutations do not directly affect FMR1 transcript levels. Since all other mutations have been excluded (SERPINA1 and G6PD via Enzyme assay, and FMR1 remains the only plausible candidate after RNA sequencing), the mutation must be **FMR1 gene expansion**.  \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 25178, "observations": [null, {"action": "Enzyme assay", "observation": 76.9022336695337}, {"action": "Tandem repeat PCR", "observation": 191.90786929412837}, {"action": "RNA sequencing", "observation": "Abnormal transcript levels"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 76.9 (within 75-100) excludes **SERPINA1 mutation** and **G6PD deficiency mutation**, leaving **FMR1 gene expansion** and **MTHFR mutation**. To distinguish between these, the most efficient assay is **DNA sequencing**, as it directly checks for mutations in the MTHFR gene. If no mutations are detected, MTHFR is excluded, confirming FMR1. If mutations are found, MTHFR is confirmed. This approach resolves the diagnosis in the fewest steps. \n\n<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing result \"Mutations detected\" confirms the presence of an **MTHFR mutation**, as this assay directly identifies mutations in the MTHFR gene. The FMR1 gene expansion (a trinucleotide repeat) would not be detected by standard DNA sequencing. Since SERPINA1 and G6PD mutations were already excluded by the Enzyme assay, the only remaining possibility is **MTHFR mutation**. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 12625, "observations": [null, {"action": "Enzyme assay", "observation": 76.9022336695337}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["Enzyme assay", "High-resolution melt analysis (HRM)", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 76.9 (75-100 range) excludes **SERPINA1 mutation** and **G6PD deficiency mutation**, leaving **FMR1 gene expansion** and **MTHFR mutation**. To distinguish between these, **High-resolution melt analysis (HRM)** is optimal. If HRM shows **no melting curve abnormalities**, MTHFR is excluded, confirming FMR1. If abnormalities are detected, MTHFR is confirmed. This assay efficiently narrows down the options in one step. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "The HRM result (no abnormalities) excludes **MTHFR mutation**, leaving only **FMR1 gene expansion** as the remaining mutation. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 8673, "observations": [null, {"action": "Enzyme assay", "observation": 76.9022336695337}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}], "seed": 10, "average_actions": 4.2, "average_tokens": 14591.6, "average_correct": 0.4, "average_parse_error": 0.0, "average_successful_action_num": 4.5, "average_successful_tokens": 16925.5}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Southern blot", "Methylation-specific PCR", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "<ANSWER> Southern blot </ANSWER>", "The remaining mutations after MLPA and Southern blot are **MECP2 mutation** and **LEP mutation**. To distinguish between them:  \n- **Methylation-specific PCR** can rule out **MECP2 mutation** if methylation is normal.  \n- **ELISA** can rule out **LEP mutation** if leptin levels are normal (0\u201325).  \n\nChoosing **Methylation-specific PCR** next will directly test for MECP2. If the result shows abnormal methylation, MECP2 is confirmed. If normal, LEP mutation is the answer. This minimizes steps by focusing on DNA-based assays first, following the prior workflow.  \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The previous steps have ruled out **FMR1 gene expansion** (Southern blot normal), **PMP22 duplication** (MLPA normal), and **MECP2 mutation** (methylation PCR normal). Only **LEP mutation** remains. While ELISA could confirm this (low leptin levels would support LEP mutation), no further assays are logically required since all other mutations have been eliminated. The final answer is **LEP mutation**.  \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 19506, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "After performing the **Southern blot** and observing a **normal-sized fragment**, **FMR1 gene expansion** is ruled out. The remaining mutations are **MECP2 mutation**, **LEP mutation**, and **PMP22 duplication**. To narrow down further, **MLPA** is the most strategic next step. If MLPA shows a **normal copy number**, it eliminates **PMP22 duplication**, leaving **MECP2 mutation** and **LEP mutation**. This reduces the remaining possibilities efficiently, allowing subsequent steps to focus on distinguishing between the two. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "After the **MLPA** result showed a **normal copy number**, **PMP22 duplication** is ruled out. The remaining mutations are **MECP2 mutation** and **LEP mutation**. To distinguish between these, the next logical step is **Methylation-specific PCR**. If it shows a **normal methylation pattern**, **MECP2 mutation** is excluded, leaving **LEP mutation** as the answer. Alternatively, if the methylation pattern is abnormal, **MECP2 mutation** is confirmed. This assay directly targets one of the remaining mutations, making it the most efficient choice. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The **Methylation-specific PCR** result showing a **normal methylation pattern** rules out **MECP2 mutation**. The only remaining mutation is **LEP mutation**, which can be confirmed by the **ELISA** assay (low leptin levels). However, since all other mutations have been systematically excluded, **LEP mutation** is the only plausible answer. No further assays are necessary. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 18497, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "ELISA", "Methylation-specific PCR", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "To determine the remaining mutation between MECP2 and LEP, the next assay should directly test one of these. **ELISA** measures leptin levels, which would rule out LEP mutation if the result is within the normal range (0\u201325). If leptin levels are abnormal, LEP mutation is confirmed. This approach efficiently narrows down the remaining options in one step. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result (82.58) is **outside the normal range (0\u201325)**, which does **not** rule out LEP mutation according to the guidebook. However, LEP mutations typically cause **low leptin**, not elevated levels. This inconsistency suggests the high leptin result might not directly confirm LEP mutation. The remaining possibilities are **MECP2** and **LEP**. To resolve this, perform **Methylation-specific PCR** to check for MECP2 mutation. If methylation is normal, LEP mutation is confirmed despite the atypical leptin level; if abnormal, MECP2 mutation is the answer.\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The **Methylation-specific PCR** result (\"Normal methylation pattern\") rules out **MECP2 mutation**, as per the guidebook. Despite the **unusually high leptin level (82.58)**, all other mutations (FMR1, PMP22, MECP2) have been excluded. While LEP mutations typically cause **low leptin**, the assay logic leaves **LEP mutation** as the only remaining possibility. The high leptin might indicate an atypical scenario (e.g., leptin resistance), but the systematic elimination of options confirms **LEP mutation** as the answer. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 21716, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "ELISA", "observation": 82.58503156561314}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "After performing the Southern blot and ruling out **FMR1 gene expansion**, the remaining mutations are MECP2 mutation, LEP mutation, and PMP22 duplication. The next logical step is to use **MLPA** to check for PMP22 duplication. If MLPA shows a normal copy number, PMP22 duplication is excluded, narrowing the possibilities to MECP2 or LEP. This approach efficiently reduces the remaining candidates by targeting a mutation with multiple available assays (MLPA, FISH, or karyotyping) while prioritizing direct copy-number analysis. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "After ruling out **FMR1 gene expansion** (via Southern blot) and **PMP22 duplication** (via MLPA), the remaining candidates are **MECP2 mutation** and **LEP mutation**. To differentiate between these, the next logical step is to perform **Methylation-specific PCR**, which directly evaluates the methylation status of MECP2. If the result shows a **normal methylation pattern**, MECP2 mutation is excluded, leaving LEP mutation as the only plausible answer. If the methylation pattern is abnormal, MECP2 mutation is confirmed. This approach efficiently targets the remaining mutations with a single assay. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The **Methylation-specific PCR** result (normal methylation pattern) ruled out **MECP2 mutation**. All other mutations (**FMR1 gene expansion**, **PMP22 duplication**, **MECP2 mutation**) have been excluded through prior assays, leaving **LEP mutation** as the only remaining possibility. Since no further assays are needed to confirm this elimination, the correct answer is:\n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 23567, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["<ANSWER> Southern blot </ANSWER>", "The Southern blot result ruled out FMR1 gene expansion. To narrow down the remaining mutations (MECP2, LEP, PMP22), **Multiplex ligation-dependent probe amplification (MLPA)** is the optimal next assay. If MLPA shows a normal copy number, PMP22 duplication is excluded, leaving MECP2 and LEP. If a duplication is detected, PMP22 duplication is confirmed. This step efficiently targets PMP22 duplication, which can be ruled out with a single assay, streamlining the process. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The previous assays ruled out FMR1 gene expansion (Southern blot) and PMP22 duplication (MLPA). The remaining mutations are **MECP2 mutation** and **LEP mutation**. To differentiate between them, **Methylation-specific PCR** directly tests for MECP2 methylation status. If methylation is normal, MECP2 is excluded, leaving LEP mutation as the answer. If abnormal, MECP2 is confirmed. This step efficiently targets one of the two remaining mutations, resolving the diagnosis in one assay. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "The Southern blot (ruled out FMR1), MLPA (ruled out PMP22 duplication), and Methylation-specific PCR (ruled out MECP2 mutation) have eliminated three possibilities. Only **LEP mutation** remains. ELISA could confirm low leptin levels, but since all other mutations are excluded, LEP mutation is definitively the answer. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 23636, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}], "seed": 11, "average_actions": 5.2, "average_tokens": 21384.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.2, "average_successful_tokens": 21384.4}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "After performing MLPA with a normal copy number result, PMP22 duplication is ruled out. The remaining mutations are SERPINA1, DMD, and PAH. The **Enzyme assay** is the most efficient next step because it can eliminate two mutations at once. If enzyme activity is between 75-100%, both SERPINA1 and PAH mutations are excluded, leaving DMD as the answer. If activity is low (0-25%), further assays like PCR or Protein Truncation Test could follow, but Enzyme assay offers the highest potential to resolve the case in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 91.53% activity (75-100% range) **rules out both SERPINA1 and PAH mutations**, leaving **DMD mutation** as the only remaining possibility. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 12869, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 91.53302714680002}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "<ANSWER> Enzyme assay </ANSWER>", "The MLPA assay ruled out PMP22 duplication (normal copy number). The enzyme assay result of 91.5 (75\u2013100 range) excluded both SERPINA1 and PAH mutations. The only remaining possibility is **DMD mutation**, as no further assays are needed to confirm after eliminating the others. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 12567, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 91.53302714680002}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 91.5 (within 75\u2013100) rules out **SERPINA1** and **PAH mutations**, leaving **DMD mutation** and **PMP22 duplication** as possibilities. To differentiate between these, the most efficient next step is **Multiplex ligation-dependent probe amplification (MLPA)**, which directly tests for copy number variations (e.g., PMP22 duplication). If MLPA shows a duplication, PMP22 is confirmed; if normal, DMD is the answer. This resolves the case in one step. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The MLPA result (normal copy number) rules out **PMP22 duplication**, leaving **DMD mutation** as the only remaining possibility. No further assays are needed since all other mutations have been excluded. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 14564, "observations": [null, {"action": "Enzyme assay", "observation": 91.53302714680002}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "The MLPA result ruled out PMP22 duplication. The remaining mutations are SERPINA1, DMD, and PAH. The **enzyme assay** can efficiently narrow down the options: if enzyme activity is 75-100%, both SERPINA1 and PAH mutations are excluded, leaving DMD as the answer. If activity is low (0-25%), further testing would be needed, but this assay offers the highest chance of resolving the case in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "The enzyme assay result of 91.53% (within the 75-100% range) **rules out both SERPINA1 and PAH mutations**, leaving **DMD mutation** as the only remaining possibility. No further assays are required. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 15760, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 91.53302714680002}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "After performing the MLPA assay and observing a **normal copy number**, PMP22 duplication is ruled out. The remaining mutations are **SERPINA1 mutation**, **DMD mutation**, and **PAH mutation**. To narrow down further, the **Enzyme assay** is the most strategic next step. If the enzyme activity is **75\u2013100**, both SERPINA1 and PAH mutations are excluded (leaving DMD as the only option). If activity is **0\u201325**, no mutations are ruled out, but this would guide subsequent steps toward DMD-specific assays (e.g., PCR or Western blot). This approach minimizes steps by potentially resolving the case in two rounds if the enzyme activity is high. \n\n<ANSWER> Enzyme assay </ANSWER>", "The enzyme assay result of **91.53** (within the 75\u2013100 range) rules out **SERPINA1 mutation** and **PAH mutation**, leaving **DMD mutation** as the only remaining possibility. No further assays are needed since all other mutations have been excluded. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 17902, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 91.53302714680002}], "successful": true, "parse_error": false}], "seed": 12, "average_actions": 4.0, "average_tokens": 14732.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 14732.4}
{"trajectories": [{"actions": ["DNA sequencing", "RFLP analysis", "Methylation-specific PCR", "PCR amplification", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "After performing DNA sequencing and detecting mutations, HBB and GJB2 remain possible since DNA sequencing only rules them out if no mutations are found. To differentiate between these, RFLP analysis is the most efficient next step. If the RFLP result shows a normal restriction pattern, HBB is ruled out (leaving GJB2). If abnormal, HBB is confirmed. This approach minimizes steps by directly targeting the remaining candidates.\n\n<ANSWER> RFLP analysis </ANSWER>", "After RFLP analysis ruled out HBB mutation, the remaining possibilities are DMD, GJB2, and UBE3A mutations. To narrow this down, **Methylation-specific PCR** is the optimal next assay. A normal methylation pattern would eliminate UBE3A (as per the guidebook), leaving DMD and GJB2. If abnormal, UBE3A remains possible. This step efficiently targets one of the remaining mutations, allowing further elimination in subsequent steps. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After ruling out HBB (via RFLP) and UBE3A (via normal methylation), the remaining candidates are **DMD** and **GJB2**. To differentiate between them, **PCR amplification** is the optimal assay. If a fragment is amplified, DMD is ruled out (leaving GJB2). If no amplification, DMD is confirmed. This directly targets the remaining mutations in the fewest steps.  \n\n<ANSWER> PCR amplification </ANSWER>", "The previous steps eliminated HBB (RFLP), UBE3A (methylation PCR), and DMD (PCR amplification). Only **GJB2 mutation** remains. No further assays are needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 25760, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "PCR amplification", "observation": "Fragment amplified"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "RFLP analysis", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "After performing DNA sequencing and detecting mutations, both HBB and GJB2 mutations remain possible (since only a \"no mutations detected\" result would rule them out). To narrow down the remaining options (DMD, GJB2, UBE3A, HBB), **RFLP analysis** is the next logical step. If the RFLP result shows a **normal restriction pattern**, the HBB mutation is ruled out. If the restriction pattern is abnormal, HBB remains possible. This assay directly targets HBB, allowing efficient elimination of one candidate mutation and streamlining subsequent steps. \n\n<ANSWER> RFLP analysis </ANSWER>", "After performing DNA sequencing and RFLP analysis, the results narrow the possibilities:  \n- **DNA sequencing** detected mutations, leaving HBB and GJB2 as potential candidates (though other mutations like DMD and UBE3A were not ruled out).  \n- **RFLP analysis** (normal restriction pattern) definitively ruled out **HBB mutation**.  \n\nThe remaining options are **DMD, GJB2, and UBE3A**. However, since DNA sequencing specifically checks for mutations in **HBB and GJB2**, and HBB is already excluded, the detected mutation in DNA sequencing **must correspond to GJB2**. This conclusion aligns with the assay outcomes, leaving **GJB2 mutation** as the only plausible answer.  \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 17412, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "RFLP analysis", "Methylation-specific PCR", "PCR amplification", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "To identify the mutation efficiently after DNA sequencing detected mutations (which didn't rule out any options), the next logical step is to use **RFLP analysis**. This assay can eliminate **HBB mutation** if a normal restriction pattern is observed. If the result is abnormal, HBB remains possible. Choosing RFLP here directly targets another candidate (HBB) and narrows the possibilities effectively. \n\n<ANSWER> RFLP analysis </ANSWER>", "After RFLP analysis ruled out the **HBB mutation**, the remaining possibilities are **DMD mutation**, **GJB2 mutation**, and **UBE3A mutation**. To efficiently narrow down the options, **Methylation-specific PCR** is the optimal next assay. If the result shows a **normal methylation pattern**, **UBE3A mutation** is excluded, leaving **DMD** and **GJB2**. If the methylation pattern is abnormal, further tests would focus on ruling out DMD (e.g., PCR amplification or Western blot). This step directly targets UBE3A and simplifies the remaining analysis.  \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After ruling out HBB and UBE3A mutations, the remaining candidates are **DMD** and **GJB2**. To distinguish between them, **PCR amplification** is the most efficient assay. If a fragment is amplified, DMD is excluded (as intact DNA suggests no deletion/mutation in the DMD gene), leaving **GJB2 mutation** as the answer. If no amplification occurs, DMD is confirmed. This step directly targets the remaining possibilities and resolves the ambiguity in one move.  \n\n<ANSWER> PCR amplification </ANSWER>", "After PCR amplification successfully amplified a fragment, **DMD mutation** is ruled out. This leaves only **GJB2 mutation** as the remaining possibility, as HBB, UBE3A, and DMD have already been excluded by prior assays. No further testing is necessary. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 28325, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "PCR amplification", "observation": "Fragment amplified"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "RFLP analysis", "Methylation-specific PCR", "Western blot", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "After performing DNA sequencing and finding mutations, none of the mutations are ruled out. The next step is to select an assay that can eliminate one of the remaining possibilities efficiently. **RFLP analysis** is a strong candidate because a normal restriction pattern would rule out **HBB mutation**, narrowing the list to three mutations (DMD, GJB2, UBE3A). This choice systematically targets HBB, which can only be excluded via RFLP or DNA sequencing (which already detected mutations). Eliminating HBB first simplifies subsequent steps. \n\n<ANSWER> RFLP analysis </ANSWER>", "After ruling out the **HBB mutation** with a normal RFLP result, the remaining possibilities are **DMD mutation**, **GJB2 mutation**, and **UBE3A mutation**. To efficiently narrow down further:  \n\n- **Methylation-specific PCR** is the optimal next assay. If it shows a **normal methylation pattern**, **UBE3A mutation** is ruled out, leaving DMD and GJB2. If the methylation pattern is abnormal, UBE3A remains possible. This test directly targets UBE3A, which cannot be ruled out by other remaining assays (e.g., Western blot or PCR amplification target DMD instead). Eliminating UBE3A first simplifies the remaining steps.  \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After ruling out **UBE3A** and **HBB mutations**, the remaining possibilities are **DMD** and **GJB2 mutations**. To distinguish between them:  \n\n- **Western blot** directly tests for the presence of dystrophin protein. If the protein is detected (normal size), **DMD mutation is ruled out**, leaving **GJB2** as the answer. If absent/truncated, **DMD mutation** is confirmed. This assay provides definitive evidence for DMD status.  \n\nAlternatively, PCR amplification could also rule out DMD if a fragment is amplified, but Western blot is more directly linked to the functional consequence of a DMD mutation.  \n\n<ANSWER> Western blot </ANSWER>", "The **Western blot** result (\"Protein of expected size detected\") rules out the **DMD mutation**, leaving **GJB2 mutation** as the only remaining possibility. All other mutations have been eliminated through prior assays. No further assays are needed.  \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 24306, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "RFLP analysis", "Methylation-specific PCR", "PCR amplification", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "To identify the mutation efficiently, the next step should focus on ruling out **HBB mutation** using **RFLP analysis**. If the restriction pattern is normal, HBB is eliminated. If abnormal, HBB remains possible. This test directly targets HBB and reduces the remaining candidates by one if successful. \n\n<ANSWER> RFLP analysis </ANSWER>", "After the RFLP analysis ruled out the HBB mutation, the remaining possibilities are **DMD mutation**, **GJB2 mutation**, and **UBE3A mutation**. To narrow this down efficiently, the next optimal step is to use **Methylation-specific PCR**. If the result shows a **normal methylation pattern**, **UBE3A mutation** can be eliminated, leaving only DMD and GJB2 for further testing. This approach directly targets UBE3A and reduces the remaining candidates to two, streamlining subsequent steps.\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "After ruling out UBE3A and HBB mutations, the remaining candidates are **DMD mutation** and **GJB2 mutation**. To distinguish between these, **PCR amplification** is the most efficient next step. If the assay amplifies a fragment, DMD mutation is ruled out (as intact DNA suggests normal dystrophin gene structure), leaving **GJB2 mutation** as the answer. If no amplification occurs, DMD mutation remains plausible. This test directly targets DMD and resolves the final ambiguity. \n\n<ANSWER> PCR amplification </ANSWER>", "The **PCR amplification** result (fragment amplified) rules out **DMD mutation**, leaving **GJB2 mutation** as the only remaining candidate. All other mutations have been systematically eliminated through previous assays. No further testing is required. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 23402, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "PCR amplification", "observation": "Fragment amplified"}], "successful": true, "parse_error": false}], "seed": 13, "average_actions": 5.6, "average_tokens": 23841.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.6, "average_successful_tokens": 23841.0}
{"trajectories": [{"actions": ["Karyotyping", "DNA sequencing", "High-resolution melt analysis (HRM)", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["<ANSWER> Karyotyping </ANSWER>", "<ANSWER> DNA sequencing </ANSWER>", "After ruling out PMP22 duplication (via karyotyping) and confirming mutations via DNA sequencing (leaving CFTR or HBB), the next step is to differentiate between CFTR and HBB. Using High-resolution melt analysis (HRM) can exclude CFTR if no abnormalities are found. This efficiently narrows down to the remaining mutation in the fewest steps.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After performing HRM and ruling out CFTR mutation, the remaining possibilities were HBB and DMD. However, DNA sequencing detected mutations, which only applies to CFTR and HBB (as per the guidebook). Since CFTR is already excluded, the mutation must be in HBB. No further assays are needed. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 18540, "observations": [null, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "After DNA sequencing detected mutations, CFTR and HBB mutations remain possible. To differentiate between them, **High-resolution melt analysis (HRM)** can exclude CFTR if no abnormalities are found. Choosing HRM next efficiently narrows down the remaining candidates. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After DNA sequencing detected mutations, the remaining candidates were CFTR and HBB. HRM ruled out CFTR, leaving HBB as the only plausible mutation. Since DNA sequencing directly detects mutations in CFTR and HBB (per the guidebook), and PMP22 duplication/DMD are not detectable via sequencing, they are excluded when mutations are found. Thus, **HBB mutation** is the answer. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 15449, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Karyotyping", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After DNA sequencing detected mutations and HRM ruled out CFTR, the remaining possibilities are HBB mutation, PMP22 duplication, and DMD mutation. Karyotyping can exclude PMP22 duplication if the result is normal. This step efficiently narrows down the remaining candidates, allowing subsequent tests to focus on HBB or DMD if necessary. \n\n<ANSWER> Karyotyping </ANSWER>", "After DNA sequencing detected mutations (implying either CFTR or HBB), HRM ruled out CFTR, and karyotyping excluded PMP22 duplication. The remaining candidates are **HBB mutation** and **DMD mutation**. However, DNA sequencing specifically targets CFTR and HBB, so the detected mutation must be in HBB (since CFTR is excluded). DMD is unrelated to the DNA sequencing result here. Thus, the only plausible mutation is **HBB mutation**. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 23132, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "Karyotyping", "observation": "Normal karyotype"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "After DNA sequencing detected mutations, CFTR and HBB mutations are possible. To differentiate, using HRM can check for CFTR mutations. If HRM shows no abnormalities, CFTR is excluded, leaving HBB. If abnormalities are present, CFTR is confirmed. This efficiently narrows down the remaining candidates.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After DNA sequencing detected mutations, CFTR and HBB mutations were possible. HRM then excluded CFTR mutations, leaving HBB as the only remaining candidate from that subset. However, PMP22 duplication and DMD mutation were not yet addressed. Since DNA sequencing detects small mutations (like HBB) but not large duplications (PMP22) or deletions (DMD), further tests would typically be needed. However, the game's logic implies that DNA sequencing's detection of mutations directly points to HBB (as CFTR is excluded), assuming PMP22 and DMD are ruled out by prior steps. Thus, **HBB mutation** is the only plausible remaining option. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 15883, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Karyotyping", "PCR amplification", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing detected mutations, so CFTR and HBB remain possible (since only their absence would exclude them). To differentiate between these, **High-resolution melt analysis (HRM)** can rule out CFTR if no melting curve abnormalities are observed. If HRM shows abnormalities, CFTR is confirmed; if not, HBB is the answer. This narrows the possibilities efficiently.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After HRM ruled out CFTR, the remaining possibilities are HBB mutation, PMP22 duplication, and DMD mutation. **Karyotyping** can directly check for PMP22 duplication. If karyotyping shows a normal result, PMP22 duplication is excluded, leaving HBB and DMD. If duplication is detected, PMP22 is confirmed. This efficiently narrows the options in one step. \n\n<ANSWER> Karyotyping </ANSWER>", "After excluding CFTR (via HRM) and PMP22 duplication (via karyotyping), the remaining candidates are **HBB mutation** and **DMD mutation**. To differentiate between them, **PCR amplification** is the most efficient assay. If PCR successfully amplifies the fragment, DMD is ruled out (leaving HBB as the answer). If amplification fails, DMD is confirmed. This step directly resolves the remaining ambiguity in one test.\n\n<ANSWER> PCR amplification </ANSWER>", "After performing PCR amplification and successfully amplifying the fragment, the **DMD mutation** is excluded (as per the guidebook). The remaining mutation is **HBB mutation**, which is the only plausible candidate. All other mutations (CFTR, PMP22 duplication, DMD) have been systematically ruled out through prior assays. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 18062, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "PCR amplification", "observation": "Fragment amplified"}], "successful": true, "parse_error": false}], "seed": 14, "average_actions": 4.8, "average_tokens": 18213.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.8, "average_successful_tokens": 18213.2}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "High-resolution melt analysis (HRM)", "TaqMan assay", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "To systematically identify the mutation, the next logical step is to use **Fluorescence in situ hybridization (FISH)**. If FISH detects no deletions, PMP22 duplication is ruled out, narrowing the possibilities to BRCA1, BRCA2, and MTHFR. If deletions are detected, PMP22 remains a candidate. This approach efficiently targets a mutation (PMP22) that can be ruled out with a single test, streamlining further steps. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After performing FISH and ruling out PMP22 duplication, the remaining mutations are BRCA1, BRCA2, and MTHFR. To narrow this down, **High-resolution melt analysis (HRM)** is the most strategic choice. If HRM shows no melting curve abnormalities, MTHFR mutation is ruled out, leaving BRCA1 and BRCA2. If abnormalities are detected, MTHFR remains a candidate. This approach efficiently targets MTHFR, which can be excluded with a single test, streamlining the process toward identifying the remaining mutation. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out PMP22 duplication (via FISH) and MTHFR mutation (via HRM), the remaining candidates are **BRCA1** and **BRCA2** mutations. To distinguish between these, the **TaqMan assay** is optimal. If the TaqMan assay shows *no amplification with the mutant probe*, BRCA1 is ruled out, leaving BRCA2 as the answer. If amplification occurs, BRCA1 is confirmed. This approach efficiently resolves the remaining ambiguity with one final test. \n\n<ANSWER> TaqMan assay </ANSWER>", "After ruling out **PMP22 duplication** (via FISH), **MTHFR mutation** (via HRM), and **BRCA1 mutation** (via TaqMan assay), the only remaining candidate is **BRCA2 mutation**. No further assays are needed, as all other mutations have been systematically excluded. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 23588, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "Mass spectrometry genotyping", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After ruling out PMP22 duplication with FISH and knowing BRCA1/BRCA2 and MTHFR are still possible, the next step is to test for MTHFR. **Mass spectrometry genotyping** can directly confirm or rule out MTHFR mutations. If no mass shifts are detected, MTHFR is eliminated, narrowing it to BRCA1/BRCA2. If mass shifts are present, MTHFR is the answer. This approach minimizes steps by targeting MTHFR first.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "After performing the Mass spectrometry genotyping and observing mass shifts, the MTHFR mutation is indicated. Since PMP22 duplication was already ruled out by FISH and the remaining options (BRCA1, BRCA2, MTHFR) were narrowed down, the Mass spectrometry result directly implicates MTHFR as the mutation. No further assays are needed to confirm this, as the detection of mass shifts in this context specifically points to MTHFR. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 22770, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}], "successful": false, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "High-resolution melt analysis (HRM)", "TaqMan assay", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "The next step is to use High-resolution melt analysis (HRM) to check for MTHFR mutation. If the result is normal, MTHFR is ruled out, narrowing the possibilities to BRCA1 and BRCA2. If abnormal, MTHFR remains a candidate. This approach efficiently targets one of the remaining mutations to minimize further steps.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out PMP22 duplication (via FISH) and MTHFR mutation (via HRM), the remaining candidates are **BRCA1** and **BRCA2**. To distinguish between them:  \n- **TaqMan assay** can directly test for BRCA1 mutation. If no amplification occurs, BRCA1 is eliminated, leaving BRCA2 as the answer.  \n- **Western blot** could also rule out BRCA1 by confirming the presence of its protein.  \n\nSince the TaqMan assay provides a direct mutation-specific result for BRCA1, it is the most efficient next step. If BRCA1 is ruled out, the remaining mutation is BRCA2.  \n\n<ANSWER> TaqMan assay </ANSWER>", "After systematically ruling out **PMP22 duplication (FISH)**, **MTHFR mutation (HRM)**, and **BRCA1 mutation (TaqMan assay)**, the only remaining candidate is **BRCA2 mutation**. No further assays are required.  \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 26540, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "High-resolution melt analysis (HRM)", "TaqMan assay", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "To systematically eliminate possibilities after NGS detected variants, the next logical step is to use **Fluorescence in situ hybridization (FISH)**. If FISH shows \"No deletions detected,\" PMP22 duplication is ruled out, narrowing the list to BRCA1, BRCA2, and MTHFR. If \"Deletion detected,\" PMP22 remains possible. This assay efficiently targets a mutation (PMP22 duplication) that cannot be addressed by other assays, streamlining subsequent steps. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After FISH ruled out PMP22 duplication, the remaining candidates are BRCA1, BRCA2, and MTHFR mutations. To proceed efficiently, **High-resolution melt analysis (HRM)** is optimal. If HRM shows *no melting curve abnormalities*, MTHFR mutation is excluded, leaving BRCA1 and BRCA2. If abnormalities are detected, MTHFR remains possible. This assay directly targets MTHFR, avoiding redundant testing (e.g., NGS already detected variants but cannot resolve MTHFR conclusively). \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out PMP22 duplication (via FISH) and MTHFR mutation (via HRM), the remaining candidates are **BRCA1** and **BRCA2 mutations**. The **TaqMan assay** directly targets BRCA1: if there is *no amplification with the mutant probe*, BRCA1 is ruled out, leaving BRCA2 as the only possibility. If amplification occurs, BRCA1 is confirmed. This assay provides a decisive step to distinguish between the two BRCA mutations efficiently. \n\n<ANSWER> TaqMan assay </ANSWER>", "After the TaqMan assay ruled out BRCA1 mutation (no amplification with mutant probe), only **BRCA2 mutation** remains. All other mutations (PMP22 duplication, MTHFR, BRCA1) have been conclusively excluded through prior assays. No further testing is necessary. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 21775, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "High-resolution melt analysis (HRM)", "TaqMan assay", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "The previous NGS result (\"Variants detected\") did not rule out any mutations, leaving all four possibilities. To systematically narrow down, the next logical step is to use **Fluorescence in situ hybridization (FISH)**. If FISH shows \"No deletions detected,\" PMP22 duplication is ruled out, reducing the options to BRCA1, BRCA2, and MTHFR. If \"Deletion detected,\" PMP22 remains possible. This assay directly targets one mutation (PMP22) efficiently. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "After ruling out PMP22 duplication with FISH, the remaining possibilities are BRCA1, BRCA2, and MTHFR mutations. The next step should focus on **MTHFR mutation** since it can be efficiently ruled out using **High-resolution melt analysis (HRM)**. If HRM shows no melting curve abnormalities, MTHFR is eliminated, narrowing the list to BRCA1 and BRCA2. If HRM detects abnormalities, MTHFR remains possible, requiring further assays. HRM directly targets one mutation (MTHFR), making it the most strategic choice here.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "After ruling out MTHFR and PMP22 duplication, the remaining mutations are BRCA1 and BRCA2. To differentiate between them, the **TaqMan assay** directly targets BRCA1. If the result shows \"No amplification with mutant probe,\" BRCA1 is ruled out, leaving BRCA2 as the answer. If amplification occurs, BRCA1 is confirmed. This assay efficiently narrows the options in one step. \n\n<ANSWER> TaqMan assay </ANSWER>", "After ruling out PMP22 duplication (via FISH), MTHFR mutation (via HRM), and BRCA1 mutation (via TaqMan assay), the only remaining possibility is **BRCA2 mutation**. No further assays are needed, as all other mutations have been systematically excluded. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 30359, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}], "successful": true, "parse_error": false}], "seed": 15, "average_actions": 5.8, "average_tokens": 25006.4, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 25565.5}
{"trajectories": [{"actions": ["Enzyme assay", "Allele-specific oligonucleotide hybridization", "ELISA", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 82.41 rules out PAH and SERPINA1 mutations (activity 75-100). Remaining candidates are LEP and GJB2. To differentiate, **Allele-specific oligonucleotide hybridization** directly tests for GJB2: if no hybridization occurs, GJB2 is ruled out (confirming LEP); if hybridization occurs, GJB2 is confirmed. This assay resolves the remaining options in one step. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "The Allele-specific oligonucleotide hybridization result (\"Hybridization with mutant probe\") does not rule out GJB2 mutation. The remaining candidates are **LEP** and **GJB2**. To distinguish between them, **ELISA** is optimal: a low signal (0-25) rules out LEP, leaving GJB2 as the answer. A high signal (75-100) would require further testing, but ELISA provides a direct path to resolution. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result of 20.37 (low signal intensity 0-25) rules out **LEP mutation**. The only remaining candidate is **GJB2 mutation**, which matches the earlier Allele-specific hybridization result (hybridization occurred, not ruling it out). No further assays are needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 20695, "observations": [null, {"action": "Enzyme assay", "observation": 82.41493409537593}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}, {"action": "ELISA", "observation": 20.372778984729823}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "DNA sequencing", "Allele-specific oligonucleotide hybridization", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 82.4 rules out PAH and SERPINA1 mutations. Remaining possibilities are LEP and GJB2. DNA sequencing can definitively identify GJB2: if no mutations are detected, GJB2 is excluded (confirming LEP); if mutations are found, GJB2 is the answer. This assay efficiently narrows down to the correct mutation in one step. \n\n<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing result detected mutations but didn't rule out any options. The remaining candidates are **LEP** and **GJB2**. To distinguish between them, **Allele-specific oligonucleotide hybridization** directly tests for GJB2 mutations. If hybridization occurs, GJB2 is confirmed; if not, LEP remains. This assay resolves the ambiguity in one step, making it the most efficient choice. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "The **Allele-specific oligonucleotide hybridization** result showed hybridization with the mutant probe, which **confirms the presence of a GJB2 mutation** (since this assay directly detects GJB2 mutations and does not rule it out when hybridization occurs). No other mutations remain plausible after prior eliminations. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 11560, "observations": [null, {"action": "Enzyme assay", "observation": 82.41493409537593}, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "DNA sequencing", "Allele-specific oligonucleotide hybridization", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 82.41 falls into the 75-100 range, ruling out **PAH mutation** and **SERPINA1 mutation**. The remaining candidates are **LEP mutation** and **GJB2 mutation**. To differentiate between these, **DNA sequencing** is the most efficient next step:  \n- If mutations are detected, **GJB2 mutation** is confirmed.  \n- If no mutations are found, **GJB2 mutation** is excluded, leaving **LEP mutation** as the answer.  \n\nThis minimizes steps, as DNA sequencing can definitively resolve the remaining possibilities in one test.  \n\n<ANSWER> DNA sequencing </ANSWER>", "The DNA sequencing detected mutations, which does not rule out any remaining candidates (**LEP mutation** or **GJB2 mutation**). To resolve this, **Allele-specific oligonucleotide hybridization** directly tests for GJB2:  \n- **No hybridization** would eliminate GJB2, leaving LEP as the answer.  \n- **Hybridization** confirms GJB2.  \n\nThis ensures a definitive result in one step, avoiding ambiguity from other assays like ELISA (which might require additional tests if signal intensity is high).  \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "The **Allele-specific oligonucleotide hybridization** result (\"Hybridization with mutant probe\") confirms the presence of **GJB2 mutation**, as this assay directly detects the mutation via probe hybridization. No other mutations remain plausible after earlier eliminations.  \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 11515, "observations": [null, {"action": "Enzyme assay", "observation": 82.41493409537593}, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Allele-specific oligonucleotide hybridization", "ELISA", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "The Enzyme assay result of 82.4 rules out PAH and SERPINA1 mutations. The remaining candidates are LEP and GJB2. To distinguish between them, **Allele-specific oligonucleotide hybridization** is optimal: if no hybridization occurs, GJB2 is ruled out (leaving LEP); if hybridization occurs, GJB2 is confirmed. This assay directly tests for GJB2, resolving the remaining ambiguity efficiently. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "After performing the **Allele-specific oligonucleotide hybridization**, the observation \"Hybridization with mutant probe\" does **not rule out GJB2 mutation** (as per the guidebook). This leaves **LEP** and **GJB2** as possible candidates. To distinguish between them, **ELISA** is the most efficient next step:  \n\n- If ELISA returns a **low signal (0-25)**, LEP mutation is ruled out (leaving GJB2).  \n- If ELISA returns a **high signal (75-100)**, LEP remains possible, requiring further testing.  \n\nSince the goal is to identify the mutation in the fewest steps, **ELISA** directly addresses the remaining ambiguity between LEP and GJB2.  \n\n<ANSWER> ELISA </ANSWER>", "The **ELISA** result of 20.4 (low signal intensity) **rules out LEP mutation** (per the guidebook). Since **PAH** and **SERPINA1** were already ruled out by the Enzyme assay (82.4), **GJB2 mutation** is the only remaining candidate. No further assays are needed.  \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 15131, "observations": [null, {"action": "Enzyme assay", "observation": 82.41493409537593}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}, {"action": "ELISA", "observation": 20.372778984729823}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Allele-specific oligonucleotide hybridization", "DNA sequencing", "ELISA", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["<ANSWER> Enzyme assay </ANSWER>", "After the enzyme assay ruled out PAH and SERPINA1 mutations, the remaining possibilities are LEP and GJB2. To distinguish between these, the **Allele-specific oligonucleotide hybridization** assay can directly check for GJB2. If there's no hybridization, GJB2 is ruled out (leaving LEP). If hybridization occurs, GJB2 remains a candidate, requiring further steps. This assay provides a clear next step to eliminate one mutation efficiently.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "After the allele-specific assay did not rule out GJB2, the remaining candidates are **LEP mutation** and **GJB2 mutation**. To resolve this, **DNA sequencing** can directly determine if a mutation exists in the GJB2 gene. If sequencing detects a mutation, GJB2 is confirmed. If no mutation is found, GJB2 is ruled out (leaving LEP). This assay provides definitive evidence for one mutation, resolving the case efficiently. \n\n<ANSWER> DNA sequencing </ANSWER>", "After DNA sequencing detected mutations but didn't rule out any options, the remaining candidates are **LEP mutation** and **GJB2 mutation**. To resolve this, **ELISA** can determine if LEP is plausible. If the ELISA signal is low (0-25), LEP is ruled out (confirming GJB2). If the signal is high (75-100), LEP remains possible. Since this assay directly addresses one of the remaining mutations, it is the most efficient next step to narrow down the possibilities. \n\n<ANSWER> ELISA </ANSWER>", "The ELISA result (20.37) rules out **LEP mutation** (since low signal intensity 0-25 excludes LEP). Only **GJB2 mutation** remains. No further assays are needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 28395, "observations": [null, {"action": "Enzyme assay", "observation": 82.41493409537593}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "ELISA", "observation": 20.372778984729823}], "successful": true, "parse_error": false}], "seed": 16, "average_actions": 5.2, "average_tokens": 17459.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.2, "average_successful_tokens": 17459.2}
{"trajectories": [{"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter performing the Enzyme assay with a result of 96.5% activity, both **PAH mutation** and **G6PD deficiency mutation** are ruled out (since normal enzyme activity excludes these). The remaining possibilities are **PMP22 duplication** and **GJB2 mutation**. To differentiate between these, **Multiplex ligation-dependent probe amplification (MLPA)** is the next logical step. If MLPA shows a normal copy number, PMP22 duplication is ruled out, leaving GJB2 mutation as the answer. If a duplication is detected, PMP22 duplication is confirmed. This approach minimizes steps by directly testing for PMP22 duplication.\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe Enzyme assay ruled out PAH and G6PD mutations. The MLPA result (normal copy number) ruled out PMP22 duplication. The only remaining possibility is **GJB2 mutation**, as it is the sole mutation not excluded by the assay outcomes. No further testing is needed since all other options have been eliminated.\n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 10369, "observations": [null, {"action": "Enzyme assay", "observation": 96.49262195482899}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "DNA sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 96.49% activity rules out both **PAH mutation** and **G6PD deficiency mutation**, leaving **PMP22 duplication** and **GJB2 mutation** as possibilities. To resolve between these, the next logical step is to use **DNA sequencing**, which directly tests for GJB2 mutations. If sequencing detects mutations, GJB2 is confirmed; if not, PMP22 duplication would remain. This approach efficiently narrows down the options in one step.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing detected mutations in the **GJB2 gene**, which directly confirms the presence of the **GJB2 mutation**. Since all other mutations (PAH and G6PD) were already ruled out by the enzyme assay, this result conclusively identifies the mutation. No further testing is needed.\n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 7348, "observations": [null, {"action": "Enzyme assay", "observation": 96.49262195482899}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 96.49% activity (75-100% range) rules out **PAH mutation** and **G6PD deficiency mutation**. The remaining possibilities are **PMP22 duplication** and **GJB2 mutation**. To distinguish between these, **Multiplex ligation-dependent probe amplification (MLPA)** is the next logical step. If MLPA shows a normal copy number, PMP22 duplication is ruled out, leaving GJB2 mutation as the answer. If a copy number variation is detected, PMP22 duplication is confirmed. This approach minimizes steps by directly testing for PMP22 duplication first. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result showing a **normal copy number** rules out **PMP22 duplication**. Since the Enzyme assay already ruled out **PAH mutation** and **G6PD deficiency mutation**, the only remaining possibility is **GJB2 mutation**. No further testing is needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 7417, "observations": [null, {"action": "Enzyme assay", "observation": 96.49262195482899}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result (96.49% activity) rules out **PAH mutation** and **G6PD deficiency mutation**, leaving **PMP22 duplication** and **GJB2 mutation** as possibilities. To differentiate between these, **Multiplex ligation-dependent probe amplification (MLPA)** is the optimal next step. A normal copy number result would eliminate PMP22 duplication, leaving GJB2 mutation as the answer. Conversely, detecting a duplication would confirm PMP22 duplication. MLPA directly tests for copy number variations (e.g., duplications), making it the most efficient choice here. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result (normal copy number) rules out **PMP22 duplication**. After the enzyme assay ruled out PAH and G6PD mutations earlier, **GJB2 mutation** remains the only plausible option. No further assays are needed since all other mutations have been eliminated. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 10235, "observations": [null, {"action": "Enzyme assay", "observation": 96.49262195482899}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nSince the Enzyme assay result (96.49% activity) rules out **PAH mutation** and **G6PD deficiency mutation**, the remaining possibilities are **PMP22 duplication** and **GJB2 mutation**. To resolve these, the **Multiplex ligation-dependent probe amplification (MLPA)** assay can check for copy number variations in PMP22. If MLPA shows a normal copy number, PMP22 duplication is ruled out, leaving GJB2 mutation. If a duplication is detected, PMP22 duplication is confirmed. This assay efficiently narrows down the remaining options. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe Enzyme assay ruled out PAH and G6PD deficiency, leaving PMP22 duplication and GJB2 mutation. The subsequent MLPA result (normal copy number) ruled out PMP22 duplication. Since only **GJB2 mutation** remains, no further assays are needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 6984, "observations": [null, {"action": "Enzyme assay", "observation": 96.49262195482899}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}], "seed": 17, "average_actions": 4.0, "average_tokens": 8470.6, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 8470.6}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter performing MLPA and Methylation-specific PCR, the normal results have ruled out UBE3A mutation, SMN1 deletion, and MECP2 mutation. The only remaining possibility is CFTR mutation. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 8566, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result ruled out UBE3A mutation and SMN1 deletion, leaving CFTR mutation and MECP2 mutation. Methylation-specific PCR can exclude MECP2 mutation if the methylation pattern is normal. If methylation is normal, CFTR mutation remains; if abnormal, MECP2 is confirmed. This assay efficiently narrows down the remaining candidates. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe MLPA ruled out UBE3A and SMN1. Methylation-specific PCR ruled out MECP2. Only CFTR mutation remains. No further assays are needed. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 11213, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter performing MLPA and Methylation-specific PCR, the results have ruled out UBE3A mutation, SMN1 deletion (via MLPA), and MECP2 mutation (via Methylation-specific PCR). The only remaining possibility is **CFTR mutation**, which is not excluded by any of the previous test outcomes. No further assays are needed.\n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 8104, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Methylation-specific PCR", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay with a normal copy number ruled out UBE3A mutation and SMN1 deletion. Remaining possibilities are CFTR mutation and MECP2 mutation. To differentiate between these, **Methylation-specific PCR** is the optimal next step. A normal methylation pattern would rule out MECP2 mutation, leaving CFTR mutation as the answer. If abnormal, MECP2 mutation remains possible. This assay directly addresses one of the two remaining mutations, narrowing the options efficiently. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe normal methylation pattern from Methylation-specific PCR rules out MECP2 mutation. With UBE3A and SMN1 already excluded by the previous MLPA result, the only remaining mutation is CFTR. No further assays are needed. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 8633, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Splice-site analysis", "High-resolution melt analysis (HRM)", "Methylation-specific PCR", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter the MLPA result ruled out UBE3A mutation and SMN1 deletion, the remaining possibilities are **CFTR mutation** and **MECP2 mutation**. \n\nTo distinguish between these two, **Splice-site analysis** is the most efficient next step:\n- A **normal result** would rule out CFTR mutation, leaving MECP2 mutation as the answer.  \n- An **abnormal result** would confirm CFTR mutation.  \n\nThis assay directly targets CFTR and provides a conclusive answer in one step. \n\n<ANSWER> Splice-site analysis </ANSWER>", "\n\nAfter the splice-site analysis detected abnormalities, **CFTR mutation** remains a strong candidate. However, **MECP2 mutation** is still possible. To differentiate between them, **High-resolution melt analysis (HRM)** is the most efficient next step:  \n- **Normal HRM result** would rule out CFTR mutation, leaving MECP2 mutation as the answer.  \n- **Abnormal HRM result** confirms CFTR mutation.  \n\nThis assay directly targets CFTR and resolves the remaining ambiguity in one step.  \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe **abnormal HRM result** does not confirm CFTR mutation but supports its possibility. Since **MECP2 mutation** remains unaddressed, the next critical step is **Methylation-specific PCR** to evaluate methylation patterns:  \n- A **normal methylation pattern** would rule out MECP2 mutation, leaving CFTR mutation as the answer.  \n- An **abnormal methylation pattern** would confirm MECP2 mutation.  \n\nThis assay directly resolves the remaining ambiguity between CFTR and MECP2 mutations.  \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe **normal methylation pattern** from the Methylation-specific PCR rules out **MECP2 mutation** (and UBE3A mutation, which was already excluded earlier). This leaves **CFTR mutation** as the only remaining possibility. All other mutations have been eliminated through previous assays. No further testing is needed.  \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 15235, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Splice-site analysis", "observation": "Splicing abnormalities detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}], "successful": true, "parse_error": false}], "seed": 18, "average_actions": 4.4, "average_tokens": 10350.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.4, "average_successful_tokens": 10350.2}
{"trajectories": [{"actions": ["DNA sequencing", "Multiplex ligation-dependent probe amplification (MLPA)", "High-resolution melt analysis (HRM)", "BRCA1 mutation", {"predicted_truth": "BRCA1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, the possible mutations remain MTHFR, PMP22 duplication, CFTR, and BRCA1. Since DNA sequencing does not assess copy number variations, PMP22 duplication (a duplication) is still a candidate. To rule out PMP22 duplication efficiently, **Multiplex ligation-dependent probe amplification (MLPA)** is the optimal next step. A normal MLPA result would exclude PMP22 duplication, narrowing the possibilities to the remaining three mutations. If MLPA detects a duplication, PMP22 duplication is confirmed. This choice strategically targets the copy-number-based mutation first, maximizing the elimination of possibilities in minimal steps.\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter MLPA ruled out PMP22 duplication, the remaining mutations are MTHFR, CFTR, and BRCA1. Performing **High-resolution melt analysis (HRM)** is strategic because a normal result would exclude both CFTR and MTHFR mutations, leaving BRCA1 as the only possibility. If HRM is abnormal, the mutation could still be CFTR or MTHFR (since BRCA1 does not affect HRM results). This step maximizes efficiency by potentially eliminating two mutations at once or narrowing the focus to two candidates for subsequent testing.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe normal HRM result rules out CFTR and MTHFR mutations. Since MLPA already excluded PMP22 duplication, the only remaining mutation is **BRCA1 mutation**. No further assays are needed; the answer is conclusively determined.\n\n<ANSWER> BRCA1 mutation </ANSWER>"], "consumed_tokens": 15621, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Multiplex ligation-dependent probe amplification (MLPA)", "High-resolution melt analysis (HRM)", "BRCA1 mutation", {"predicted_truth": "BRCA1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nSince DNA sequencing detected mutations but did not rule out any possibilities, the next logical step is to use MLPA. MLPA can directly identify PMP22 duplication (a copy number variation) or rule it out if normal. If duplication is detected, PMP22 is confirmed; if not, it's eliminated. This efficiently narrows down the remaining mutations. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter MLPA ruled out PMP22 duplication, the remaining mutations are MTHFR, CFTR, and BRCA1. High-resolution melt analysis (HRM) can eliminate two possibilities (CFTR and MTHFR) if the result is normal, leaving BRCA1 as the only remaining mutation. This makes HRM the most efficient next step to narrow down the possibilities. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nSince HRM's normal outcome eliminated CFTR and MTHFR mutations, the only remaining mutation is BRCA1. No further assays are needed to confirm this conclusion. \n\n<ANSWER> BRCA1 mutation </ANSWER>"], "consumed_tokens": 14582, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "BRCA1 mutation", {"predicted_truth": "BRCA1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing detected mutations, which means CFTR, BRCA1, or MTHFR mutations are possible (since a normal result would have ruled them out). PMP22 duplication is likely ruled out because DNA sequencing detects point mutations, not copy number variations like duplications. To narrow down further, performing **High-resolution melt analysis (HRM)** can check for CFTR and MTHFR mutations. If HRM results are normal, both are excluded, leaving BRCA1. If abnormal, CFTR or MTHFR remain. This step efficiently reduces possibilities.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter performing DNA sequencing (mutations detected) and HRM (no abnormalities), the remaining possibilities are **BRCA1 mutation** and **PMP22 duplication**. DNA sequencing detects point mutations but not duplications. Since mutations were found in DNA sequencing (ruling out CFTR and MTHFR via HRM), the detected mutation must be in BRCA1. PMP22 duplication is a copy number variation and would not be detected by DNA sequencing. Thus, the logical conclusion is **BRCA1 mutation** without needing further assays.\n\n<ANSWER> BRCA1 mutation </ANSWER>"], "consumed_tokens": 14974, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "High-resolution melt analysis (HRM)", "BRCA1 mutation", {"predicted_truth": "BRCA1 mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter performing MLPA and observing a normal copy number, PMP22 duplication is ruled out. The remaining mutations are MTHFR, CFTR, and BRCA1. To narrow this down, **High-resolution melt analysis (HRM)** is the next logical step. A normal HRM result would exclude both MTHFR and CFTR mutations, leaving BRCA1 as the only possibility. If HRM is abnormal, further assays like NGS or splice-site analysis could be used in subsequent steps. For efficiency, HRM offers the best chance to eliminate two mutations at once if the result is normal.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter MLPA ruled out **PMP22 duplication** and HRM excluded **MTHFR** and **CFTR** mutations (due to normal results), the only remaining possibility is **BRCA1 mutation**. No further assays are required, as all other mutations have been eliminated. \n\n<ANSWER> BRCA1 mutation </ANSWER>"], "consumed_tokens": 10017, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Multiplex ligation-dependent probe amplification (MLPA)", "BRCA1 mutation", {"predicted_truth": "BRCA1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing detected mutations, all four mutations remain possible. To efficiently narrow down the options, **High-resolution melt analysis (HRM)** is the best next step. If HRM shows a normal outcome (no melting curve abnormalities), it would rule out **CFTR** and **MTHFR mutations**, leaving **PMP22 duplication** and **BRCA1 mutation** as possibilities. This reduces the candidates by two, making it a strategic choice. If HRM is abnormal, further steps can target the remaining mutations. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter HRM ruled out CFTR and MTHFR mutations, the remaining possibilities are **PMP22 duplication** and **BRCA1 mutation**. To differentiate between these, **Multiplex ligation-dependent probe amplification (MLPA)** is the most efficient next step. MLPA directly checks for copy number variations (e.g., duplications), which would confirm or exclude PMP22 duplication. If MLPA shows a normal copy number, PMP22 duplication is ruled out, leaving BRCA1 as the only remaining mutation. This approach resolves the ambiguity in one step.\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe previous step ruled out PMP22 duplication via MLPA, leaving only **BRCA1 mutation** as the remaining possibility. Since all other mutations have been excluded through prior assays (HRM excluded CFTR/MTHFR; MLPA excluded PMP22), no further testing is needed. The correct answer is **BRCA1 mutation**.\n\n<ANSWER> BRCA1 mutation </ANSWER>"], "consumed_tokens": 15300, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}], "seed": 19, "average_actions": 4.6, "average_tokens": 14098.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.6, "average_successful_tokens": 14098.8}
{"trajectories": [{"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter the FISH assay detected a deletion, the possible mutations are narrowed to **DMD mutation** or **SMN1 deletion** (since FISH detects deletions in these genes). To differentiate between them, **MLPA** is the optimal next step. MLPA detects copy number variations and can confirm or rule out an SMN1 deletion. If MLPA shows a normal copy number for SMN1, the deletion detected by FISH must be in the DMD gene. Conversely, if MLPA detects an SMN1 deletion, it confirms the mutation. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe FISH assay detected a deletion (ruling out COL1A1 and CFTR mutations). MLPA then showed a **normal copy number**, which rules out SMN1 deletion. The only remaining mutation is **DMD mutation**. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 8771, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nSince FISH detected a deletion, the possible mutations are narrowed to **DMD mutation** (if a DMD gene deletion is present) or **SMN1 deletion**. To differentiate between these, **MLPA** can assess SMN1 copy number. If MLPA shows a normal copy number, SMN1 deletion is ruled out, leaving DMD mutation as the cause. If MLPA detects a copy number variation, SMN1 deletion is confirmed. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nSince MLPA ruled out SMN1 deletion and FISH detected a deletion (consistent with DMD mutation), no further assays are needed. The remaining mutation is **DMD mutation**.\n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 10521, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH assay detected a deletion, which means the mutation is either **DMD mutation** or **SMN1 deletion** (as FISH rules these out only if *no* deletion is observed). To differentiate between these two, **Multiplex ligation-dependent probe amplification (MLPA)** is the most appropriate next step. MLPA detects copy number variations, and a normal SMN1 copy number would rule out SMN1 deletion, leaving DMD mutation as the answer. Conversely, detecting a deletion via MLPA would confirm SMN1 deletion. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay showing a **normal copy number** rules out **SMN1 deletion** (since SMN1 deletion is a copy number loss, which MLPA detects). The only remaining mutation from the FISH result (which implicated DMD mutation or SMN1 deletion) is **DMD mutation**. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 10918, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter detecting a deletion with FISH, the remaining possible mutations are **DMD mutation** and **SMN1 deletion**, as FISH detects deletions but cannot differentiate between them. **MLPA** is ideal to distinguish these because it specifically evaluates copy number variations (e.g., SMN1 deletion). If MLPA shows a deletion in SMN1, that confirms the mutation. If SMN1 is normal, the deletion must be in DMD. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter the FISH assay detected a deletion, the possible mutations were narrowed down to **DMD mutation** and **SMN1 deletion**. The subsequent MLPA result showing **normal copy number** rules out **SMN1 deletion** (as MLPA detects SMN1 copy number abnormalities). This leaves **DMD mutation** as the only remaining possibility. No further assays are needed since the deletion detected by FISH must correspond to the DMD gene. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 12576, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH assay detected a deletion, which indicates that either the **DMD mutation** or **SMN1 deletion** is present (since a normal FISH result would rule both out). To differentiate between these two, **Multiplex ligation-dependent probe amplification (MLPA)** is the optimal next step. MLPA can assess copy number variations in the SMN1 gene. If SMN1 deletion is confirmed via MLPA, that mutation is identified; if MLPA shows a normal copy number, SMN1 is ruled out, leaving DMD mutation as the answer. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result showing a normal copy number rules out **SMN1 deletion** (as MLPA detects SMN1 copy number). Since FISH detected a deletion (which could only be DMD or SMN1), and SMN1 is now excluded, the remaining mutation is **DMD mutation**. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 8157, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}], "seed": 20, "average_actions": 4.0, "average_tokens": 10188.6, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 10188.6}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "DNA sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter performing the MLPA assay and observing a normal copy number, the UBE3A mutation is excluded. The remaining possible mutations are G6PD deficiency, LEP, and GJB2. To narrow down further, the **Enzyme assay** is a strategic next choice because it can directly evaluate G6PD activity. If the enzyme activity level is normal (75-100), G6PD deficiency mutation would be excluded, leaving LEP and GJB2 mutations. This approach minimizes steps by targeting a mutation that can be conclusively ruled out with a single test result. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result of 84.28 (within 75-100) excludes the **G6PD deficiency mutation**. This leaves **LEP mutation** and **GJB2 mutation** as possibilities. To differentiate, **ELISA** is the optimal next step: a low leptin concentration (0-25) would exclude LEP mutation, leaving GJB2 as the answer. A high concentration (75-100) would not exclude LEP, requiring a follow-up test for GJB2. However, selecting **DNA sequencing** could also resolve the remaining options in one step by checking for GJB2 mutations. Since DNA sequencing directly targets GJB2 and can conclusively exclude it (if no mutations are detected) or confirm it, it is the most efficient choice here. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, the guidebook indicates this does not exclude **GJB2 mutation**. The remaining candidates are **LEP mutation** and **GJB2 mutation**. To confirm GJB2 definitively, **Allele-specific oligonucleotide hybridization** could be used: hybridization with the mutant probe would confirm GJB2. However, since DNA sequencing already detected mutations (specific to GJB2 per the guidebook), this strongly supports GJB2 as the answer. Further testing would be redundant, as the logical conclusion from prior steps (excluding UBE3A and G6PD) and the DNA sequencing result points to **GJB2 mutation** as the correct diagnosis. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 24686, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 84.27616729080269}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Allele-specific oligonucleotide hybridization", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter the DNA sequencing detected mutations, the next step is to confirm or exclude the GJB2 mutation using another assay. Allele-specific oligonucleotide hybridization can directly check for the presence of the GJB2 mutation. If hybridization with the mutant probe occurs, GJB2 is confirmed; if not, it is excluded. This approach efficiently narrows down the possibilities. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe allele-specific oligonucleotide hybridization assay detected hybridization with the mutant probe, confirming the presence of the GJB2 mutation. No further assays are needed since this conclusively identifies the mutation. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 12743, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Allele-specific oligonucleotide hybridization", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, GJB2 mutation remains a possibility. To confirm or exclude GJB2, the most efficient next step is **Allele-specific oligonucleotide hybridization**, as it directly tests for the presence of a specific GJB2 mutation. If hybridization occurs, GJB2 is confirmed; if not, it can be excluded, narrowing the list further. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nAfter performing **Allele-specific oligonucleotide hybridization**, the observation \"Hybridization with mutant probe\" indicates the presence of the GJB2 mutation. This result confirms the GJB2 mutation, as the assay is designed to detect specific alleles. Since all other mutations (UBE3A, G6PD deficiency, LEP) remain unaddressed but the detected hybridization directly identifies GJB2 as the causative mutation, no further assays are needed. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 17514, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "Hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Multiplex ligation-dependent probe amplification (MLPA)", "DNA sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 84.276 falls within the normal activity range (75-100), which excludes the **G6PD deficiency mutation**. The remaining possibilities are **UBE3A mutation**, **LEP mutation**, and **GJB2 mutation**. To narrow this down, the next logical step is to use **MLPA** to check for copy number variations in UBE3A. If MLPA results show a normal copy number, UBE3A mutation is excluded. This approach systematically eliminates one mutation, leaving fewer options for subsequent tests. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result showing a normal copy number excludes the **UBE3A mutation**, leaving **LEP mutation** and **GJB2 mutation** as possibilities. To differentiate between these, the **ELISA** assay can measure leptin concentration. If the leptin level is low (0-25), it excludes the LEP mutation, pointing to GJB2. If the leptin level is normal (75-100), LEP remains possible, and further testing for GJB2 (e.g., DNA sequencing) would be required. However, using **DNA sequencing** now would directly check for GJB2 mutations, resolving the remaining ambiguity in one step. If sequencing detects mutations, GJB2 is confirmed; if none are found, LEP is the answer. This approach minimizes steps.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result showing mutations detected confirms the **GJB2 mutation** since this assay specifically targets GJB2. With previous steps excluding G6PD and UBE3A mutations, and LEP mutation ruled out by elimination (no assay yet for LEP, but DNA sequencing already identified GJB2), the final diagnosis is GJB2 mutation.\n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 16663, "observations": [null, {"action": "Enzyme assay", "observation": 84.27616729080269}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Enzyme assay", "ELISA", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\nTo determine the correct genetic mutation efficiently, the first step should prioritize excluding a mutation with a single specific assay. Choosing **Multiplex ligation-dependent probe amplification (MLPA)** allows us to test for UBE3A mutation. If the MLPA result shows a normal copy number, UBE3A mutation is immediately excluded. This narrows the possibilities to the remaining three mutations, streamlining subsequent steps. If a copy number variation is detected, UBE3A remains a candidate, but this assay provides critical initial information. Starting with MLPA optimizes the elimination of one mutation early, reducing complexity in further testing.\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result excluded UBE3A mutation. Next, using the **Enzyme assay** can test for G6PD deficiency. A normal activity level (75-100) would exclude G6PD deficiency, narrowing the possibilities to LEP or GJB2 mutations. If the enzyme activity is low (0-25), G6PD deficiency is confirmed. This step efficiently reduces the remaining options with a single assay.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 84.28 (within the 75-100 range) excludes **G6PD deficiency mutation**, leaving **LEP mutation** and **GJB2 mutation** as possibilities. To further narrow down, **ELISA** is the optimal choice. If the leptin concentration is low (0-25), LEP mutation is excluded, confirming GJB2 mutation. If high (75-100), LEP mutation is confirmed. This step directly targets the remaining mutations efficiently. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (14.63) falls in the 0-25 range, which **excludes LEP mutation**. After excluding UBE3A, G6PD, and LEP mutations via prior assays, the only remaining possibility is **GJB2 mutation**. No further testing is required, as all other mutations have been conclusively ruled out.\n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 12355, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Enzyme assay", "observation": 84.27616729080269}, {"action": "ELISA", "observation": 14.634062429553104}], "successful": true, "parse_error": false}], "seed": 21, "average_actions": 4.6, "average_tokens": 16792.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.6, "average_successful_tokens": 16792.2}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out CFTR and HBB mutations, leaving PAH and APC. To differentiate between these, the **Enzyme assay** can check PAH enzyme activity. If activity is 75-100%, PAH is excluded, pinpointing APC. If low, PAH remains possible (but APC would still need testing). This assay provides the quickest next step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 82.76% activity (\u226575%) rules out the **PAH mutation**. Since NGS already excluded CFTR and HBB, the only remaining mutation is **APC gene mutation**. No further testing is needed. \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 6012, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 82.76703011645351}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out CFTR and HBB mutations, leaving PAH and APC. The **Enzyme assay** directly tests PAH enzyme activity. If activity is 75-100%, PAH is excluded, leaving APC. If low (0-25%), PAH remains possible. This efficiently narrows down the remaining candidates. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 82.8% activity (\u226575%) **rules out PAH mutation**. Only **APC gene mutation** remains. No further assays are needed since all other candidates have been excluded. \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 9386, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 82.76703011645351}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Protein truncation test", "Enzyme assay", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter performing the NGS assay, **CFTR** and **HBB mutations** were ruled out. The subsequent Protein truncation test detected **truncated proteins**, leaving **APC gene mutation** and **PAH mutation** as possibilities. To differentiate, the **Enzyme assay** is the optimal next step. If PAH enzyme activity is normal (75\u2013100%), PAH mutation is ruled out, leaving **APC gene mutation** as the answer. If activity is low (0\u201325%), PAH mutation would be confirmed. Since the remaining assays (Sanger sequencing, DNA sequencing, HRM) only target already-excluded mutations, the Enzyme assay is critical here.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of **82.76% activity** (within the 75\u2013100% range) **rules out the PAH mutation**. This leaves only **APC gene mutation** as the remaining candidate. No further assays are necessary because all other mutations (CFTR, HBB, PAH) have already been excluded through prior tests. \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 10989, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "Enzyme assay", "observation": 82.76703011645351}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Protein truncation test", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out CFTR and HBB mutations, leaving **PAH mutation** and **APC gene mutation** as possibilities. To distinguish between these, the **Protein truncation test** directly checks for APC mutations. If truncated proteins are detected, APC is confirmed; if not, PAH remains. This assay resolves the remaining ambiguity in one step. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test detected truncated proteins, which directly indicates an **APC gene mutation** (as this assay specifically identifies truncating mutations in the APC gene). This result excludes PAH mutation as the cause. \n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 7623, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Next-generation sequencing (NGS)", "APC gene mutation", {"predicted_truth": "APC gene mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter the Protein Truncation Test detected truncated proteins, the APC gene mutation remains a candidate, but other mutations (CFTR, PAH, HBB) are still possible. To efficiently narrow down the options, the best next step is **Next-generation sequencing (NGS)**. If NGS detects no variants, CFTR and HBB mutations are ruled out, leaving PAH and APC. If variants are found, further testing would be needed. However, choosing NGS maximizes the number of mutations ruled out in one step, making it the optimal choice.\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing the Protein Truncation Test (detecting truncated proteins) and NGS (no variants detected), the remaining candidates are **PAH mutation** and **APC gene mutation**. The Protein Truncation Test specifically targets truncations in the APC gene, and detecting truncated proteins strongly suggests an APC mutation. Since NGS ruled out CFTR and HBB mutations, the only plausible explanation for the observed truncated proteins is the **APC gene mutation**. No further assays are needed to confirm this conclusion.\n\n<ANSWER> APC gene mutation </ANSWER>"], "consumed_tokens": 16274, "observations": [null, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}], "seed": 22, "average_actions": 4.2, "average_tokens": 10056.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.2, "average_successful_tokens": 10056.8}
{"trajectories": [{"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot detected an expanded fragment, which directly confirms the presence of the **FMR1 gene expansion** (since this assay is specific for identifying trinucleotide expansions). All other mutations (GJB2, APC, BRCA2) are unrelated to this result and can be ruled out. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 3113, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot assay detected an expanded fragment, which directly confirms an **FMR1 gene expansion** (since Southern blot is used to detect expansions in the FMR1 gene). This result rules out all other mutations, as none of them involve expansions detectable by Southern blot. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 5851, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing an expanded fragment directly confirms an **FMR1 gene expansion**, as this assay is specific for detecting such expansions. All other mutations (GJB2, APC, BRCA2) are unrelated to Southern blot outcomes. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 3832, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result \"Expanded fragment detected\" directly confirms the presence of an FMR1 gene expansion, as this assay specifically identifies such expansions. All other mutations (GJB2, APC, BRCA2) are unrelated to this assay's outcome. Thus, the correct diagnosis is **FMR1 gene expansion**. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 3239, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing an expanded fragment directly confirms the presence of an **FMR1 gene expansion**, as this assay detects DNA structural expansions like those in Fragile X syndrome. Since this result is conclusive for FMR1, no further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 4016, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}], "seed": 23, "average_actions": 3.0, "average_tokens": 4010.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.0, "average_successful_tokens": 4010.2}
{"trajectories": [{"actions": ["Southern blot", "ELISA", "Sanger sequencing", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\nTo determine the genetic mutation efficiently, the first step should be the **Southern blot** assay. This test can immediately rule out the **HTT gene expansion** if a normal-sized fragment is detected. If an expanded fragment is found, HTT would be confirmed. Starting with this assay quickly narrows down the possibilities, as HTT expansion is uniquely identified by this method. Subsequent steps can then focus on the remaining mutations using other assays if needed. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out **HTT gene expansion** via Southern blot, the remaining possibilities are **UBE3A mutation**, **BRCA1 mutation**, and **LEP mutation**. The **ELISA** assay is the next logical choice because it can directly exclude the **LEP mutation** if the result shows low protein concentration (0\u201325 units). If LEP is ruled out, subsequent steps can focus on differentiating between UBE3A and BRCA1 mutations. If the ELISA result does not exclude LEP, further assays targeting BRCA1 (e.g., Sanger sequencing) can narrow the options. This approach minimizes steps by prioritizing assays that eliminate specific mutations conclusively.\n\n<ANSWER> ELISA </ANSWER>", "\n\nAfter the Southern blot ruled out **HTT gene expansion** and the ELISA result (11 units) excluded **LEP mutation** (per the guidebook's instruction that 0\u201325 units rules out LEP), the remaining candidates are **UBE3A mutation** and **BRCA1 mutation**. To differentiate between these, **Sanger sequencing** is the most direct assay. If no mutations are detected in BRCA1 via Sanger sequencing, it would conclusively rule out the **BRCA1 mutation**, leaving **UBE3A mutation** as the only remaining possibility. This approach efficiently narrows down the options with minimal steps.\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter ruling out **HTT gene expansion** (Southern blot), **LEP mutation** (ELISA), and **BRCA1 mutation** (Sanger sequencing), the only remaining mutation is **UBE3A mutation**. No further assays are necessary, as all other options have been conclusively excluded. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 20731, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "ELISA", "observation": 11.034443875357564}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "ELISA", "Sanger sequencing", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out the HTT gene expansion with the Southern blot result, the remaining possibilities are UBE3A mutation, BRCA1 mutation, and LEP mutation. To narrow these down efficiently, the next logical step is to use the **ELISA** assay. If the ELISA result shows a protein concentration of 0-25 units, the LEP mutation would be excluded, leaving UBE3A and BRCA1. If the concentration is higher, LEP remains a possibility. This approach minimizes steps by targeting a mutation (LEP) that can be directly ruled out with a single assay result.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of 11.03 units (within 0-25 units) rules out the LEP mutation. The remaining possibilities are UBE3A mutation and BRCA1 mutation. To differentiate between these, **Sanger sequencing** is the most direct assay. If no mutations are detected, BRCA1 is excluded, leaving UBE3A as the answer. If mutations are detected, BRCA1 is confirmed. This step efficiently narrows down the remaining candidates.\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe remaining mutation after excluding HTT (Southern blot), LEP (ELISA), and BRCA1 (Sanger sequencing) is **UBE3A mutation**. No further assays are needed since all other options have been eliminated. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 13690, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "ELISA", "observation": 11.034443875357564}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "ELISA", "Sanger sequencing", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out **HTT gene expansion** with the Southern blot result, the remaining possibilities are UBE3A mutation, BRCA1 mutation, and LEP mutation. To efficiently narrow down further, **ELISA** is the next logical step. If the leptin concentration is low (0-25 units), it would exclude the LEP mutation, leaving only UBE3A and BRCA1. This approach minimizes steps by targeting a mutation (LEP) that can be conclusively ruled out with a single assay result. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of ~11 units (within 0-25) rules out the **LEP mutation**. The remaining possibilities are **UBE3A mutation** and **BRCA1 mutation**. To differentiate between these, **Sanger sequencing** is optimal. If no mutations are detected in BRCA1, it would exclude that mutation, leaving UBE3A as the answer. If mutations are detected, BRCA1 is confirmed. This assay directly targets BRCA1 and provides a definitive result. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe **Sanger sequencing** result (\"No mutations detected\") rules out the **BRCA1 mutation**. With **HTT gene expansion** and **LEP mutation** already excluded earlier, the only remaining possibility is **UBE3A mutation**. No further assays are needed to confirm this conclusion, as all other mutations have been conclusively ruled out. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 16096, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "ELISA", "observation": 11.034443875357564}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "ELISA", "Sanger sequencing", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter performing the Southern blot and observing a normal-sized fragment, **HTT gene expansion** is ruled out. The remaining possibilities are **UBE3A mutation**, **BRCA1 mutation**, and **LEP mutation**. To narrow down further, **ELISA** is a strategic next step. If the leptin protein concentration is low (0-25 units), **LEP mutation** would be excluded. If the result is normal (75-100 units), LEP remains a possibility, but this assay provides critical information to reduce uncertainty efficiently. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of 11.03 units (within 0-25 units) **rules out the LEP mutation**. This leaves **UBE3A mutation** and **BRCA1 mutation** as possibilities. To distinguish between these, **Sanger sequencing** is optimal. If no BRCA1 mutation is detected, UBE3A would be confirmed. If a mutation is found, BRCA1 is the answer. This assay directly tests for BRCA1 mutations and resolves the remaining ambiguity in one step. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe Sanger sequencing result of \"No mutations detected\" **rules out the BRCA1 mutation**, leaving **UBE3A mutation** as the only remaining possibility. All other mutations have been excluded through prior assays. No further testing is needed, as the correct mutation is now confirmed. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 12040, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "ELISA", "observation": 11.034443875357564}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "ELISA", "Sanger sequencing", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out HTT gene expansion. Now, remaining possibilities are UBE3A mutation, BRCA1 mutation, and LEP mutation. Performing **ELISA** could check leptin levels to address LEP mutation. If leptin is low (0-25 units), LEP mutation is excluded, narrowing to UBE3A or BRCA1. If normal (75-100), LEP remains possible. This step efficiently targets a specific mutation. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of 11.03 units falls within the 0-25 range, which rules out the **LEP mutation** per the guidebook. The remaining possibilities are **UBE3A mutation** and **BRCA1 mutation**. To differentiate between these, **Sanger sequencing** is the most efficient next step. If no mutations are detected, BRCA1 is ruled out, leaving UBE3A as the answer. If mutations are detected, BRCA1 is confirmed. This assay directly targets BRCA1, making it the optimal choice. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe Sanger sequencing result (\"No mutations detected\") rules out the **BRCA1 mutation** per the guidebook. With HTT (Southern blot), LEP (ELISA), and BRCA1 (Sanger) all excluded, the only remaining possibility is **UBE3A mutation**. No further assays are needed, as all other mutations have been systematically eliminated. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 11347, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "ELISA", "observation": 11.034443875357564}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}], "seed": 24, "average_actions": 5.0, "average_tokens": 14780.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 14780.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Southern blot", "Sanger sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nSince NGS detected variants but didn't rule out any mutations, the next logical step is to test for HTT gene expansion, which requires assays specific to large tandem repeats. Southern blot is the gold standard for detecting HTT expansions. If Southern blot is normal, HTT can be ruled out, narrowing the possibilities to BRCA1, BRCA2, or GJB2. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out HTT gene expansion with Southern blot, the remaining possibilities are BRCA1, BRCA2, and GJB2 mutations. Sanger sequencing can directly assess BRCA1 and BRCA2. If no mutations are detected, both BRCA1 and BRCA2 are ruled out, leaving GJB2 as the only remaining option. This approach minimizes steps by leveraging Sanger sequencing's ability to exclude two mutations at once.\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter ruling out HTT (via Southern blot) and BRCA1/BRCA2 (via Sanger sequencing), the only remaining mutation is **GJB2 mutation**. All other possibilities have been eliminated through prior assays. No further testing is required. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 9451, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "Southern blot", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe previous Sanger sequencing result ruled out BRCA1 and BRCA2 mutations, leaving HTT gene expansion and GJB2 mutation as possibilities. To differentiate between these, the **Southern blot** assay directly checks for HTT gene expansion (CAG repeats). If the Southern blot shows a normal fragment, HTT is excluded, leaving GJB2 as the answer. If an expanded fragment is detected, HTT is confirmed. This assay efficiently narrows down the remaining candidates in one step.\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out HTT gene expansion. With BRCA1 and BRCA2 already eliminated by Sanger sequencing, the only remaining possibility is **GJB2 mutation**. No further assays are needed since all other mutations have been excluded. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 13767, "observations": [null, {"action": "Sanger sequencing", "observation": "No mutations detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Next-generation sequencing (NGS)", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nTo determine the genetic mutation efficiently after the Tandem repeat PCR indicated a high repeat count (127.9 repeats), the next logical step is to use **Next-generation sequencing (NGS)**. If NGS returns \"no variants detected,\" it would rule out BRCA1, BRCA2, and GJB2 mutations, leaving **HTT gene expansion** as the only remaining possibility. This approach minimizes steps by leveraging NGS's ability to exclude three mutations at once. \n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe Tandem Repeat PCR result (127.9 repeats) strongly suggests **HTT gene expansion**, as this assay detects large CAG repeat expansions characteristic of Huntington's disease. The NGS result (\"Variants detected\") does not rule out HTT, as repeat expansions are often not reliably detected by standard NGS. Since Southern blot is the definitive test for HTT expansions, performing it would confirm the mutation. However, given the TR-PCR result already aligns with HTT and no other mutations explain the observations, the most efficient conclusion is to identify **HTT gene expansion** as the truth. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 14631, "observations": [null, {"action": "Tandem repeat PCR", "observation": 127.90264171909645}, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}], "successful": false, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "Sanger sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result detected variants, which doesn't rule out any mutations. To narrow down, **Southern blot** can determine if the HTT gene expansion is present. If Southern blot shows a normal fragment, HTT is excluded, focusing on BRCA1, BRCA2, or GJB2. If an expanded fragment is found, HTT gene expansion is confirmed. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out HTT gene expansion via Southern blot, the remaining possibilities are BRCA1, BRCA2, or GJB2 mutations. **Sanger sequencing** can detect BRCA1/BRCA2 mutations. If no mutations are found, GJB2 mutation remains as the only option. If mutations are detected, BRCA1/BRCA2 is confirmed. This efficiently narrows down the possibilities in one step. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nSince **Sanger sequencing** ruled out BRCA1 and BRCA2 mutations, and **Southern blot** excluded HTT gene expansion, the only remaining possibility is **GJB2 mutation**. No further assays are needed\u2014GJB2 is the only mutation not excluded by prior test results. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 8530, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "Sanger sequencing", "GJB2 mutation", {"predicted_truth": "GJB2 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe previous NGS result detected variants, which doesn't rule out any mutations. To narrow down the possibilities efficiently, **Southern blot** is the best next step. If the Southern blot shows a normal-sized fragment, HTT gene expansion is ruled out. If an expanded fragment is detected, HTT gene expansion is confirmed. This approach minimizes steps by directly testing for HTT, which could resolve the case immediately if positive. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out HTT gene expansion via Southern blot, the remaining possibilities are BRCA1, BRCA2, and GJB2 mutations. **Sanger sequencing** can efficiently address BRCA1 and BRCA2 in one step. If no mutations are detected, both BRCA1 and BRCA2 are ruled out, leaving GJB2 as the only remaining mutation. This approach minimizes steps, as a negative result directly identifies GJB2, while a positive result would require further testing (e.g., splice-site analysis for BRCA1). \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter ruling out **HTT gene expansion** (via Southern blot) and **BRCA1/BRCA2 mutations** (via Sanger sequencing), the only remaining possibility is **GJB2 mutation**. No further assays are required since all other mutations have been conclusively eliminated. \n\n<ANSWER> GJB2 mutation </ANSWER>"], "consumed_tokens": 16459, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Sanger sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}], "seed": 25, "average_actions": 4.6, "average_tokens": 12567.6, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 4.75, "average_successful_tokens": 12051.75}
{"trajectories": [{"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result \"Expanded fragment detected\" directly indicates the presence of the FMR1 gene expansion, as this assay detects large repeat expansions characteristic of Fragile X syndrome. Since no other mutations would cause this result, the remaining possibilities are eliminated. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 9522, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result ruled out BRCA1 and MTHFR mutations, leaving FMR1 expansion and G6PD deficiency. To distinguish between these, Southern blot directly tests for FMR1 expansions. A normal fragment would rule out FMR1, leaving G6PD deficiency as the answer. An expanded fragment confirms FMR1. This is the most efficient next step. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot's expanded fragment directly confirms FMR1 gene expansion, as this assay detects triplet repeat expansions. All other mutations have been ruled out (BRCA1 and MTHFR via DNA sequencing) or are incompatible with the results. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 11615, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "DNA sequencing", "Enzyme assay", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter the Southern blot result (\"Expanded fragment detected\"), FMR1 gene expansion remains possible. To narrow down the options efficiently, DNA sequencing is the next logical step. If DNA sequencing returns \"No mutations detected,\" it would rule out BRCA1 and MTHFR mutations, leaving FMR1 and G6PD deficiency. If mutations are detected, further testing would be needed. This approach minimizes steps by potentially eliminating two mutations at once. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing ruled out BRCA1 and MTHFR mutations, the remaining possibilities are **FMR1 gene expansion** and **G6PD deficiency mutation**. The Southern blot result (\"Expanded fragment detected\") does not rule out FMR1, and DNA sequencing does not impact these two mutations. To differentiate between them, the **Enzyme assay** is the most efficient next step. If enzyme activity is normal (75\u2013100), G6PD deficiency is excluded, leaving FMR1 as the answer. If activity is low (0\u201325), G6PD deficiency is confirmed. Since no other assays can directly resolve these two mutations, the Enzyme assay is critical here. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of **94.66** falls within the **75\u2013100** range, which **rules out G6PD deficiency mutation**. Only **FMR1 gene expansion** remains possible, as it was not excluded by the Southern blot (result: \"Expanded fragment detected\") and all other mutations have been eliminated. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 12474, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Enzyme assay", "observation": 94.65761085832469}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result \"Expanded fragment detected\" strongly suggests the presence of FMR1 gene expansion, as this assay detects repeat expansions characteristic of Fragile X syndrome. Since other mutations (BRCA1, G6PD, MTHFR) do not involve repeat expansions detectable by Southern blot, this result confirms FMR1 as the mutation. No further assays are needed. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 6464, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "FMR1 gene expansion", {"predicted_truth": "FMR1 gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result \"Expanded fragment detected\" does not rule out any mutations according to the guidebook. However, since this assay is specific to detecting FMR1 gene expansions and the result indicates an expanded fragment, it strongly suggests that FMR1 gene expansion is the correct mutation. No other mutations would cause this result. Thus, further testing is unnecessary, and the answer can be confidently determined. \n\n<ANSWER> FMR1 gene expansion </ANSWER>"], "consumed_tokens": 5384, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}], "seed": 26, "average_actions": 3.6, "average_tokens": 9091.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.6, "average_successful_tokens": 9091.8}
{"trajectories": [{"actions": ["Protein truncation test", "Allele-specific oligonucleotide hybridization", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter the Protein Truncation Test ruled out **BRCA1 mutation** and **DMD mutation**, the remaining possibilities are **SERPINA1 mutation** and **GJB2 mutation**. To distinguish between these, **Allele-specific oligonucleotide hybridization** is the most efficient next step. If the result shows **no hybridization with the mutant probe**, GJB2 mutation is ruled out, leaving SERPINA1 mutation as the answer. If **hybridization occurs**, GJB2 mutation is confirmed. This assay directly resolves the remaining ambiguity in one step.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-specific oligonucleotide hybridization** result (no hybridization) rules out **GJB2 mutation**, leaving **SERPINA1 mutation** as the only remaining possibility. No further assays are needed since all other mutations have been eliminated.\n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 7603, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Allele-specific oligonucleotide hybridization", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein Truncation Test ruled out **BRCA1** and **DMD** mutations. Remaining candidates are **SERPINA1** and **GJB2**. The **Allele-specific oligonucleotide hybridization** assay can directly rule out **GJB2** if no hybridization occurs (or confirm it if hybridization occurs). This is the most efficient next step. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-specific oligonucleotide hybridization** result (\"No hybridization\") rules out **GJB2 mutation**. Only **SERPINA1 mutation** remains. No further testing is needed. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 5662, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Allele-specific oligonucleotide hybridization", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein Truncation Test ruled out **BRCA1** and **DMD** mutations. Remaining candidates are **SERPINA1** and **GJB2**. The **Allele-specific oligonucleotide hybridization** assay directly targets **GJB2** mutations. If the result shows no hybridization, **GJB2** is excluded, leaving **SERPINA1** as the answer. If hybridization occurs, **GJB2** is confirmed. This assay is the most efficient next step to distinguish between the two remaining mutations. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-specific oligonucleotide hybridization** result (\"No hybridization with mutant probe\") eliminates **GJB2 mutation**. Only **SERPINA1 mutation** remains as the viable candidate. No further assays are needed since all other mutations have been ruled out. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 7244, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Allele-specific oligonucleotide hybridization", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein Truncation Test ruled out **BRCA1 mutation** and **DMD mutation**, leaving **SERPINA1 mutation** and **GJB2 mutation**. To distinguish between these, **Allele-specific oligonucleotide hybridization** can directly test for GJB2 mutations. If there is no hybridization with the mutant probe, GJB2 is ruled out (confirming SERPINA1). If hybridization occurs, GJB2 is confirmed. This assay resolves the remaining possibilities efficiently. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-specific oligonucleotide hybridization** result (\"No hybridization with mutant probe\") rules out **GJB2 mutation**, leaving **SERPINA1 mutation** as the only remaining possibility. No further assays are needed. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 6148, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Allele-specific oligonucleotide hybridization", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein Truncation Test result (\"No truncated proteins detected\") rules out **BRCA1 mutation** and **DMD mutation**, leaving **SERPINA1 mutation** and **GJB2 mutation** as possibilities. To distinguish between these, **Allele-specific oligonucleotide hybridization** is the most efficient next step. If the assay shows no hybridization with the mutant probe, GJB2 is ruled out (confirming SERPINA1). If hybridization occurs, GJB2 is confirmed. This test directly targets GJB2, making it the optimal choice. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-specific oligonucleotide hybridization** result (\"No hybridization with mutant probe\") definitively rules out **GJB2 mutation**. With **BRCA1** and **DMD** already excluded earlier, **SERPINA1 mutation** is the only remaining possibility. No further assays are required. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 8547, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}], "seed": 27, "average_actions": 4.0, "average_tokens": 7040.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 7040.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "RFLP analysis", "DNA sequencing", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result detected variants, ruling out the possibility of UBE3A mutation (since a \"No Variants Detected\" NGS result would have excluded CFTR, HBB, and COL1A1, leaving UBE3A). The remaining candidates are **CFTR, COL1A1, and HBB**. To narrow further, **RFLP analysis** can directly check for HBB mutation. If RFLP shows a normal restriction pattern, HBB is excluded, leaving CFTR and COL1A1. If abnormal, HBB is confirmed. This is the most efficient next step.\n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out HBB via RFLP and UBE3A via NGS, the remaining candidates are **CFTR** and **COL1A1**. DNA sequencing can conclusively determine if a CFTR mutation exists. If no mutations are detected, CFTR is excluded, leaving **COL1A1** as the only possible mutation. If mutations are detected, **CFTR** is confirmed. This is the most direct next step to resolve the remaining ambiguity. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter ruling out **HBB** (via RFLP) and **CFTR** (via DNA sequencing), the remaining candidates are **COL1A1** and **UBE3A**. To resolve this, **Multiplex ligation-dependent probe amplification (MLPA)** can assess copy number variations. If MLPA shows a normal copy number, UBE3A is excluded, confirming **COL1A1 mutation**. If abnormal, UBE3A is confirmed. Since MLPA is the only assay left to distinguish between these two, it is the logical next step. \n\n<ANSWER> COL1A1 mutation </ANSWER>\n\n**Note**: Based on prior steps, **UBE3A mutation** could not be ruled out yet (as MLPA wasn't performed). However, since all other mutations are excluded, **COL1A1 mutation** is the only remaining possibility. This conclusion assumes the game's setup ensures one correct answer exists."], "consumed_tokens": 14754, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Multiplex ligation-dependent probe amplification (MLPA)", "DNA sequencing", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nTo narrow down the possibilities after NGS detected variants, **Multiplex ligation-dependent probe amplification (MLPA)** is the optimal next step. MLPA can assess UBE3A copy number: a normal result would exclude UBE3A mutation, leaving CFTR, COL1A1, or HBB. An abnormal result would directly identify UBE3A as the mutation. This approach efficiently reduces the candidate mutations in one step. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter MLPA ruled out UBE3A and NGS detected variants (excluding no variants), the remaining candidates are **CFTR, COL1A1, and HBB**. **DNA sequencing** can directly determine if CFTR or HBB mutations are present. If sequencing detects mutations, it identifies the specific gene. If no mutations are found, COL1A1 is confirmed (since NGS already detected variants, and COL1A1 is the only remaining option). This step resolves all possibilities efficiently. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing ruled out CFTR and HBB mutations, the only remaining candidate is **COL1A1 mutation**. Since all other possibilities have been excluded through prior assays (NGS detected variants, MLPA excluded UBE3A, DNA sequencing excluded CFTR/HBB), no further testing is needed. The final diagnosis is COL1A1 mutation. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 9078, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Multiplex ligation-dependent probe amplification (MLPA)", "RFLP analysis", "High-resolution melt analysis (HRM)", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter the NGS detected variants, the possible mutations are CFTR, COL1A1, HBB (since variants in these genes were found), and UBE3A (not ruled out by NGS). To efficiently narrow down the possibilities, **MLPA** is chosen next. If MLPA shows a normal copy number, UBE3A is excluded, leaving the remaining mutations linked to the NGS-detected variants. If MLPA shows an abnormal copy number, UBE3A mutation is confirmed. This step efficiently addresses UBE3A, which was unaffected by the prior NGS result, and reduces the list of candidates.\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter MLPA ruled out UBE3A, the remaining candidates are CFTR, COL1A1, and HBB. **RFLP analysis** can exclude HBB if a normal restriction pattern is observed. If HBB is ruled out, subsequent steps can focus on distinguishing between CFTR and COL1A1 (e.g., using HRM or DNA sequencing). This approach minimizes steps by targeting HBB first, which is efficiently tested via RFLP. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out UBE3A (via MLPA) and HBB (via RFLP), the remaining candidates are **CFTR** and **COL1A1**. To differentiate between them, **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows no melting curve abnormalities, CFTR is excluded, leaving COL1A1 as the mutation. If abnormalities are detected, CFTR is confirmed. This approach directly tests CFTR and resolves the remaining ambiguity in one step. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter HRM ruled out CFTR mutation (due to no melting curve abnormalities), **COL1A1 mutation** is the only remaining candidate. All other mutations (UBE3A, HBB, CFTR) have been excluded through prior assays. No further testing is required. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 19021, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Multiplex ligation-dependent probe amplification (MLPA)", "DNA sequencing", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing NGS and detecting variants, the possible mutations are still CFTR, COL1A1, HBB, and UBE3A. To narrow down, **MLPA** is the optimal next step. If MLPA shows a normal copy number, UBE3A is ruled out, leaving CFTR, COL1A1, or HBB. If MLPA shows an abnormal copy number, UBE3A is confirmed. This assay efficiently tests UBE3A directly, which wasn't addressed by NGS, making it critical for elimination. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter MLPA ruled out UBE3A, the remaining mutations are **CFTR, COL1A1, and HBB**. **DNA sequencing** can exclude CFTR and HBB if no mutations are detected, leaving **COL1A1** as the answer. If mutations are detected, further steps would be needed, but DNA sequencing is the most efficient next assay to narrow possibilities. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nSince DNA sequencing detected no mutations, **CFTR** and **HBB** mutations are excluded. Only **COL1A1 mutation** remains possible. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 12924, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "DNA sequencing", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter the NGS result detected variants, UBE3A is ruled out (since NGS would only detect variants in CFTR, HBB, or COL1A1). The remaining mutations are CFTR, HBB, and COL1A1. To narrow down, **DNA sequencing** is the next logical step. If DNA sequencing shows \"No mutations detected,\" CFTR and HBB are excluded, leaving COL1A1. If mutations are detected, it confirms either CFTR or HBB, which can be resolved with subsequent assays. This minimizes steps by potentially eliminating two mutations at once.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing **Next-generation sequencing (NGS)** (which detected variants) and **DNA sequencing** (which ruled out CFTR and HBB mutations), the remaining possibilities are **COL1A1 mutation** and **UBE3A mutation**. However, since NGS detected variants in CFTR, HBB, or COL1A1 (and UBE3A is not analyzed by NGS), the mutation **must** be among the three genes tested by NGS. With CFTR and HBB excluded by DNA sequencing, **COL1A1 mutation** is the only remaining valid option. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 14965, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "Variants detected"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}], "seed": 28, "average_actions": 5.0, "average_tokens": 14148.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 14148.4}
{"trajectories": [{"actions": ["Protein truncation test", "Enzyme assay", "Allele-specific oligonucleotide hybridization", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out the **APC gene mutation** using the Protein Truncation Test, the remaining possibilities are **LEP mutation**, **PAH mutation**, and **GJB2 mutation**. The next logical step is to select an assay that can eliminate one of these three mutations efficiently. \n\nThe **Enzyme assay** directly targets the **PAH mutation** by measuring phenylalanine hydroxylase activity. If enzyme activity is **75\u2013100%**, the PAH mutation is ruled out, narrowing the options to LEP and GJB2 mutations. If activity is **0\u201325%**, no exclusions occur, but this result still provides critical information for subsequent steps. This assay is highly specific to PAH and offers a clear path to ruling out one candidate, making it the most strategic choice at this stage.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter the Enzyme Assay result of **77.59%**, the **PAH mutation** is ruled out (since activity \u226575%). This leaves **LEP mutation** and **GJB2 mutation** as the remaining candidates. To distinguish between them, the **Allele-Specific Oligonucleotide Hybridization** assay is the most efficient choice. If no hybridization occurs with the mutant probe, **GJB2 mutation** is excluded, leaving **LEP mutation** as the answer. If hybridization occurs, **GJB2 mutation** is confirmed. This assay directly targets GJB2 and resolves the remaining ambiguity in one step. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-Specific Oligonucleotide Hybridization** result (\"No hybridization with mutant probe\") rules out the **GJB2 mutation**. With **APC**, **PAH**, and **GJB2** mutations excluded, the only remaining possibility is the **LEP mutation**. No further assays are required, as all other candidates have been eliminated. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 18245, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Enzyme assay", "observation": 77.5933172269576}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Enzyme assay", "ELISA", "DNA sequencing", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter performing the **Protein Truncation Test**, the absence of truncated proteins ruled out the **APC gene mutation**. The remaining possibilities are **LEP mutation**, **PAH mutation**, and **GJB2 mutation**. To narrow these down further, the **Enzyme assay** is the most strategic choice. If the enzyme activity is **75\u2013100%**, the **PAH mutation** (linked to phenylketonuria) can be ruled out, leaving only **LEP** and **GJB2**. If enzyme activity is **0\u201325%**, PAH remains a possibility, but this still provides critical information to guide subsequent steps. This approach efficiently splits the remaining options and reduces the number of follow-up assays needed.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe **Enzyme assay** result of **77.6%** activity (between 75\u2013100%) rules out the **PAH mutation**, leaving **LEP mutation** and **GJB2 mutation** as possibilities. To distinguish between these, **ELISA** is the logical next step. If leptin concentration (via ELISA) is **low (0\u201325)**, the **LEP mutation** is excluded, leaving **GJB2 mutation** as the answer. If leptin is **normal (75\u2013100)**, **LEP mutation** remains plausible. This assay directly targets the remaining uncertainty between the two options.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe **ELISA result of 86.1** (within 75\u2013100) does not rule out the **LEP mutation**, leaving **LEP** and **GJB2** as the remaining candidates. To resolve this, **DNA sequencing** is the most direct assay to test for **GJB2 mutations**. If DNA sequencing detects mutations, **GJB2** is confirmed. If no mutations are found, **GJB2 is ruled out**, leaving **LEP mutation** as the answer. This assay directly targets the unresolved genetic question with high specificity.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe **DNA sequencing** result showing **no mutations detected** rules out the **GJB2 mutation** (as per the guidebook). With **APC**, **PAH**, and **GJB2** all excluded, the only remaining possibility is the **LEP mutation**. No further assays are needed since all other candidates have been eliminated.\n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 19823, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Enzyme assay", "observation": 77.5933172269576}, {"action": "ELISA", "observation": 86.11758214462493}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Enzyme assay", "Allele-specific oligonucleotide hybridization", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out the APC gene mutation using the Protein Truncation Test, the remaining possibilities are LEP mutation, PAH mutation, and GJB2 mutation. The **Enzyme assay** can help determine whether the PAH mutation is present by measuring enzyme activity. If enzyme activity is high (75\u2013100%), the PAH mutation is ruled out, narrowing the options to LEP and GJB2. If enzyme activity is low (0\u201325%), no mutations are excluded, but further assays can then be prioritized. This step strategically targets the PAH mutation, which is directly linked to enzyme activity, making it a logical next choice to reduce the remaining candidates efficiently.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme Assay result of ~77.59% enzyme activity (within 75\u2013100%) rules out the **PAH mutation**. The remaining possibilities are **LEP mutation** and **GJB2 mutation**. To differentiate between these, the **Allele-Specific Oligonucleotide Hybridization** assay directly targets the GJB2 mutation. If no hybridization occurs with the mutant probe, GJB2 is ruled out, leaving LEP as the answer. If hybridization occurs, GJB2 is confirmed. This assay provides a decisive outcome in one step, making it the most efficient choice to resolve the remaining candidates.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe **Allele-Specific Oligonucleotide Hybridization** assay ruled out the **GJB2 mutation** by showing no hybridization with the mutant probe. With **APC**, **PAH**, and **GJB2** mutations eliminated, the only remaining possibility is **LEP mutation**. All other candidates have been systematically excluded through prior assay results. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 21550, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Enzyme assay", "observation": 77.5933172269576}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Enzyme assay", "ELISA", "Next-generation sequencing (NGS)", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out the APC gene mutation with the Protein Truncation Test, the remaining possibilities are LEP mutation, PAH mutation, and GJB2 mutation. The **Enzyme assay** is the most logical next step because it directly evaluates enzyme activity linked to the PAH mutation. If enzyme activity is high (75\u2013100%), PAH mutation is excluded, narrowing the list to LEP and GJB2. If activity is low (0\u201325%), PAH remains a candidate, and subsequent tests (e.g., ELISA or NGS) can further narrow the options. This approach efficiently targets a mutation with a direct biochemical assay, optimizing the diagnostic pathway.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme Assay result of 77.59% activity (75\u2013100%) rules out the **PAH mutation**. This leaves **LEP mutation** and **GJB2 mutation** as possibilities. The next logical step is to use **ELISA** to measure leptin levels. If leptin concentration is low (0\u201325), LEP mutation is excluded, leaving GJB2 as the answer. If leptin levels are normal (75\u2013100), GJB2-specific assays (e.g., NGS) would follow. ELISA directly addresses one of the two remaining mutations, making it the most efficient next step.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of 86.12% (within 75\u2013100%) does not exclude the LEP mutation. With PAH and APC mutations already ruled out, the remaining candidates are **LEP mutation** and **GJB2 mutation**. To distinguish between them, **Next-generation sequencing (NGS)** is the optimal choice. If NGS detects no variants, GJB2 is excluded, leaving LEP as the answer. If variants are found, GJB2 is confirmed. This directly addresses the remaining ambiguity in the fewest steps.\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result showing no variants detected **rules out the GJB2 mutation**. With APC (excluded by Protein Truncation Test), PAH (excluded by Enzyme Assay), and GJB2 (excluded by NGS) mutations eliminated, the only remaining possibility is the **LEP mutation**. No further assays are needed since all other candidates have been ruled out.\n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 23870, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Enzyme assay", "observation": 77.5933172269576}, {"action": "ELISA", "observation": 86.11758214462493}, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Protein truncation test", "Allele-specific oligonucleotide hybridization", "LEP mutation", {"predicted_truth": "LEP mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 77.59% enzyme activity rules out the PAH mutation (as activity \u226575% excludes PAH). The remaining possibilities are LEP mutation, APC gene mutation, and GJB2 mutation. The **Protein truncation test** can check for APC mutations. If truncated proteins are absent, APC is excluded, narrowing it to LEP or GJB2. This approach efficiently reduces candidates in one step. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test ruled out APC, leaving LEP and GJB2. To differentiate, **Allele-specific oligonucleotide hybridization** directly checks GJB2. If no hybridization, GJB2 is excluded (confirming LEP); if hybridization occurs, GJB2 is confirmed. This assay provides a definitive answer in one step, efficiently resolving the remaining candidates.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe Allele-specific oligonucleotide hybridization result (\"No hybridization with mutant probe\") rules out GJB2 mutation. With PAH (enzyme assay) and APC (protein truncation test) already excluded, the only remaining possibility is **LEP mutation**. \n\n<ANSWER> LEP mutation </ANSWER>"], "consumed_tokens": 17739, "observations": [null, {"action": "Enzyme assay", "observation": 77.5933172269576}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}], "seed": 29, "average_actions": 5.4, "average_tokens": 20245.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.4, "average_successful_tokens": 20245.4}
{"trajectories": [{"actions": ["Sanger sequencing", "Allele-specific oligonucleotide hybridization", "ELISA", "Western blot", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nTo identify the mutation efficiently, the next step should target a mutation that can be ruled out with a single assay. The **Allele-specific oligonucleotide hybridization** assay can definitively rule out the **GJB2 mutation** if no hybridization is observed. This narrows the possibilities to three mutations (LEP, BRCA1, BRCA2) if GJB2 is excluded, or keeps it in contention if hybridization occurs. This approach prioritizes eliminating one mutation quickly. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe previous result from **Allele-specific oligonucleotide hybridization** ruled out **GJB2 mutation** (no hybridization with the mutant probe). The remaining possibilities are **LEP mutation**, **BRCA1 mutation**, and **BRCA2 mutation**. \n\nThe **ELISA** assay can directly rule out the **LEP mutation** if the protein concentration falls in the *0-25* range. If the result is *75-100*, LEP remains possible, and further assays targeting BRCA1/BRCA2 would be needed. Choosing ELISA here efficiently narrows the list by potentially eliminating LEP in one step. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe **ELISA** result (0.19) falls in the *0-25* range, which rules out the **LEP mutation**. The remaining candidates are **BRCA1 mutation** and **BRCA2 mutation**. To distinguish between these, the **Western blot** assay can rule out **BRCA1 mutation** if the protein of expected size is detected. If the protein is absent or truncated, BRCA1 remains possible. This step efficiently narrows the possibilities to one mutation. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe **Western blot** result (\"Protein of expected size detected\") rules out **BRCA1 mutation**, leaving **BRCA2 mutation** as the only remaining possibility. All other mutations have been systematically eliminated through prior assays. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 15586, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}, {"action": "ELISA", "observation": 0.19016694156173686}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "TaqMan assay", "Allele-specific oligonucleotide hybridization", "ELISA", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nSince the Sanger sequencing detected mutations, BRCA1 and BRCA2 remain possible. To differentiate between them, the TaqMan assay can rule out BRCA1 if no amplification occurs. Choosing this assay efficiently narrows down the remaining candidates.\n\n<ANSWER> TaqMan assay </ANSWER>", "\n\nTo narrow down the remaining possibilities (BRCA2, LEP, GJB2), the **Allele-specific oligonucleotide hybridization** assay can directly check for the **GJB2 mutation**. If the result shows *no hybridization with the mutant probe*, GJB2 is ruled out, leaving BRCA2 and LEP. If hybridization occurs, GJB2 remains possible. This step efficiently reduces the candidate list further. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe remaining possible mutations are **BRCA2** and **LEP** after ruling out GJB2 and BRCA1. To distinguish between them, **ELISA** can test for leptin protein levels. If the concentration is **0-25**, LEP mutation is ruled out, leaving **BRCA2** as the answer. If it's **75-100**, LEP mutation is confirmed. Since this directly addresses the remaining candidates, ELISA is the optimal next step.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (0.19) falls in the **0-25** range, which rules out the **LEP mutation** according to the guidebook. With **BRCA1**, **GJB2**, and **LEP** already excluded, the only remaining mutation is **BRCA2 mutation**.\n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 20064, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}, {"action": "ELISA", "observation": 0.19016694156173686}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "Allele-specific oligonucleotide hybridization", "ELISA", "Western blot", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter performing Sanger sequencing and observing \"Mutations detected,\" BRCA1 and BRCA2 mutations remain possible, as this result does not rule out any mutations. To narrow down the options, the next logical step is to use **Allele-specific oligonucleotide hybridization** to check for the GJB2 mutation. If the assay shows no hybridization with the mutant probe, the GJB2 mutation can be ruled out. If hybridization occurs, GJB2 remains a candidate. This approach directly targets one of the non-BRCA mutations (GJB2), allowing efficient elimination of a possible cause in a single step.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nAfter ruling out GJB2 mutation via Allele-specific oligonucleotide hybridization, the remaining candidates are LEP mutation, BRCA1 mutation, and BRCA2 mutation. To efficiently narrow down further, **ELISA** is the optimal next step. If the ELISA result shows a protein concentration in the 0\u201325 range, the LEP mutation can be ruled out, leaving BRCA1 and BRCA2. If the result is 75\u2013100, LEP remains possible. This assay directly targets LEP mutation, allowing elimination of one candidate in a single step. \n\n<ANSWER> ELISA </ANSWER>", "\n\nAfter ruling out LEP mutation via ELISA (protein concentration 0\u201325), the remaining candidates are **BRCA1** and **BRCA2**. To distinguish between these, **Western blot** is the most efficient next step: if the protein of expected size is detected, BRCA1 mutation is ruled out, leaving BRCA2 as the answer. If the protein is absent/truncated, BRCA1 remains possible. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result (protein detected) ruled out BRCA1. The only remaining mutation is **BRCA2 mutation**. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 19157, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}, {"action": "ELISA", "observation": 0.19016694156173686}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "Western blot", "ELISA", "Allele-specific oligonucleotide hybridization", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe previous Sanger sequencing detected mutations, so BRCA1 and BRCA2 remain possible. To narrow down, selecting an assay that can eliminate a mutation regardless of the result is optimal. **Western blot** can rule out BRCA1 if the protein is detected, or leave it as a possibility if not. This step efficiently splits the remaining mutations into clearer groups. \n\n<ANSWER> Western blot </ANSWER>", "\n\nAfter the Western blot ruled out BRCA1, the remaining possibilities are LEP, GJB2, and BRCA2. The ELISA assay can directly test for the LEP mutation. If the protein concentration falls in the 0-25 range, LEP is ruled out, narrowing the options to GJB2 and BRCA2. If the result is 75-100, LEP remains, but further elimination is still needed. Choosing ELISA next provides a clear pathway to eliminate LEP or confirm it as a candidate, streamlining subsequent steps.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (0.19) falls in the 0-25 range, ruling out the **LEP mutation**. After previous eliminations (BRCA1 via Western blot, LEP via ELISA), the remaining candidates are **GJB2 mutation** and **BRCA2 mutation**. To distinguish between these, **Allele-specific oligonucleotide hybridization** directly tests for GJB2. If no hybridization occurs, GJB2 is eliminated, leaving BRCA2 as the answer. If hybridization occurs, GJB2 is confirmed. This assay provides a decisive next step.\n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nThe Allele-specific oligonucleotide hybridization result (\"No hybridization with mutant probe\") rules out the **GJB2 mutation**. After eliminating LEP (via ELISA), BRCA1 (Western blot), and GJB2 (hybridization), the only remaining mutation is **BRCA2 mutation**. No further assays are needed since all other candidates have been excluded.\n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 18739, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "ELISA", "observation": 0.19016694156173686}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "Allele-specific oligonucleotide hybridization", "ELISA", "TaqMan assay", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter performing Sanger sequencing and detecting mutations, none of the mutations can be ruled out. To narrow down the possibilities, the next logical step is to target **GJB2 mutation** using **Allele-specific oligonucleotide hybridization**. If the assay shows no hybridization with the mutant probe, GJB2 mutation is ruled out. If hybridization occurs, GJB2 remains a candidate. This approach systematically reduces the list of potential mutations efficiently. \n\n<ANSWER> Allele-specific oligonucleotide hybridization </ANSWER>", "\n\nAfter ruling out the GJB2 mutation using **Allele-specific oligonucleotide hybridization**, the remaining possibilities are **LEP mutation**, **BRCA1 mutation**, and **BRCA2 mutation**. To narrow this down efficiently, the next logical step is to perform **ELISA** to assess leptin protein levels. If the ELISA result shows a protein concentration in the range of **0-25**, the **LEP mutation** can be ruled out, leaving **BRCA1** and **BRCA2** for further testing. If the result is **75-100**, LEP remains a candidate. This approach minimizes steps by targeting the mutation with a single, definitive assay.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result of **0.19** falls into the **0-25 protein concentration range**, which rules out the **LEP mutation** (as per the guidebook). The remaining candidates are **BRCA1 mutation** and **BRCA2 mutation**. To distinguish between these, the optimal next step is to use the **TaqMan assay**. If the TaqMan assay shows *no amplification with the mutant probe*, BRCA1 is ruled out, leaving **BRCA2 mutation** as the answer. If amplification occurs, BRCA1 is confirmed. This approach minimizes steps by directly targeting BRCA1.\n\n<ANSWER> TaqMan assay </ANSWER>", "\n\nThe **TaqMan assay** result (\"No amplification with mutant probe\") rules out the **BRCA1 mutation** (as per the guidebook). All other mutations (LEP, GJB2, BRCA1) have already been excluded via previous assays. The only remaining candidate is the **BRCA2 mutation**. No further testing is required. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 23618, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "Allele-specific oligonucleotide hybridization", "observation": "No hybridization with mutant probe"}, {"action": "ELISA", "observation": 0.19016694156173686}, {"action": "TaqMan assay", "observation": "No amplification with mutant probe"}], "successful": true, "parse_error": false}], "seed": 30, "average_actions": 6.0, "average_tokens": 19432.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 19432.8}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA2 and CFTR mutations. The remaining possibilities are SERPINA1 and HTT. To distinguish between them, the **Enzyme assay** directly tests for SERPINA1 mutation (abnormal enzyme levels indicate this mutation). If enzyme levels are normal, HTT gene expansion is the only remaining option. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 3.414 (far below the normal range of 75-100) strongly indicates a **SERPINA1 mutation**, as abnormal enzyme levels are characteristic of this mutation. Since HTT gene expansion was already ruled out by earlier steps (NGS eliminated BRCA2 and CFTR), SERPINA1 mutation is the only remaining possibility.\n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 7434, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 3.414463108623253}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA2 and CFTR mutations, leaving SERPINA1 and HTT. The Southern blot can determine if HTT is present by fragment size. If the fragment is normal, HTT is ruled out, confirming SERPINA1. If abnormal, HTT is confirmed. This step resolves the remaining possibilities in one move. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot's normal fragment rules out HTT gene expansion, leaving SERPINA1 mutation as the only remaining option. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 5780, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing NGS and ruling out BRCA2 and CFTR mutations, the remaining possibilities are SERPINA1 mutation and HTT gene expansion. The **Enzyme assay** directly evaluates SERPINA1 mutation by measuring enzyme levels. If enzyme levels are normal (75-100), SERPINA1 is ruled out, leaving HTT gene expansion as the only remaining option. This assay efficiently narrows down the choices in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result of 3.41 indicates significantly **abnormal enzyme levels** (far below the normal range of 75-100). According to the guidebook, abnormal enzyme levels strongly support the presence of a **SERPINA1 mutation**, as this mutation disrupts alpha-1 antitrypsin production. Since BRCA2 and CFTR mutations were already ruled out by NGS, and HTT gene expansion would not affect enzyme levels, the only remaining diagnosis is SERPINA1 mutation. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 7881, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 3.414463108623253}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter the NGS result ruled out BRCA2 and CFTR mutations, the remaining possibilities are SERPINA1 and HTT. The **Enzyme assay** directly tests for SERPINA1 mutation by measuring enzyme levels. If enzyme levels are normal (75\u2013100), SERPINA1 is ruled out, leaving HTT as the answer. If levels are low, SERPINA1 is confirmed. This assay resolves the remaining uncertainty in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 3.41 (well below the normal 75\u2013100 range) confirms **SERPINA1 mutation** as the cause. Since HTT gene expansion was the only remaining alternative and cannot explain low alpha-1 antitrypsin levels, no further testing is needed. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 6454, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 3.414463108623253}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "SERPINA1 mutation", {"predicted_truth": "SERPINA1 mutation"}], "generated_text": ["\n\nTo efficiently identify the genetic mutation, the optimal first step is **Next-generation sequencing (NGS)**. If NGS detects variants, it narrows the possibilities to BRCA2 or CFTR mutations, allowing follow-up assays (e.g., splice-site analysis for CFTR). If no variants are found, BRCA2 and CFTR mutations are ruled out, leaving SERPINA1 or HTT gene expansion, which can then be resolved with assays like Southern blot or Enzyme assay. This approach minimizes steps by leveraging NGS's ability to eliminate two mutations at once. \n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nSince NGS ruled out BRCA2 and CFTR mutations, the remaining possibilities are **SERPINA1 mutation** and **HTT gene expansion**. To differentiate, **Southern blot** would check for the HTT expansion. If Southern blot shows a normal-sized fragment, HTT is ruled out, leaving SERPINA1. If abnormal, HTT is confirmed. This is the most direct next step.\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out BRCA2, CFTR, and HTT mutations via NGS and Southern blot, the only remaining possibility is **SERPINA1 mutation**. No further assays are needed. \n\n<ANSWER> SERPINA1 mutation </ANSWER>"], "consumed_tokens": 7395, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}], "seed": 31, "average_actions": 4.0, "average_tokens": 6988.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 6988.8}
{"trajectories": [{"actions": ["DNA sequencing", "Enzyme assay", "High-resolution melt analysis (HRM)", "Next-generation sequencing (NGS)", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing, mutations were detected, which means CFTR, BRCA2, and MTHFR mutations are still possible (since the test did not rule them out). However, SERPINA1 mutation was unaffected by the DNA sequencing result. To determine if SERPINA1 is the culprit, the next logical step is the **Enzyme assay**. If the enzyme activity is between 75-100, SERPINA1 is ruled out. If not, SERPINA1 mutation remains the likely candidate. This assay efficiently narrows down the remaining possibilities. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter ruling out SERPINA1 with the Enzyme assay (activity = 87.14), the remaining mutations are **BRCA2, MTHFR, and CFTR**. To efficiently narrow this down, **High-resolution melt analysis (HRM)** is the best next step. If HRM shows *no melting curve abnormalities*, both CFTR and MTHFR are ruled out, leaving **BRCA2** as the only possible mutation. If abnormalities are detected, further testing (e.g., Mass spectrometry genotyping for MTHFR) would be needed. Since HRM can eliminate two mutations in one step, it optimizes efficiency.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter HRM detected abnormal melting curves, the remaining possible mutations are **BRCA2, MTHFR, and CFTR**. To efficiently rule out two mutations at once, **Next-generation sequencing (NGS)** is the best next step. If NGS results in *no variants detected*, both **CFTR and BRCA2** are excluded, leaving **MTHFR** as the only plausible mutation. If variants are detected, further testing (e.g., Sanger sequencing) would narrow it down. However, proceeding with NGS optimizes the elimination of possibilities. \n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter NGS results ruled out **BRCA2** and **CFTR**, the only remaining mutation is **MTHFR**. No further assays are required since all other options have been eliminated. The final answer is **MTHFR mutation**.\n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 17482, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Enzyme assay", "observation": 87.1367370208137}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Mass spectrometry genotyping", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nTo narrow down the remaining mutations (BRCA2, MTHFR, CFTR) after DNA sequencing detected mutations, **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows **no melting curve abnormalities**, it rules out CFTR and MTHFR, leaving BRCA2 as the mutation. If abnormalities are detected, further assays like Mass spectrometry genotyping can then target MTHFR. This approach minimizes steps by potentially eliminating two mutations at once. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter DNA sequencing detected mutations and HRM found abnormalities, BRCA2 is ruled out (since HRM abnormalities only occur with CFTR/MTHFR). The remaining possibilities are **CFTR** and **MTHFR**. To distinguish between them, **Mass spectrometry genotyping** is optimal. If no mass shifts are detected, MTHFR is excluded, leaving CFTR. If mass shifts are observed, MTHFR is confirmed. This directly targets the remaining candidates efficiently.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nAfter DNA sequencing detected mutations (ruling out SERPINA1), HRM abnormalities narrowed it to CFTR or MTHFR. Mass spectrometry genotyping detected mass shifts, which specifically confirm **MTHFR mutation** (as per the guidebook: mass shifts = MTHFR). No further assays are needed. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 15664, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Mass spectrometry genotyping", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, the remaining possible mutations are **BRCA2**, **CFTR**, and **MTHFR** (since DNA sequencing only rules these out if no mutations are detected). To further narrow down the options, **High-resolution melt analysis (HRM)** is the most strategic next step. If HRM shows no melting curve abnormalities, both CFTR and MTHFR mutations are ruled out, leaving **BRCA2** as the definitive answer. If abnormalities are detected, CFTR or MTHFR would remain, requiring another assay. This approach minimizes steps by potentially resolving the case in one action. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter HRM detected abnormalities, the possible mutations are **CFTR** and **MTHFR** (since HRM abnormalities only occur with these two). To differentiate between them, **Mass spectrometry genotyping** is the optimal choice. If no mass shifts are detected, MTHFR is ruled out, leaving CFTR. If mass shifts are detected, MTHFR is confirmed. This directly resolves the ambiguity in one step. \n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nAfter detecting mass shifts with **Mass spectrometry genotyping**, the only mutation consistent with this result is **MTHFR mutation** (since mass shifts indicate MTHFR variants). All other mutations (SERPINA1, BRCA2, CFTR) have been ruled out through previous assays. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 15975, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "High-resolution melt analysis (HRM)", "Mass spectrometry genotyping", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result detected mutations, ruling out SERPINA1 (since DNA sequencing would not detect SERPINA1 mutations and would have returned \"no mutations detected\" if the mutation were SERPINA1). The remaining possibilities are CFTR, BRCA2, and MTHFR. To narrow these down, the **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows no melting curve abnormalities, it would rule out CFTR and MTHFR, leaving BRCA2 as the mutation. If abnormalities are detected, further testing (e.g., Mass spectrometry genotyping) can differentiate between CFTR and MTHFR. This approach minimizes steps by potentially resolving the case in one action if the mutation is BRCA2.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter DNA sequencing detected mutations, SERPINA1 was ruled out, leaving BRCA2, CFTR, and MTHFR. HRM detected abnormal melting curves, which rules out BRCA2 (since HRM only detects CFTR and MTHFR mutations). Now, the remaining possibilities are **CFTR** and **MTHFR**. To differentiate between these, **Mass spectrometry genotyping** is optimal. If no mass shifts are detected, MTHFR is ruled out, leaving CFTR. If mass shifts are detected, MTHFR is confirmed. This approach resolves the case in one step.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nThe **Mass spectrometry genotyping** detected mass shifts, which confirms the presence of the **MTHFR mutation** (as this assay rules out MTHFR *only* if no mass shifts are observed). Since mass shifts were detected, MTHFR is confirmed. All other mutations (SERPINA1, BRCA2, CFTR) have been ruled out through previous assays. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 16995, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Enzyme assay", "High-resolution melt analysis (HRM)", "Mass spectrometry genotyping", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nTo identify the mutation efficiently, the next step should focus on ruling out **SERPINA1 mutation**, as it hasn't been tested yet. The **Enzyme assay** can directly determine if SERPINA1 is involved by measuring enzyme activity. If activity falls between 75-100, SERPINA1 is excluded, narrowing the possibilities to BRCA2, MTHFR, or CFTR. If not, SERPINA1 remains a candidate. This approach minimizes steps by addressing an untested mutation first. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 87.14 rules out **SERPINA1 mutation** (since activity between 75-100 excludes it). The remaining possibilities are BRCA2, MTHFR, and CFTR. To efficiently narrow this down, **High-resolution melt analysis (HRM)** is the best next step. If HRM shows no melting curve abnormalities, it would exclude both **CFTR and MTHFR**, leaving **BRCA2** as the only remaining mutation. If abnormalities are detected, further testing (e.g., Mass spectrometry genotyping) could resolve between CFTR and MTHFR. This minimizes steps by targeting two mutations at once.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter the HRM detected abnormal melting curves, the remaining mutations are **BRCA2, MTHFR, and CFTR**. The next step should target **MTHFR** since it can be ruled out with **Mass spectrometry genotyping**. If no mass shifts are observed, MTHFR is excluded, narrowing the options to BRCA2 and CFTR. If mass shifts are detected, MTHFR is confirmed. This approach directly addresses one of the HRM-linked mutations (MTHFR) and reduces ambiguity efficiently.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nThe Mass spectrometry genotyping detected mass shifts, confirming the presence of the **MTHFR mutation** (since mass shifts indicate MTHFR is not ruled out). With SERPINA1 already excluded by the Enzyme assay and HRM abnormalities pointing to CFTR or MTHFR, the positive mass shifts confirm MTHFR. No further testing is needed. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 21992, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Enzyme assay", "observation": 87.1367370208137}, {"action": "High-resolution melt analysis (HRM)", "observation": "Abnormal melting curves detected"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}], "successful": true, "parse_error": false}], "seed": 32, "average_actions": 5.4, "average_tokens": 17621.6, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.4, "average_successful_tokens": 17621.6}
{"trajectories": [{"actions": ["Tandem repeat PCR", "Methylation-specific PCR", "DNA sequencing", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nAfter ruling out FMR1 gene expansion with the Tandem Repeat PCR result (8.47 repeats), the remaining possibilities are UBE3A mutation, HBB mutation, or DMD mutation. The next logical step is to use **Methylation-specific PCR** to check for UBE3A mutation. If the result shows a normal methylation pattern, UBE3A can be excluded, narrowing the options to HBB or DMD. If abnormal, UBE3A remains a candidate. This assay efficiently targets one of the remaining mutations, helping to systematically narrow down the possibilities.\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe normal methylation pattern from the Methylation-specific PCR rules out UBE3A mutation. With FMR1 already excluded via Tandem Repeat PCR, only **HBB mutation** and **DMD mutation** remain. To differentiate, **DNA sequencing** can confirm or rule out HBB mutation. If DNA sequencing detects no mutations, HBB is excluded, leaving DMD mutation as the only remaining possibility. This approach efficiently narrows down the options with a single assay.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nWith FMR1, UBE3A, and HBB mutations ruled out through prior assays, the only remaining possibility is **DMD mutation**. No further assays are needed as all other candidates have been excluded. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 13341, "observations": [null, {"action": "Tandem repeat PCR", "observation": 8.46613703896727}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Methylation-specific PCR", "DNA sequencing", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nSince the Tandem Repeat PCR result was 8.466 (well below 30), **FMR1 gene expansion** is ruled out. The remaining mutations are UBE3A, HBB, or DMD. To narrow further, **Methylation-specific PCR** is the most efficient next step. If methylation is normal, UBE3A mutation is excluded; if abnormal, UBE3A remains possible. This assay directly addresses one of the remaining candidates, making it the logical choice. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter ruling out **FMR1** (via Tandem Repeat PCR) and **UBE3A** (via normal methylation), only **HBB** and **DMD** remain. To distinguish between them, **DNA sequencing** is optimal. If no mutations are detected, HBB is excluded (leaving DMD). If mutations are found, HBB is confirmed. This directly targets one of the remaining candidates with high specificity.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nDNA sequencing ruled out **HBB mutation** (no mutations detected), leaving **DMD mutation** as the only remaining possibility. All other mutations (FMR1, UBE3A, HBB) have been excluded through prior assays. No further testing is needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 14799, "observations": [null, {"action": "Tandem repeat PCR", "observation": 8.46613703896727}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Methylation-specific PCR", "Protein truncation test", "DNA sequencing", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nTo determine the genetic mutation, the next step should focus on eliminating one of the remaining possibilities (UBE3A, HBB, or DMD). **Methylation-specific PCR** can rule out UBE3A if the methylation pattern is normal. This assay directly addresses UBE3A, which is linked to methylation abnormalities in Angelman syndrome. If UBE3A is ruled out, the focus can shift to HBB and DMD in subsequent steps. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter ruling out **FMR1 gene expansion** (via Tandem Repeat PCR) and **UBE3A mutation** (via normal methylation-specific PCR), the remaining possibilities are **HBB mutation** and **DMD mutation**. The **Protein truncation test** directly addresses DMD mutations by detecting truncated proteins. If no truncated proteins are observed, DMD is ruled out, leaving HBB as the only remaining mutation. This assay provides a definitive answer in one step.\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out **FMR1 gene expansion** (via Tandem Repeat PCR) and **UBE3A mutation** (via normal methylation-specific PCR), the remaining possibilities are **HBB mutation** and **DMD mutation**. The Protein Truncation Test detected truncated proteins, which does not rule out DMD but does not confirm it either. To differentiate between HBB and DMD, **DNA sequencing** is the most definitive assay. If no mutations are found in HBB, it will be ruled out, leaving DMD as the only remaining mutation. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and finding **no mutations detected**, the HBB mutation is ruled out. The remaining possibilities were already narrowed down to **DMD mutation** (since FMR1 and UBE3A were previously excluded). With HBB ruled out via DNA sequencing, the only remaining mutation is **DMD mutation**. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 21537, "observations": [null, {"action": "Tandem repeat PCR", "observation": 8.46613703896727}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Methylation-specific PCR", "Tandem repeat PCR", "DNA sequencing", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe Methylation-specific PCR result ruled out the UBE3A mutation. Now, the remaining possibilities are **FMR1 gene expansion, HBB mutation, and DMD mutation**. To narrow this down efficiently, **Tandem repeat PCR** can directly test for FMR1 gene expansion by assessing CGG repeat size. If the repeat size is normal (0-30), FMR1 can be excluded, leaving HBB and DMD mutations. If the repeat size is abnormal (30-200), FMR1 remains a possibility. This assay provides actionable information to eliminate one of the three remaining candidates. \n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nThe Tandem repeat PCR result of **8.466** (well below 30 CGG repeats) rules out **FMR1 gene expansion**. Now, only **HBB mutation** and **DMD mutation** remain. To differentiate between these, **DNA sequencing** can directly check for mutations in the HBB gene. If no mutations are found, HBB is excluded, leaving DMD as the answer. If mutations are detected, HBB is confirmed. This assay provides a definitive result for one of the remaining candidates. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result (\"No mutations detected\") rules out **HBB mutation**, leaving **DMD mutation** as the only remaining possibility. Since all other mutations have been excluded, the answer is conclusively **DMD mutation**. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 15200, "observations": [null, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "Tandem repeat PCR", "observation": 8.46613703896727}, {"action": "DNA sequencing", "observation": "No mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Methylation-specific PCR", "Protein truncation test", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nAfter ruling out FMR1 gene expansion with the Tandem repeat PCR result (8.46 repeats, well below the 30 threshold), the remaining possibilities are UBE3A mutation, HBB mutation, and DMD mutation. To narrow this down, the next logical step is to use **Methylation-specific PCR** to assess UBE3A. If normal methylation is observed, UBE3A mutation can be ruled out, leaving HBB and DMD. If abnormal, UBE3A remains a candidate. This assay efficiently targets one of the remaining mutations, streamlining the diagnostic process.\n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter ruling out FMR1 and UBE3A mutations, the remaining candidates are **HBB mutation** and **DMD mutation**. The **Protein truncation test** directly checks for truncated proteins caused by DMD mutations. If no truncations are detected, DMD is ruled out, leaving HBB as the answer. If truncations are found, DMD is confirmed. This assay provides a definitive next step with a binary outcome, making it the most efficient choice.\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test detected truncated proteins, which confirms the presence of a **DMD mutation** (as this test specifically rules out DMD mutation only if *no* truncations are found). All other mutations (FMR1, UBE3A, HBB) have already been excluded by prior assay results. No further testing is needed.\n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 19293, "observations": [null, {"action": "Tandem repeat PCR", "observation": 8.46613703896727}, {"action": "Methylation-specific PCR", "observation": "Normal methylation pattern"}, {"action": "Protein truncation test", "observation": "Truncated proteins detected"}], "successful": true, "parse_error": false}], "seed": 33, "average_actions": 5.2, "average_tokens": 16834.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.2, "average_successful_tokens": 16834.0}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "PMP22 duplication", {"predicted_truth": "PMP22 duplication"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out HBB and BRCA2 mutations, leaving PMP22 duplication and PAH mutation. To differentiate, the **Enzyme assay** directly tests for PAH enzyme activity. If activity is normal (75-100%), PAH mutation is excluded, confirming PMP22 duplication. If reduced, PAH mutation is the cause. This assay efficiently narrows the remaining candidates. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 77.41% (within the 75-100% range) rules out a **PAH mutation**, leaving **PMP22 duplication** as the only remaining possibility. All other mutations (BRCA2, HBB, PAH) have been excluded by prior assays. No further testing is required.\n\n<ANSWER> PMP22 duplication </ANSWER>"], "consumed_tokens": 6171, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 77.41234177243516}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "PMP22 duplication", {"predicted_truth": "PMP22 duplication"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing Next-generation sequencing (NGS), \"No variants detected\" **rules out** BRCA2 and HBB mutations. The remaining candidates are **PMP22 duplication** and **PAH mutation**. \n\nTo distinguish between these, the **Enzyme assay** directly tests for PAH enzyme activity. If enzyme activity is normal (75-100%), PAH mutation is ruled out, leaving PMP22 duplication as the answer. If activity is reduced, PAH mutation is confirmed. This approach resolves the case in the fewest steps. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of **77.4%** (within 75-100%) **rules out** PAH mutation. Since NGS already excluded BRCA2 and HBB mutations, the only remaining possibility is **PMP22 duplication**. No further assays are required. \n\n<ANSWER> PMP22 duplication </ANSWER>"], "consumed_tokens": 9067, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 77.41234177243516}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Next-generation sequencing (NGS)", "PMP22 duplication", {"predicted_truth": "PMP22 duplication"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result (77.41%) rules out the PAH mutation. Next, using NGS can check for BRCA2 and HBB mutations. If NGS shows \"no variants detected,\" both are eliminated, leaving PMP22 duplication as the only option. This step efficiently narrows down two possibilities at once. \n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe Enzyme assay ruled out PAH mutation (77.41% activity). NGS (\"No variants detected\") eliminated BRCA2 and HBB mutations. Only PMP22 duplication remains. No further assays are needed since all other options are excluded. \n\n<ANSWER> PMP22 duplication </ANSWER>"], "consumed_tokens": 5239, "observations": [null, {"action": "Enzyme assay", "observation": 77.41234177243516}, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "PMP22 duplication", {"predicted_truth": "PMP22 duplication"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result \"Copy number variation detected\" directly indicates a duplication, which aligns with PMP22 duplication. Since other mutations (PAH, BRCA2, HBB) involve point mutations or deletions and not duplications, PMP22 duplication is confirmed. \n\n<ANSWER> PMP22 duplication </ANSWER>"], "consumed_tokens": 9623, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Copy number variation detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Enzyme assay", "PMP22 duplication", {"predicted_truth": "PMP22 duplication"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe remaining possible mutations after the NGS result are PMP22 duplication and PAH mutation. The Enzyme assay can directly assess PAH enzyme activity: normal activity (75-100%) would rule out PAH mutation, leaving PMP22 duplication as the answer. If activity is low, PAH mutation is confirmed. This assay efficiently narrows down the options in one step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result (77.41%) falls within the 75-100% range, which **rules out PAH mutation** (as per the guidebook). This leaves **PMP22 duplication** as the only remaining mutation. No further assays are needed. \n\n<ANSWER> PMP22 duplication </ANSWER>"], "consumed_tokens": 11354, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Enzyme assay", "observation": 77.41234177243516}], "successful": true, "parse_error": false}], "seed": 34, "average_actions": 3.8, "average_tokens": 8290.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.8, "average_successful_tokens": 8290.8}
{"trajectories": [{"actions": ["Southern blot", "Western blot", "ELISA", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out FMR1 gene expansion. Next, using Western blot can determine if COL1A1 mutation is present. If the protein is normal size, COL1A1 is excluded. If abnormal, COL1A1 is confirmed. This efficiently narrows down the remaining options (LEP, SMN1, COL1A1). \n\n<ANSWER> Western blot </ANSWER>", "\n\nAfter ruling out FMR1 and COL1A1 mutations, the remaining possibilities are **LEP mutation** and **SMN1 deletion**. Using **ELISA** can directly test for LEP mutation: a result in the 0\u201325 range excludes LEP mutation, leaving SMN1 deletion as the answer. If the result exceeds 25, LEP mutation is confirmed. This approach resolves the diagnosis in the fewest steps. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (20.13) falls within the 0\u201325 range, ruling out the **LEP mutation**. With **FMR1**, **COL1A1**, and **LEP** mutations already excluded, the only remaining possibility is **SMN1 deletion**. No further assays are needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 9119, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "ELISA", "observation": 20.135305582982394}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "PCR amplification", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter performing the Southern blot and ruling out the FMR1 gene expansion, the remaining possibilities are LEP mutation, SMN1 deletion, and COL1A1 mutation. To narrow down further, the **PCR amplification** assay is a logical next step. If the SMN1 deletion is present, the fragment would not amplify, directly identifying SMN1 deletion. If the fragment amplifies, SMN1 deletion is ruled out, leaving LEP and COL1A1 mutations to test next with assays like ELISA or Western blot. This approach efficiently reduces the remaining candidates with minimal steps.\n\n<ANSWER> PCR amplification </ANSWER>", "\n\nThe **PCR amplification** result showing **No amplification** directly indicates the presence of the **SMN1 deletion** (since deletions prevent amplification). With FMR1 already ruled out by the Southern blot, and no amplification confirming SMN1 deletion, no further assays are needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 9794, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Western blot", "ELISA", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out FMR1 gene expansion. Now, the remaining possibilities are LEP mutation, SMN1 deletion, and COL1A1 mutation. To narrow further, **Western blot** is the optimal next step. If the Western blot detects a protein of expected size, COL1A1 mutation is eliminated. If abnormal, COL1A1 is confirmed. This efficiently reduces the list to two mutations (LEP or SMN1) or identifies COL1A1 directly. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result ruled out COL1A1 mutation. Now, the remaining possibilities are **LEP mutation** and **SMN1 deletion**. The next logical step is to use **ELISA** to assess leptin levels. If the ELISA result falls within the 0-25 range, the LEP mutation is excluded, leaving SMN1 deletion as the answer. If outside this range, LEP mutation is confirmed. This approach efficiently narrows the options to one mutation in a single step. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (20.13) falls within the 0-25 range, ruling out the **LEP mutation**. With **FMR1 gene expansion**, **COL1A1 mutation**, and **LEP mutation** already excluded via prior assays, the only remaining possibility is **SMN1 deletion**. No further assays are needed since all other mutations have been eliminated. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 10897, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "ELISA", "observation": 20.135305582982394}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "PCR amplification", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\nTo efficiently identify the genetic mutation, starting with the Southern blot is strategic. A normal result would rule out FMR1 gene expansion, narrowing the focus to the remaining three mutations. An abnormal result would immediately confirm FMR1 as the answer. This approach offers a quick resolution if FMR1 is the culprit or effectively reduces the possibilities by one-third if not. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out FMR1 gene expansion, leaving LEP mutation, SMN1 deletion, and COL1A1 mutation. To narrow further, testing for SMN1 deletion via PCR amplification is efficient. If the fragment amplifies, SMN1 deletion is excluded, leaving LEP and COL1A1. If not, SMN1 deletion is confirmed. This step maximizes diagnostic efficiency by targeting a high-impact mutation next.\n\n<ANSWER> PCR amplification </ANSWER>", "\n\nThe PCR amplification result showing no amplification directly indicates the presence of the SMN1 deletion, as the deletion prevents successful amplification of the fragment. This conclusively identifies the mutation. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 10548, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Western blot", "ELISA", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter performing the Southern blot and observing a normal-sized fragment, the FMR1 gene expansion is ruled out. The remaining mutations are LEP mutation, SMN1 deletion, and COL1A1 mutation. To proceed, the Western blot assay is the most strategic choice. If the Western blot detects a protein of expected size, the COL1A1 mutation is eliminated. If not, COL1A1 mutation is confirmed. This step efficiently narrows down the possibilities to either COL1A1 or remaining options (LEP/SMN1). \n\n<ANSWER> Western blot </ANSWER>", "\n\nAfter the Southern blot ruled out FMR1 gene expansion and the Western blot excluded COL1A1 mutation, the remaining possibilities are **LEP mutation** and **SMN1 deletion**. To differentiate between these, **ELISA** is the most efficient next step. If the ELISA result falls within 0-25, LEP mutation is ruled out, leaving SMN1 deletion as the answer. If the result exceeds 25, LEP mutation is confirmed. This approach resolves the remaining ambiguity in one step. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (20.14) falls within the 0-25 range, ruling out the **LEP mutation**. With **FMR1 gene expansion** (Southern blot), **COL1A1 mutation** (Western blot), and **LEP mutation** (ELISA) eliminated, the only remaining mutation is **SMN1 deletion**. No further testing is needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 10237, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "ELISA", "observation": 20.135305582982394}], "successful": true, "parse_error": false}], "seed": 35, "average_actions": 4.6, "average_tokens": 10119.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.6, "average_successful_tokens": 10119.0}
{"trajectories": [{"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter the NGS result ruled out BRCA2 and GJB2 mutations, the remaining possibilities are **SMN1 deletion** and **MTHFR mutation**. To differentiate between these, the most direct approach is to test for **SMN1 deletion** using **Fluorescence in situ hybridization (FISH)**. If FISH detects no deletions, SMN1 is ruled out, leaving MTHFR mutation as the answer. If deletions are detected, SMN1 deletion is confirmed. This minimizes steps by directly targeting one of the two remaining mutations.\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe **FISH result** showing a deletion directly confirms **SMN1 deletion**, as this assay specifically detects deletions. Since SMN1 deletion was one of the two remaining candidates after NGS ruled out BRCA2 and GJB2, the detection of a deletion conclusively identifies it as the mutation. No further assays are needed.\n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 7918, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "High-resolution melt analysis (HRM)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA2 and GJB2 mutations, leaving SMN1 deletion and MTHFR mutation as possibilities. To distinguish between these, selecting an assay targeting MTHFR (e.g., HRM) would efficiently confirm or exclude it. If HRM shows no abnormalities, MTHFR is ruled out, leaving SMN1 deletion as the answer. If abnormalities are detected, MTHFR is confirmed. This approach minimizes steps by focusing on the remaining mutations.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe NGS assay ruled out BRCA2 and GJB2 mutations. The HRM assay then ruled out MTHFR mutation. The only remaining possibility is SMN1 deletion. No further assays are needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 7114, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "High-resolution melt analysis (HRM)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA2 and GJB2 mutations, leaving SMN1 deletion and MTHFR mutation. To differentiate between these, using High-resolution melt analysis (HRM) can directly check for MTHFR mutations. If HRM shows no abnormalities, MTHFR is ruled out, leaving SMN1 deletion as the answer. This approach efficiently narrows down the possibilities in the fewest steps.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe HRM result ruled out the MTHFR mutation, leaving SMN1 deletion as the only remaining mutation. Since all other possibilities have been eliminated, the correct answer is SMN1 deletion. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 6622, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "High-resolution melt analysis (HRM)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter the NGS result ruled out BRCA2 and GJB2 mutations, the remaining possibilities are **SMN1 deletion** and **MTHFR mutation**. To resolve this efficiently, **High-resolution melt analysis (HRM)** is the optimal next assay. HRM detects mutations like MTHFR by analyzing DNA melting curves. If HRM shows no abnormalities, MTHFR is ruled out, leaving SMN1 deletion as the answer. If abnormalities are detected, MTHFR mutation is confirmed. This approach minimizes steps by directly targeting one of the two remaining mutations. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter ruling out **MTHFR mutation** via HRM (no abnormalities), only **SMN1 deletion** remains. No further assays are needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 9333, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nBased on the NGS result ruling out BRCA2 and GJB2, the remaining candidates are SMN1 deletion and MTHFR mutation. To differentiate between them, **Fluorescence in situ hybridization (FISH)** can directly check for SMN1 deletion. If no deletions are detected, SMN1 is ruled out, leaving MTHFR as the mutation. Conversely, deletions observed would confirm SMN1. This assay efficiently narrows down the possibilities in one step. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH result showing a deletion directly confirms **SMN1 deletion**, as this assay detects chromosomal deletions. No further testing is needed since SMN1 deletion is the only remaining plausible mutation after NGS eliminated BRCA2 and GJB2. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 5385, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}], "seed": 36, "average_actions": 4.0, "average_tokens": 7274.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 7274.4}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Protein truncation test", "High-resolution melt analysis (HRM)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter the MLPA assay ruled out PMP22 duplication, the remaining mutations are APC gene mutation, MTHFR mutation, and PAH mutation. The next logical step is to use the **protein truncation test** to check for APC gene mutation. If this test shows no truncated proteins, APC would be ruled out, narrowing the options to MTHFR and PAH. This approach efficiently reduces the possibilities and sets up subsequent assays to resolve the remaining mutations in fewer steps. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out APC gene mutation and PMP22 duplication, the remaining possibilities are **MTHFR mutation** and **PAH mutation**. The next logical step is to use **High-resolution melt analysis (HRM)**. If HRM shows no melting curve abnormalities, MTHFR mutation is ruled out, leaving PAH mutation as the answer. If abnormalities are detected, further testing would be needed, but since the goal is to minimize steps, HRM is the most efficient choice here. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe previous assays have systematically ruled out three mutations:  \n1. **MLPA (normal) \u2192 PMP22 duplication excluded**.  \n2. **Protein truncation test (no truncation) \u2192 APC mutation excluded**.  \n3. **HRM (normal) \u2192 MTHFR mutation excluded**.  \n\nOnly **PAH mutation** remains. No further assays are needed since all other possibilities have been eliminated.  \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 19016, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Protein truncation test", "Multiplex ligation-dependent probe amplification (MLPA)", "High-resolution melt analysis (HRM)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out APC gene mutation with the Protein Truncation Test, the remaining possibilities are PMP22 duplication, MTHFR mutation, and PAH mutation. The next logical step is to test for PMP22 duplication using **Multiplex ligation-dependent probe amplification (MLPA)**. If MLPA shows a normal copy number, PMP22 duplication is excluded, narrowing the options to MTHFR mutation or PAH mutation. This approach efficiently reduces the candidate mutations in the fewest steps. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter ruling out APC gene mutation and PMP22 duplication, the remaining candidates are **MTHFR mutation** and **PAH mutation**. Using **High-resolution melt analysis (HRM)** is optimal here:  \n- If HRM shows **no melting curve abnormalities**, MTHFR mutation is excluded, leaving PAH mutation as the answer.  \n- If HRM detects abnormalities, further testing would be needed, but this assay offers the fastest path to exclusion.  \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter ruling out **MTHFR mutation** via HRM (no melting curve abnormalities), the only remaining candidate is **PAH mutation**. No further testing is required since all other mutations have been excluded. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 15180, "observations": [null, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Protein truncation test", "High-resolution melt analysis (HRM)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter performing the MLPA assay, the normal copy number result ruled out **PMP22 duplication**, leaving APC gene mutation, MTHFR mutation, and PAH mutation as possible candidates. To efficiently narrow down the remaining options, the next logical step is to use the **Protein truncation test**. If this test detects no truncated proteins, it will conclusively rule out the **APC gene mutation**, leaving only MTHFR and PAH mutations. This approach minimizes the number of steps by systematically eliminating mutations based on assay specificity. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter performing the MLPA and Protein truncation tests, **PMP22 duplication** and **APC gene mutation** have been ruled out, leaving **MTHFR mutation** and **PAH mutation** as candidates. To resolve the remaining ambiguity, the most efficient step is to use **High-resolution melt analysis (HRM)**. If HRM shows no melting curve abnormalities, it will conclusively exclude **MTHFR mutation**, leaving **PAH mutation** as the only possible answer. This approach minimizes further testing by leveraging HRM's specificity for MTHFR detection.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe **HRM assay** showing no melting curve abnormalities rules out **MTHFR mutation**, leaving **PAH mutation** as the only remaining candidate. All other mutations (PMP22 duplication, APC, MTHFR) have been excluded via prior assays. Since no further testing is needed, the correct answer is the **PAH mutation**. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 17037, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Protein truncation test", "High-resolution melt analysis (HRM)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["\n\nTo determine the genetic mutation efficiently, the first step should focus on ruling out a mutation with a specific assay. The **Multiplex ligation-dependent probe amplification (MLPA)** assay can check for PMP22 duplication. If the result is normal, PMP22 duplication is eliminated, narrowing the possibilities. This approach optimizes the process by addressing a mutation with a clear exclusion criterion early, allowing subsequent steps to target the remaining mutations systematically. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter ruling out PMP22 duplication with the MLPA result, the next step is to test for APC gene mutation using the **Protein truncation test**. If this assay returns \"No truncated proteins detected,\" APC is eliminated, leaving MTHFR and PAH mutations. This approach systematically narrows down the remaining candidates, ensuring efficiency in identifying the correct mutation. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nAfter ruling out PMP22 duplication and APC gene mutation, the remaining possibilities are **MTHFR mutation** and **PAH mutation**. The **High-resolution melt analysis (HRM)** can determine if MTHFR mutation is present: a normal result would eliminate MTHFR, leaving PAH as the only option. This assay provides a direct way to resolve the remaining candidates efficiently.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe HRM result rules out MTHFR mutation. With PMP22 duplication (MLPA), APC gene (truncation test), and MTHFR (HRM) all excluded, the only remaining mutation is **PAH mutation**. No further assays are needed, as all other possibilities have been systematically eliminated. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 17946, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Protein truncation test", "High-resolution melt analysis (HRM)", "PAH mutation", {"predicted_truth": "PAH mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay ruled out PMP22 duplication. Next, using the Protein Truncation Test can check for APC gene mutation. If no truncated proteins are detected, APC mutation would be excluded, narrowing the possibilities to MTHFR or PAH mutations. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein Truncation Test ruled out APC gene mutation, leaving MTHFR and PAH mutations. To differentiate, High-resolution melt analysis (HRM) can check for MTHFR mutation. If HRM shows no melting curve abnormalities, MTHFR mutation is excluded, confirming PAH mutation as the answer. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe HRM result rules out MTHFR mutation. With PMP22 duplication (MLPA), APC (Protein Truncation Test), and MTHFR (HRM) excluded, the only remaining possibility is PAH mutation. No further assays are needed, as PAH mutation is the only viable option. \n\n<ANSWER> PAH mutation </ANSWER>"], "consumed_tokens": 11388, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}], "seed": 37, "average_actions": 5.0, "average_tokens": 16113.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 16113.4}
{"trajectories": [{"actions": ["Southern blot", "Enzyme assay", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out FMR1 gene expansion. The remaining possibilities are G6PD deficiency mutation, CFTR mutation, and APC gene mutation. Performing an **Enzyme assay** would directly test G6PD enzyme activity. If the result shows activity between 75-100%, G6PD deficiency can be excluded, narrowing the options to CFTR or APC mutations. This is the most efficient next step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 83.2% activity rules out G6PD deficiency mutation. Now, the remaining possibilities are **CFTR mutation** and **APC gene mutation**. The **Protein truncation test** directly tests for APC mutations by detecting truncated proteins. If no truncated proteins are observed, APC mutation is excluded, leaving CFTR mutation as the answer. If truncated proteins are detected, APC mutation is confirmed. This is the most targeted next step to resolve the remaining options efficiently.\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test result ruled out APC gene mutation. The only remaining possibility is **CFTR mutation**, as all other mutations (FMR1, G6PD deficiency, APC) have been excluded. No further testing is required. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 10105, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 83.20096605773331}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter performing the Southern blot, the normal-sized fragment ruled out **FMR1 gene expansion**. The remaining possibilities are **G6PD deficiency mutation**, **CFTR mutation**, and **APC gene mutation**. To narrow these down, the **Enzyme assay** is the most logical next step. If enzyme activity is between 75-100%, **G6PD deficiency mutation** can be excluded, leaving only CFTR and APC mutations. If activity is low (0-25%), G6PD deficiency remains a candidate. This assay efficiently targets one of the remaining mutations, making it the optimal next action.\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result of **83.2% activity** (within 75-100%) rules out **G6PD deficiency mutation**. The remaining candidates are **CFTR mutation** and **APC gene mutation**. The next optimal step is the **Protein truncation test**, which can exclude APC mutation if no truncated proteins are detected. If truncated proteins are found, APC mutation is confirmed. This assay directly targets one of the remaining mutations, streamlining the process.\n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test result (**no truncated proteins**) rules out **APC gene mutation**. The only remaining possibility is **CFTR mutation**, as all other mutations (FMR1, G6PD deficiency, APC) have been excluded through prior assays. No further testing is needed since only one candidate remains.\n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 10497, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 83.20096605773331}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Southern blot ruled out FMR1 gene expansion (normal-sized fragment), and the enzyme assay (83.2% activity) eliminated G6PD deficiency. The remaining possibilities are **CFTR mutation** and **APC gene mutation**. The **Protein truncation test** can determine if APC is involved: a result of \"No truncated proteins\" would exclude APC, leaving CFTR as the answer. This assay directly targets APC and resolves the remaining ambiguity in one step. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test ruled out APC gene mutation. The only remaining mutation is **CFTR mutation**, as G6PD deficiency and FMR1 expansion were previously excluded. No further assays are needed since all other possibilities have been eliminated. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 7935, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 83.20096605773331}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Enzyme assay", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result (normal-sized fragment) rules out FMR1 gene expansion. The remaining possibilities are G6PD deficiency mutation, CFTR mutation, and APC gene mutation. The Enzyme assay can check for G6PD deficiency by measuring enzyme activity. If enzyme activity is 75-100%, G6PD deficiency is excluded. If low (0-25%), it supports G6PD deficiency. This assay efficiently narrows down the remaining candidates. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe enzyme assay result of 83.2% activity (within the 75-100% range) rules out G6PD deficiency mutation. The remaining candidates are CFTR mutation and APC gene mutation. The Protein truncation test can determine APC mutation by detecting truncated proteins. If no truncations are found, APC is excluded, leaving CFTR mutation as the answer. If truncations are detected, APC is confirmed. This assay efficiently distinguishes between the remaining two possibilities. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test result (no truncated proteins) rules out APC gene mutation. The only remaining possibility is CFTR mutation, as all other candidates (FMR1, G6PD, APC) have been excluded. No further assays are needed. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 13854, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Enzyme assay", "observation": 83.20096605773331}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Southern blot", "Protein truncation test", "CFTR mutation", {"predicted_truth": "CFTR mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter the Enzyme assay showed 83.2% activity (between 75-100%), G6PD deficiency is ruled out. The remaining possibilities are FMR1, CFTR, and APC. To narrow further, the **Southern blot** can check for FMR1 gene expansion. If the result is a normal fragment, FMR1 is excluded; an expanded fragment confirms FMR1. This step efficiently reduces the candidates. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot's normal fragment rules out FMR1 gene expansion. Now, the remaining mutations are **CFTR** and **APC**. The **Protein truncation test** can check for APC mutations: if no truncated proteins are detected, APC is excluded, leaving CFTR. This test directly addresses one of the two remaining candidates efficiently. \n\n<ANSWER> Protein truncation test </ANSWER>", "\n\nThe Protein truncation test ruled out APC gene mutation. Only **CFTR mutation** remains. No further testing is needed since all other possibilities have been eliminated. \n\n<ANSWER> CFTR mutation </ANSWER>"], "consumed_tokens": 8941, "observations": [null, {"action": "Enzyme assay", "observation": 83.20096605773331}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Protein truncation test", "observation": "No truncated proteins detected"}], "successful": true, "parse_error": false}], "seed": 38, "average_actions": 5.0, "average_tokens": 10266.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.0, "average_successful_tokens": 10266.4}
{"trajectories": [{"actions": ["Western blot", "Fluorescence in situ hybridization (FISH)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing an absent or truncated protein indicates either a BRCA1 or DMD mutation, as these affect the proteins detected by this assay. To differentiate between these two, the next logical step is to use Fluorescence in Situ Hybridization (FISH), which can detect large deletions commonly associated with DMD mutations. If FISH shows deletions, the mutation is DMD; if not, it points to BRCA1.\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH assay detected a deletion, which is characteristic of DMD mutations (large deletions in the DMD gene). Since BRCA1 mutations do not involve deletions detectable by FISH, this confirms the mutation as DMD. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 13285, "observations": [null, {"action": "Western blot", "observation": "Protein absent or truncated"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Western blot", "Fluorescence in situ hybridization (FISH)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result indicated an absent or truncated protein, which suggests either BRCA1 or DMD mutations (as these mutations disrupt the corresponding proteins). To differentiate between these, **FISH** is optimal. If FISH detects deletions (common in DMD mutations), DMD is confirmed; if no deletions are found, BRCA1 remains. This assay directly addresses the remaining candidates efficiently. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH result detected a deletion, which is characteristic of DMD mutations (large deletions in the dystrophin gene). This conclusively identifies **DMD mutation** as the correct answer. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 14790, "observations": [null, {"action": "Western blot", "observation": "Protein absent or truncated"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA1 and BRCA2 mutations, leaving DMD mutation and HTT gene expansion. Performing a **Western blot** can check for dystrophin protein (DMD-related) or BRCA1 protein. If the Western blot detects a protein of expected size, DMD mutation is ruled out (since DMD causes absent/truncated dystrophin), leaving HTT gene expansion as the only possibility. If the protein is abnormal, DMD mutation is confirmed. This assay efficiently narrows down the remaining options. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing absent/truncated protein directly confirms a **DMD mutation** (since dystrophin is absent in DMD). BRCA1/BRCA2 were already ruled out by NGS, and HTT expansion would not affect protein size here. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 11845, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Southern blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\nTo determine the correct mutation efficiently, the best first step is to use **Next-generation sequencing (NGS)**. This assay can rule out two possibilities (BRCA1 and BRCA2) if no variants are detected, narrowing the options to DMD or HTT. If variants are found, it suggests BRCA1 or BRCA2, allowing further targeted testing. This approach maximizes the elimination of possibilities in one step. \n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nUsing **Next-generation sequencing (NGS)** ruled out BRCA1 and BRCA2 mutations, leaving **DMD mutation** and **HTT gene expansion** as possibilities. The next optimal step is **Southern blot**, which directly tests for HTT gene expansion. If the Southern blot shows a normal-sized fragment, HTT is excluded, confirming DMD mutation. If abnormal, HTT is confirmed. This approach resolves the remaining options in one step. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter NGS and Southern blot eliminated BRCA1, BRCA2, and HTT, the only remaining possibility is **DMD mutation**. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 11247, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Fluorescence in situ hybridization (FISH)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nThe NGS result ruled out BRCA1 and BRCA2 mutations. The remaining possibilities are DMD mutation and HTT gene expansion. To distinguish between them, **Fluorescence in situ hybridization (FISH)** can detect deletions in the DMD gene. If no deletions are found, DMD is ruled out, leaving HTT as the answer. If deletions are present, DMD is confirmed. This assay resolves the remaining options in one step. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH result showing a deletion confirms the presence of a **DMD mutation**, as DMD mutations are typically caused by large deletions in the gene. All other options (BRCA1, BRCA2, HTT) have been ruled out by prior assays. No further testing is needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 9714, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}], "seed": 39, "average_actions": 4.0, "average_tokens": 12176.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 12176.2}
{"trajectories": [{"actions": ["DNA sequencing", "RNA sequencing", "Karyotyping", "Sanger sequencing", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing detected mutations, the possible mutations are still all four. To narrow down efficiently, the next step is to use RNA sequencing. If RNA transcript levels are normal, MECP2 mutation can be excluded, leaving PMP22 duplication, HBB mutation, and MTHFR mutation. This approach targets a mutation (MECP2) that can be ruled out with a single assay result, streamlining the process.\n\n<ANSWER> RNA sequencing </ANSWER>", "\n\nAfter RNA sequencing ruled out MECP2 mutation, the remaining possibilities are **PMP22 duplication**, **MTHFR mutation**, and **HBB mutation**. To narrow further, **Karyotyping** can exclude PMP22 duplication if the result is normal. This would leave MTHFR and HBB mutations, which can be differentiated later using assays like Sanger sequencing or NGS. Karyotyping is a strategic next step to efficiently eliminate PMP22 duplication.  \n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter ruling out MECP2 (RNA sequencing) and PMP22 duplication (karyotyping), the remaining possibilities are **MTHFR mutation** and **HBB mutation**. To differentiate, **Sanger sequencing** can directly check for the **HBB mutation**. If no mutations are detected, HBB is excluded, leaving MTHFR as the answer. If mutations are found, HBB is confirmed. This assay provides a definitive resolution.  \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter Sanger sequencing detected mutations, the **HBB mutation** is confirmed as the correct diagnosis. This assay specifically targets HBB, and its positive result directly identifies the mutation. No further testing is needed.  \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 21079, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RNA sequencing", "observation": "Normal transcript levels"}, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["DNA sequencing", "RNA sequencing", "Karyotyping", "Sanger sequencing", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing detected mutations, the remaining possibilities are **HBB mutation**, **MTHFR mutation**, **MECP2 mutation**, and **PMP22 duplication**. To narrow this down, **RNA sequencing** is the most strategic next step. If RNA transcript levels are normal, **MECP2 mutation** can be excluded, leaving three possibilities. If abnormal, **MECP2 mutation** is confirmed. This assay directly targets one mutation, reducing uncertainty efficiently.\n\n<ANSWER> RNA sequencing </ANSWER>", "\n\nAfter ruling out **MECP2 mutation** via RNA sequencing, the remaining possibilities are **PMP22 duplication**, **HBB mutation**, and **MTHFR mutation**. To efficiently narrow down the options, **Karyotyping** is the best next step. If the karyotype is normal, **PMP22 duplication** can be excluded, leaving only **HBB** and **MTHFR**. This approach directly targets one of the three remaining mutations and minimizes the number of subsequent steps required.\n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter ruling out **PMP22 duplication** via karyotyping, the remaining possibilities are **HBB mutation** and **MTHFR mutation**. To distinguish between these, **Sanger sequencing** is the most efficient next step. If Sanger sequencing detects no mutations, **HBB mutation** is excluded, leaving **MTHFR mutation** as the answer. If mutations are detected, **HBB mutation** is confirmed. This assay directly targets one of the two remaining mutations, resolving the diagnosis in minimal steps.\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter **Sanger sequencing** detected mutations, this directly confirms the presence of an **HBB mutation** (since Sanger sequencing is specific to HBB). The remaining possibility, **MTHFR mutation**, is excluded because DNA sequencing (which detects both HBB and MTHFR) already indicated mutations were present, and Sanger sequencing now pinpoints HBB. No further assays are needed. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 22946, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RNA sequencing", "observation": "Normal transcript levels"}, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["DNA sequencing", "RNA sequencing", "Karyotyping", "Sanger sequencing", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing with \"Mutations detected,\" HBB and MTHFR remain possible (since their exclusion requires a negative result). The next step is to eliminate another mutation. RNA sequencing can rule out **MECP2 mutation** if transcript levels are normal. This assay efficiently narrows the list by addressing a mutation unrelated to the previous test. \n\n<ANSWER> RNA sequencing </ANSWER>", "\n\nAfter RNA sequencing ruled out **MECP2 mutation**, the remaining possibilities are **PMP22 duplication**, **HBB mutation**, and **MTHFR mutation**. To narrow further, **Karyotyping** can exclude **PMP22 duplication** if the karyotype is normal. If PMP22 is ruled out, the focus shifts to distinguishing between HBB and MTHFR using subsequent assays (e.g., NGS or Sanger sequencing). However, if Karyotyping reveals an abnormal result (e.g., duplication), **PMP22 duplication** would be confirmed. Given the goal of minimizing steps, Karyotyping directly addresses PMP22 duplication, making it the most efficient next step. \n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter Karyotyping ruled out **PMP22 duplication**, the remaining mutations are **HBB** and **MTHFR**. To distinguish between them, **Sanger sequencing** can directly test for the **HBB mutation**. If no mutations are detected, HBB is excluded, leaving **MTHFR mutation** as the only possibility. This approach efficiently narrows the options to a definitive answer in one step.\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter detecting mutations in **Sanger sequencing**, the only remaining possibilities are **HBB mutation** and **MTHFR mutation**. Since Sanger sequencing directly tests for **HBB mutations**, the observation \"Mutations detected\" confirms the presence of an **HBB mutation**. No further assays are needed. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 22285, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "RNA sequencing", "observation": "Normal transcript levels"}, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["DNA sequencing", "Karyotyping", "RNA sequencing", "Sanger sequencing", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, we know that HBB and MTHFR mutations are still possible (since only their absence would exclude them). However, MECP2 and PMP22 duplication remain candidates. To narrow down efficiently, selecting **Karyotyping** next is strategic. If karyotyping shows a normal result, PMP22 duplication is excluded, leaving MECP2, HBB, and MTHFR. If abnormal, PMP22 duplication is confirmed. This step optimizes eliminating a mutation type (large duplication) not detectable by sequencing methods used earlier. \n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter performing DNA sequencing (mutations detected) and karyotyping (normal, ruling out PMP22 duplication), the remaining candidates are **MECP2 mutation**, **HBB mutation**, and **MTHFR mutation**. To proceed efficiently:\n\n- **RNA sequencing** is the most strategic next step. If RNA sequencing shows **abnormal transcript levels**, it confirms **MECP2 mutation** (as normal levels would exclude it). If RNA sequencing is normal, we can eliminate MECP2, leaving HBB and MTHFR. From prior DNA sequencing (mutations detected), both HBB and MTHFR remain possible. Subsequent steps could then use **Sanger sequencing** (to target HBB specifically) or **NGS** (to resolve HBB and MTHFR). However, RNA sequencing directly addresses MECP2, which is a critical candidate here. \n\n<ANSWER> RNA sequencing </ANSWER>", "\n\nAfter RNA sequencing ruled out **MECP2 mutation**, the remaining candidates are **HBB mutation** and **MTHFR mutation**. DNA sequencing detected mutations (so neither is excluded), and karyotyping ruled out **PMP22 duplication**. To differentiate between HBB and MTHFR, **Sanger sequencing** is the most efficient next step. If Sanger sequencing detects mutations, it confirms **HBB mutation**; if no mutations are detected, **MTHFR mutation** is the answer. This directly targets HBB, leveraging the guidebook\u2019s rule that \"no mutations detected\" in Sanger sequencing excludes HBB. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter performing **Sanger sequencing** and detecting mutations, the guidebook specifies that this assay directly assesses the **HBB mutation**. Since mutations were detected, this confirms the presence of the **HBB mutation**, and no further assays are needed. The remaining candidate, **MTHFR mutation**, is not excluded by DNA sequencing (since mutations were detected), but Sanger sequencing\u2019s positive result definitively identifies **HBB mutation** as the answer. \n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 23791, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Karyotyping", "observation": "Normal karyotype"}, {"action": "RNA sequencing", "observation": "Normal transcript levels"}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}, {"actions": ["DNA sequencing", "Sanger sequencing", "HBB mutation", {"predicted_truth": "HBB mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing detected mutations, the remaining possibilities include HBB and MTHFR mutations, as DNA sequencing's \"no mutations detected\" outcome would have excluded these two. However, since mutations were found, these genes are still in play. To differentiate between them, **Sanger sequencing** can directly test for the HBB mutation. If no mutations are detected via Sanger sequencing, HBB is ruled out, leaving MTHFR as the likely mutation. This approach minimizes steps by leveraging assays with specific exclusions. \n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter DNA sequencing detected mutations, HBB and MTHFR mutations remained possible. Performing Sanger sequencing (which specifically evaluates HBB) also detected mutations, confirming the presence of an **HBB mutation**. Since Sanger sequencing's detection directly implicates HBB and no further steps are needed to exclude other mutations, the correct answer is:\n\n<ANSWER> HBB mutation </ANSWER>"], "consumed_tokens": 13422, "observations": [null, {"action": "DNA sequencing", "observation": "Mutations detected"}, {"action": "Sanger sequencing", "observation": "Mutations detected"}], "successful": false, "parse_error": false}], "seed": 40, "average_actions": 5.6, "average_tokens": 20704.6, "average_correct": 0.0, "average_parse_error": 0.0, "average_successful_action_num": 0, "average_successful_tokens": 0}
{"trajectories": [{"actions": ["Fluorescence in situ hybridization (FISH)", "RFLP analysis", "Tandem repeat PCR", "Karyotyping", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter performing FISH and detecting a deletion, SMN1 deletion remains a possibility, but other mutations are still in play. To efficiently narrow down the options, the next step is to use **RFLP analysis** to check for the HBB mutation. If the restriction pattern is normal, HBB mutation can be ruled out, leaving HTT, SMN1, and UBE3A. This approach strategically targets a mutation that can be directly ruled out with a single assay, optimizing the number of steps required.\n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out HBB mutation with RFLP analysis and detecting a deletion via FISH, the remaining possibilities are **HTT gene expansion**, **SMN1 deletion**, and **UBE3A mutation**. The next logical step is to use **Tandem repeat PCR** to check for the HTT gene expansion. If the result shows **(0, 30) repeats**, HTT gene expansion is ruled out, narrowing the options to SMN1 deletion and UBE3A mutation. This approach efficiently targets a mutation that can be directly ruled out with a single assay, optimizing the remaining steps.\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nAfter ruling out HTT and HBB mutations, the remaining possibilities are **SMN1 deletion** and **UBE3A mutation**. Performing **karyotyping** will determine if SMN1 deletion is present. A normal karyotype would rule out SMN1 deletion, leaving UBE3A mutation as the only remaining option. If karyotyping detects an abnormality, SMN1 deletion is confirmed. This step directly addresses one of the two remaining mutations, leading to a definitive conclusion.  \n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter performing **Karyotyping** and observing a normal karyotype, **SMN1 deletion** is ruled out. The remaining possible mutation is **UBE3A mutation**, as all other options (HTT gene expansion, HBB mutation, SMN1 deletion) have been excluded through previous assays. No further testing is required to identify the mutation conclusively.  \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 33805, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Tandem repeat PCR", "observation": 19.84742917072265}, {"action": "Karyotyping", "observation": "Normal karyotype"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Fluorescence in situ hybridization (FISH)", "RFLP analysis", "Karyotyping", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nTo identify the mutation efficiently, the next step should focus on ruling out another possible candidate. After ruling out HTT gene expansion with Tandem Repeat PCR and detecting a deletion via FISH (which does not confirm SMN1 deletion), the remaining candidates are SMN1 deletion, HBB mutation, and UBE3A mutation. **RFLP analysis** can help rule out HBB mutation if a normal restriction pattern is observed, narrowing the options further. This assay directly tests for HBB mutations and is a logical next step to eliminate HBB from consideration. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nThe remaining mutations are SMN1 deletion and UBE3A mutation. Karyotyping can rule out SMN1 deletion if the result is normal, leaving UBE3A as the only possibility. If the karyotype is abnormal (detects a deletion), SMN1 deletion is confirmed. This is the most efficient next step to narrow down the options.\n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter systematically eliminating other mutations through previous assays:  \n- **HTT gene expansion** ruled out by Tandem Repeat PCR (19.85 repeats <30).  \n- **HBB mutation** ruled out by normal RFLP.  \n- **SMN1 deletion** ruled out by normal karyotyping.  \n\nOnly **UBE3A mutation** remains. No further assays are needed to confirm.  \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 28322, "observations": [null, {"action": "Tandem repeat PCR", "observation": 19.84742917072265}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Karyotyping", "observation": "Normal karyotype"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "Fluorescence in situ hybridization (FISH)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nThe Tandem repeat PCR result of (0, 30) repeats rules out **HTT gene expansion** (since expansions \u226530 would indicate a mutation). Now, the remaining possibilities are SMN1 deletion, HBB mutation, and UBE3A mutation. To narrow further, **Fluorescence in situ hybridization (FISH)** is the most efficient next step. If FISH detects no deletions, SMN1 deletion is ruled out, leaving HBB and UBE3A. If a deletion is detected, SMN1 remains possible. This assay directly addresses SMN1 deletion, allowing quick elimination of one mutation. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH assay detected a deletion, which directly supports **SMN1 deletion** (the only deletion-based mutation in the remaining candidates). Since the other mutations (HBB, UBE3A) are not deletions and no assays can rule out UBE3A, the logical conclusion is SMN1 deletion. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 19175, "observations": [null, {"action": "Tandem repeat PCR", "observation": 19.84742917072265}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": false, "parse_error": false}, {"actions": ["Tandem repeat PCR", "RFLP analysis", "Karyotyping", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nAfter ruling out HTT gene expansion with Tandem repeat PCR, the next logical step is to check for the HBB mutation. RFLP analysis can confirm or rule out HBB mutation based on the restriction pattern. If the result is normal, HBB mutation is eliminated, narrowing the possibilities to SMN1 deletion and UBE3A mutation. If abnormal, HBB remains a candidate. This approach efficiently narrows down the options.\n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out HTT gene expansion and HBB mutation, the remaining possibilities are SMN1 deletion and UBE3A mutation. To differentiate between them, Karyotyping can check for SMN1 deletion. A normal karyotype would eliminate SMN1 deletion, leaving UBE3A mutation as the only remaining option. This approach efficiently narrows down the candidates with minimal steps.\n\n<ANSWER> Karyotyping </ANSWER>", "\n\nAfter ruling out HTT gene expansion (via Tandem repeat PCR), HBB mutation (via RFLP analysis), and SMN1 deletion (via normal karyotyping), the only remaining possibility is **UBE3A mutation**. All other mutations have been systematically eliminated. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 16148, "observations": [null, {"action": "Tandem repeat PCR", "observation": 19.84742917072265}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Karyotyping", "observation": "Normal karyotype"}], "successful": true, "parse_error": false}, {"actions": ["Tandem repeat PCR", "RFLP analysis", "Karyotyping", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Tandem repeat PCR </ANSWER>", "\n\nThe Tandem repeat PCR result of (0, 30) repeats rules out **HTT gene expansion**. The remaining mutations are SMN1 deletion, HBB mutation, and UBE3A mutation. To narrow further, **RFLP analysis** is the most efficient next step. If RFLP shows a normal restriction pattern, HBB mutation is eliminated, leaving SMN1 deletion and UBE3A mutation. If abnormal, HBB remains possible. Choosing RFLP now targets HBB directly, allowing faster elimination of one candidate. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nThe RFLP analysis's normal result has ruled out the HBB mutation. The remaining possibilities are **SMN1 deletion** and **UBE3A mutation**. To differentiate between these, **Karyotyping** is the most efficient next step. A normal karyotype would eliminate SMN1 deletion, leaving UBE3A mutation as the only remaining option. If the karyotype is abnormal, SMN1 deletion is confirmed. Since SMN1 deletion is a chromosomal-level deletion detectable via karyotyping, this assay directly addresses one of the two remaining candidates. \n\n<ANSWER> Karyotyping </ANSWER>", "\n\nThe normal karyotype result rules out **SMN1 deletion**, leaving **UBE3A mutation** as the only remaining possibility. Since all other mutations (HTT, HBB, SMN1) have been eliminated through prior assays, no further testing is needed. The correct answer is **UBE3A mutation**.\n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 16281, "observations": [null, {"action": "Tandem repeat PCR", "observation": 19.84742917072265}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Karyotyping", "observation": "Normal karyotype"}], "successful": true, "parse_error": false}], "seed": 41, "average_actions": 5.2, "average_tokens": 22746.2, "average_correct": 0.8, "average_parse_error": 0.0, "average_successful_action_num": 5.5, "average_successful_tokens": 23639.0}
{"trajectories": [{"actions": ["Sanger sequencing", "RFLP analysis", "High-resolution melt analysis (HRM)", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter performing **Sanger sequencing** and observing \"Mutations detected,\" the remaining possibilities are **CFTR mutation**, **BRCA2 mutation**, or **HBB mutation** (since DMD mutation is ruled out if Sanger detects mutations in the other genes). To narrow down further, **RFLP analysis** is chosen next. A normal RFLP result would eliminate HBB mutation, while an abnormal result would keep HBB as a candidate. This step efficiently targets HBB, allowing progression toward distinguishing between CFTR and BRCA2 if needed.\n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter **RFLP analysis** showed a **normal restriction pattern**, the **HBB mutation** is ruled out. The remaining candidates are **CFTR mutation** and **BRCA2 mutation**. To differentiate between these, **High-resolution melt analysis (HRM)** is selected next. If HRM shows **no melting curve abnormalities**, the CFTR mutation would be excluded, leaving BRCA2 as the answer. If abnormalities are detected, CFTR remains a candidate. This step efficiently targets the CFTR gene directly.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter **HRM showed no melting curve abnormalities**, the **CFTR mutation** is ruled out. The only remaining candidate is **BRCA2 mutation**, as all other mutations (HBB, CFTR, DMD) have been excluded through prior tests. No further assays are needed for confirmation.\n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 17739, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "RFLP analysis", "Western blot", "High-resolution melt analysis (HRM)", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nAfter performing Sanger sequencing and detecting mutations, all four mutations (CFTR, BRCA2, DMD, HBB) remain possible. To narrow down the options efficiently, **RFLP analysis** is a strategic next step. A normal RFLP result would rule out the HBB mutation, while an abnormal result keeps HBB in contention. This assay directly targets HBB and provides clarity in one step, streamlining subsequent testing. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out the HBB mutation via RFLP analysis (normal restriction pattern), the remaining candidates are **CFTR mutation**, **BRCA2 mutation**, and **DMD mutation**. To distinguish between these, the **Western blot** assay is the most efficient next step. If the Western blot detects a protein of expected size, the **DMD mutation** is ruled out (since DMD causes truncated/absent dystrophin protein). This would leave **CFTR** and **BRCA2**, requiring further testing. However, if the Western blot shows **absent or truncated protein**, the **DMD mutation** is confirmed, ending the game. Given the remaining possibilities, this test directly addresses one mutation (DMD) conclusively in one step.  \n\n<ANSWER> Western blot </ANSWER>", "\n\nAfter ruling out HBB (via RFLP) and DMD (via Western blot), the remaining candidates are **CFTR mutation** and **BRCA2 mutation**. To distinguish between these, **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows **no melting curve abnormalities**, the CFTR mutation is ruled out (as HRM detects nucleotide changes in CFTR), leaving **BRCA2 mutation** as the answer. If HRM detects **abnormal curves**, CFTR mutation is confirmed. Since HRM directly targets CFTR and resolves the ambiguity in one step, it is the optimal choice here.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe remaining mutation after ruling out HBB (RFLP), DMD (Western blot), and CFTR (HRM) is **BRCA2 mutation**. No further assays are needed as all other possibilities have been eliminated. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 15992, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "RFLP analysis", "Western blot", "High-resolution melt analysis (HRM)", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nThe initial Sanger sequencing detected mutations but did not rule out any of the four mutations. To efficiently narrow down the possibilities, **RFLP analysis** is a strategic next step. A normal result would eliminate HBB mutation, reducing the candidates to CFTR, BRCA2, and DMD. If abnormal, HBB remains possible, but this assay provides critical information to proceed systematically. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out HBB mutation with a normal RFLP result, the remaining possibilities are **CFTR, BRCA2, and DMD mutations**. To efficiently narrow down, **Western blot** is the optimal next step. If the Western blot detects the protein of expected size, it would rule out DMD, leaving CFTR and BRCA2. If the protein is absent or truncated, DMD remains possible. This approach systematically eliminates candidates with minimal steps.\n\n<ANSWER> Western blot </ANSWER>", "\n\nThe remaining mutations are **CFTR and BRCA2** after ruling out HBB (via RFLP) and DMD (via Western blot). To differentiate between CFTR and BRCA2, **High-resolution melt analysis (HRM)** is optimal. A normal HRM result would definitively rule out CFTR, leaving BRCA2 as the only remaining mutation. This approach minimizes steps, as an abnormal HRM would still require further testing (e.g., splice-site analysis), but a normal result provides immediate clarity.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe HRM result showing **no melting curve abnormalities** definitively rules out the **CFTR mutation**, as per the guidebook. This leaves only **BRCA2 mutation** as the remaining possibility. No further assays are needed since all other mutations (HBB, DMD, CFTR) have been excluded through prior tests. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 15894, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "RFLP analysis", "Western blot", "High-resolution melt analysis (HRM)", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nTo narrow down the possibilities after Sanger sequencing detected mutations, the next step is to use **RFLP analysis**. If the result shows a **normal restriction pattern**, the HBB mutation can be ruled out. If the pattern is abnormal, HBB remains a candidate. This assay efficiently targets the HBB mutation, allowing elimination of one option early in the process. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out the HBB mutation with RFLP analysis (normal restriction pattern), the remaining candidates are **CFTR mutation**, **BRCA2 mutation**, and **DMD mutation**. To further narrow down, **Western blot** is the optimal choice. If the protein of expected size is detected, the DMD mutation is ruled out. If absent/truncated, DMD remains possible. This step efficiently reduces the list to two mutations (CFTR or BRCA2) or confirms DMD, streamlining subsequent analysis.\n\n<ANSWER> Western blot </ANSWER>", "\n\nAfter ruling out HBB (via RFLP) and DMD (via Western blot), the remaining candidates are **CFTR mutation** and **BRCA2 mutation**. To distinguish between them, **High-resolution melt analysis (HRM)** is the most efficient next step. If HRM shows **no melting curve abnormalities**, CFTR is ruled out, leaving BRCA2 as the answer. If abnormalities are detected, CFTR is confirmed. This approach resolves the remaining ambiguity in one step.\n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nThe HRM result (no melting curve abnormalities) rules out the **CFTR mutation**, leaving **BRCA2 mutation** as the only remaining candidate. All other mutations (HBB, DMD, CFTR) have been excluded through previous assays. No further testing is required. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 18720, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "Western blot", "observation": "Protein of expected size detected"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Sanger sequencing", "RFLP analysis", "High-resolution melt analysis (HRM)", "Western blot", "BRCA2 mutation", {"predicted_truth": "BRCA2 mutation"}], "generated_text": ["\n\n<ANSWER> Sanger sequencing </ANSWER>", "\n\nTo narrow down the remaining possibilities (CFTR, HBB, BRCA2), the next logical step is to perform **RFLP analysis**. If the restriction pattern is normal, HBB mutation is ruled out, leaving CFTR and BRCA2. If abnormal, HBB remains a candidate. This efficiently targets one mutation (HBB) and reduces the pool further. \n\n<ANSWER> RFLP analysis </ANSWER>", "\n\nAfter ruling out HBB with RFLP analysis, the remaining possibilities are CFTR, BRCA2, and DMD. The next step is to target **CFTR mutation** using **High-resolution melt analysis (HRM)**. If HRM shows no melting curve abnormalities, CFTR is ruled out, leaving BRCA2 and DMD. If abnormalities are detected, CFTR remains a candidate. This approach efficiently narrows the pool by focusing on CFTR first, allowing subsequent steps to address DMD if necessary. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter ruling out CFTR and HBB, the remaining possibilities are BRCA2 and DMD. To distinguish between these, the **Western blot** assay is ideal. If the Western blot detects a protein of expected size (normal dystrophin), the DMD mutation is ruled out, leaving BRCA2 as the correct answer. If the protein is absent or truncated, DMD is confirmed. This step directly targets the DMD mutation, which is critical for resolving the remaining options. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe remaining possibilities after previous assays (HBB, CFTR, DMD ruled out) leave only **BRCA2 mutation** as the correct answer. No further assays are needed. \n\n<ANSWER> BRCA2 mutation </ANSWER>"], "consumed_tokens": 23874, "observations": [null, {"action": "Sanger sequencing", "observation": "Mutations detected"}, {"action": "RFLP analysis", "observation": "Normal restriction pattern"}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}, {"action": "Western blot", "observation": "Protein of expected size detected"}], "successful": true, "parse_error": false}], "seed": 42, "average_actions": 5.8, "average_tokens": 18443.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.8, "average_successful_tokens": 18443.8}
{"trajectories": [{"actions": ["DNA sequencing", "Western blot", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter the DNA sequencing result ruled out MTHFR and GJB2 mutations, the remaining possibilities are COL1A1 and MECP2. To differentiate between these, **Western blot** is the most direct assay. If the protein is normal in size, COL1A1 is excluded, leaving MECP2 as the answer. If the protein is abnormal, COL1A1 is confirmed. This step minimizes further testing by directly targeting COL1A1 via protein analysis. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing a truncated protein confirms a **COL1A1 mutation**, as this gene produces type I collagen. Abnormal protein size directly implicates COL1A1, and MECP2 is unrelated to protein truncation. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 8244, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Western blot", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and ruling out GJB2 and MTHFR mutations, the remaining possibilities are COL1A1 and MECP2 mutations. To differentiate between these, **Western blot** is the most efficient next step. If the protein detected is of the expected size, COL1A1 is ruled out, leaving MECP2 as the mutation. If the protein is abnormal, COL1A1 is confirmed. This assay directly addresses one of the remaining mutations, minimizing steps.\n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing \"Protein absent or truncated\" confirms a **COL1A1 mutation**, as this assay directly tests for structural defects in type I collagen. Since COL1A1 mutations lead to abnormal collagen proteins (e.g., truncated or absent), this observation rules out MECP2 (which affects brain proteins, not collagen) and matches COL1A1. All other mutations have already been excluded. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 8574, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Western blot", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter DNA sequencing ruled out **GJB2** and **MTHFR mutations**, the remaining candidates are **COL1A1** and **MECP2**. To distinguish between them, **Western blot** can directly assess COL1A1 by detecting the presence of normal type I collagen protein. If the protein is of expected size, COL1A1 is excluded, leaving MECP2 as the answer. If abnormal, COL1A1 is confirmed. This is the most efficient next step. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing **absent/truncated protein** directly confirms a **COL1A1 mutation**, as this gene encodes type I collagen. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 6311, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Western blot", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\nTo identify the mutation efficiently, starting with **DNA sequencing** is optimal. If no mutations are detected, it rules out both **GJB2** and **MTHFR**, leaving **COL1A1** and **MECP2**. Subsequent steps (e.g., Western blot) can then narrow it further. If mutations are found, follow-up tests (e.g., HRM or Allele-specific hybridization) can distinguish between **GJB2** and **MTHFR**. This approach minimizes steps by potentially eliminating two mutations at once.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter **DNA sequencing** ruled out **GJB2** and **MTHFR**, the remaining candidates are **COL1A1** and **MECP2**. To distinguish between them, **Western blot** directly assesses COL1A1's protein product. If the protein is normal, COL1A1 is excluded, leaving **MECP2** as the answer. If abnormal, COL1A1 is confirmed. This approach resolves the mutation in the fewest steps.\n\n<ANSWER> Western blot </ANSWER>", "\n\nThe **Western blot** result showing **absent/truncated protein** confirms a **COL1A1 mutation** (abnormal collagen protein). Since DNA sequencing already ruled out **GJB2** and **MTHFR**, and **MECP2** remains unaddressed, the truncated protein directly implicates **COL1A1 mutation**. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 8576, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["DNA sequencing", "Western blot", "COL1A1 mutation", {"predicted_truth": "COL1A1 mutation"}], "generated_text": ["\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result (\"No mutations detected\") rules out GJB2 and MTHFR mutations, leaving COL1A1 and MECP2 as possibilities. To differentiate between these, **Western blot** would test for COL1A1 by checking for abnormal collagen protein. If the protein is normal, COL1A1 is ruled out, leaving MECP2 as the only remaining mutation. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result (\"Protein absent or truncated\") confirms a COL1A1 mutation, as abnormal collagen protein indicates this mutation. No further assays are needed. \n\n<ANSWER> COL1A1 mutation </ANSWER>"], "consumed_tokens": 7326, "observations": [null, {"action": "DNA sequencing", "observation": "No mutations detected"}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}], "seed": 43, "average_actions": 4.0, "average_tokens": 7806.2, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 7806.2}
{"trajectories": [{"actions": ["Fluorescence in situ hybridization (FISH)", "Enzyme assay", "Methylation-specific PCR", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nSince the FISH assay showed no deletions detected, we can rule out **PMP22 duplication**. The remaining possible mutations are:  \n- **G6PD deficiency mutation** (requires Enzyme assay to rule out)  \n- **CFTR mutation** (requires HRM, DNA sequencing, or Sanger sequencing to rule out)  \n- **UBE3A mutation** (requires Methylation-specific PCR to rule out).  \n\nTo narrow down further, **Enzyme assay** is the most efficient next step. If enzyme activity is normal (75-100), G6PD deficiency is ruled out. If abnormal (0-25), G6PD deficiency remains a candidate. This approach prioritizes ruling out one mutation definitively.  \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of **77.5** (normal range: 75-100) rules out **G6PD deficiency mutation**. The remaining candidates are **CFTR mutation** and **UBE3A mutation**.  \n\nTo differentiate between these, **Methylation-specific PCR** is the most efficient next step:  \n- **Normal methylation pattern** \u2192 Rules out UBE3A mutation \u2192 CFTR mutation is confirmed.  \n- **Abnormal methylation pattern** \u2192 Confirms UBE3A mutation.  \n\nThis assay directly addresses one of the remaining mutations, allowing definitive exclusion or confirmation.  \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe **abnormal methylation pattern** from Methylation-specific PCR does not rule out **UBE3A mutation** (as per the guidebook), leaving **CFTR mutation** and **UBE3A mutation** as candidates. To differentiate:  \n- **High-resolution melt analysis (HRM)** would determine if CFTR mutation is present.  \n  - *No melting curve abnormalities* \u2192 Rules out CFTR \u2192 Confirms UBE3A.  \n  - *Abnormal melting curves* \u2192 CFTR remains possible.  \n\nSince **UBE3A mutation** cannot be directly confirmed by methylation results alone, **HRM** is the logical next step to resolve ambiguity between the remaining mutations.  \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 13924, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Enzyme assay", "observation": 77.504502638558}, {"action": "Methylation-specific PCR", "observation": "Abnormal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Methylation-specific PCR", "Enzyme assay", "High-resolution melt analysis (HRM)", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\nTo identify the genetic mutation efficiently, starting with the Fluorescence in situ Hybridization (FISH) assay is strategic. If FISH detects a PMP22 duplication, it immediately confirms the mutation. If no duplication is found, PMP22 duplication is ruled out, narrowing the list to three possibilities. This approach prioritizes assays that can confirm a mutation with a positive result, potentially solving the case in one step. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter ruling out PMP22 duplication with the FISH result, the remaining mutations are G6PD deficiency, CFTR mutation, and UBE3A mutation. To narrow this down, **Methylation-specific PCR** is the logical next step. If the methylation pattern is normal, UBE3A mutation is ruled out, leaving G6PD and CFTR. If abnormal, UBE3A is confirmed. This assay directly addresses one of the three remaining possibilities, making it efficient for elimination or confirmation. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nAfter the abnormal methylation result, UBE3A remains a possible mutation. However, G6PD deficiency and CFTR mutations are still in play. To efficiently narrow the options, the **Enzyme assay** is the next logical step. If G6PD enzyme activity is normal, G6PD deficiency is ruled out, leaving CFTR and UBE3A. If abnormal, G6PD deficiency remains a candidate. This approach systematically eliminates one of the three remaining mutations, guiding further testing toward the correct answer. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter ruling out G6PD deficiency (enzyme assay normal) and PMP22 duplication (FISH negative), the remaining possibilities are **CFTR mutation** and **UBE3A mutation**. The abnormal methylation pattern (from Methylation-specific PCR) does not confirm UBE3A but keeps it as a candidate. To distinguish between CFTR and UBE3A, the **High-resolution melt analysis (HRM)** assay is the most efficient next step. If HRM shows no melting curve abnormalities, CFTR is ruled out, leaving UBE3A as the answer. If abnormalities are detected, CFTR remains a possibility. This approach minimizes steps by targeting CFTR directly. \n\n<ANSWER> High-resolution melt analysis (HRM) </ANSWER>", "\n\nAfter performing HRM and observing no melting curve abnormalities, the CFTR mutation is ruled out. With G6PD deficiency eliminated by the normal enzyme assay and PMP22 duplication excluded via FISH, the only remaining mutation is **UBE3A mutation**. The abnormal methylation pattern from earlier aligns with this conclusion, as it does not rule out UBE3A. All other possibilities have been systematically excluded. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 26206, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Methylation-specific PCR", "observation": "Abnormal methylation pattern"}, {"action": "Enzyme assay", "observation": 77.504502638558}, {"action": "High-resolution melt analysis (HRM)", "observation": "No melting curve abnormalities"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Fluorescence in situ hybridization (FISH)", "Methylation-specific PCR", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 77.5 (normal range) ruled out **G6PD deficiency mutation**. The remaining mutations are PMP22 duplication, CFTR mutation, and UBE3A mutation. To narrow further, **Fluorescence in situ hybridization (FISH)** is the next logical choice. If FISH detects no PMP22 duplication, that mutation is eliminated, leaving CFTR or UBE3A. If a duplication is found, PMP22 duplication is confirmed. This assay provides a direct way to test for PMP22 duplication, which is one of the remaining candidates. \n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH result (\"No deletions detected\") ruled out **PMP22 duplication**, leaving **CFTR mutation** and **UBE3A mutation** as possibilities. To differentiate between these, **Methylation-specific PCR** is the optimal next step. If the assay shows a **normal methylation pattern**, UBE3A mutation is ruled out, confirming CFTR mutation. If an **abnormal methylation pattern** is observed, UBE3A mutation is confirmed. This directly tests one of the remaining candidates, minimizing further steps. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe abnormal methylation pattern from Methylation-specific PCR strongly suggests **UBE3A mutation**, as this assay detects methylation abnormalities characteristic of Angelman syndrome (linked to UBE3A). Since CFTR mutations are unrelated to methylation, and all other mutations (G6PD deficiency, PMP22 duplication) were ruled out in earlier steps, **UBE3A mutation** is the only remaining possibility. No further assays are needed. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 10967, "observations": [null, {"action": "Enzyme assay", "observation": 77.504502638558}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Methylation-specific PCR", "observation": "Abnormal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Enzyme assay", "Methylation-specific PCR", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter performing FISH and ruling out PMP22 duplication, the remaining mutations are G6PD deficiency, CFTR mutation, and UBE3A mutation. The **Enzyme assay** directly tests for G6PD deficiency. If enzyme activity is normal (75-100), G6PD deficiency is ruled out, narrowing the options to CFTR and UBE3A. If abnormal (0-25), G6PD deficiency is confirmed. This assay efficiently reduces possibilities with a single step. \n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result (77.5) rules out G6PD deficiency, leaving CFTR and UBE3A mutations. To distinguish between these, **Methylation-specific PCR** directly evaluates UBE3A. A normal methylation pattern would confirm UBE3A is ruled out, leaving CFTR as the answer. If abnormal, UBE3A is confirmed. This assay efficiently resolves the remaining possibilities in one step. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe abnormal methylation pattern from Methylation-specific PCR confirms the presence of a UBE3A mutation. All other mutations (PMP22 duplication, G6PD deficiency, and CFTR mutation) have been ruled out by prior assays. This leaves **UBE3A mutation** as the only remaining possibility. \n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 15634, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Enzyme assay", "observation": 77.504502638558}, {"action": "Methylation-specific PCR", "observation": "Abnormal methylation pattern"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Fluorescence in situ hybridization (FISH)", "Methylation-specific PCR", "UBE3A mutation", {"predicted_truth": "UBE3A mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nAfter performing the Enzyme assay, the result of 77.5 falls within the normal range (75-100), ruling out **G6PD deficiency mutation**. The remaining possibilities are PMP22 duplication, CFTR mutation, and UBE3A mutation. To narrow this down, **Fluorescence in situ hybridization (FISH)** is the next logical step. FISH detects PMP22 duplication: a result of \"No Deletions Detected\" would rule out PMP22 duplication, leaving CFTR and UBE3A mutations. This approach systematically eliminates one mutation with a single assay, advancing toward identifying the correct mutation efficiently.\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH result (\"No deletions detected\") rules out **PMP22 duplication**, leaving **CFTR mutation** and **UBE3A mutation** as possibilities. To distinguish between these, **Methylation-specific PCR** is the optimal next step. A normal methylation pattern would rule out UBE3A mutation, leaving CFTR mutation as the answer. Conversely, an abnormal methylation pattern would confirm UBE3A mutation. This assay directly targets one of the remaining mutations, resolving the case efficiently. \n\n<ANSWER> Methylation-specific PCR </ANSWER>", "\n\nThe abnormal methylation pattern from the Methylation-specific PCR does **not** rule out UBE3A mutation (it only rules it out if the pattern is normal). This leaves **CFTR mutation** and **UBE3A mutation** as possibilities. To resolve this, **DNA sequencing** is the most definitive assay. If no CFTR mutations are detected, CFTR is ruled out, leaving UBE3A as the answer. If mutations are detected, CFTR is confirmed. Since all other mutations have been eliminated, DNA sequencing will directly address the remaining ambiguity.\n\n<ANSWER> UBE3A mutation </ANSWER>"], "consumed_tokens": 14856, "observations": [null, {"action": "Enzyme assay", "observation": 77.504502638558}, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "No deletions detected"}, {"action": "Methylation-specific PCR", "observation": "Abnormal methylation pattern"}], "successful": true, "parse_error": false}], "seed": 44, "average_actions": 5.2, "average_tokens": 16317.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 5.2, "average_successful_tokens": 16317.4}
{"trajectories": [{"actions": ["Enzyme assay", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 95.19 falls within the 75\u2013100 activity range, ruling out **G6PD deficiency mutation** and **SERPINA1 mutation**. Now, the remaining possibilities are **DMD mutation** and **FMR1 gene expansion**. To differentiate between these, the **Western blot** assay can detect the presence/truncation of the DMD-associated protein. If the protein is of expected size, DMD is excluded, leaving FMR1 as the answer. If truncated/absent, DMD is confirmed. This assay efficiently narrows down the options. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing **absent/truncated protein** aligns with the **DMD mutation**, as this mutation disrupts the production of functional dystrophin protein. Since **G6PD deficiency** and **SERPINA1 mutation** were already ruled out by the enzyme assay, the only remaining possibility is **DMD mutation**. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 5509, "observations": [null, {"action": "Enzyme assay", "observation": 95.19151134746268}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of ~95.19 falls within the 75\u2013100 activity range, ruling out **SERPINA1 mutation** and **G6PD deficiency mutation**. The remaining possibilities are **DMD mutation** and **FMR1 gene expansion**. To differentiate between these, the **Western blot** is the most efficient next step. If the Western blot detects a protein of expected size, it excludes the DMD mutation (as the mutation would result in a truncated/absent protein). Conversely, if the protein is absent or truncated, DMD mutation is confirmed. This assay directly addresses the remaining candidates in one step. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result showing absent/truncated protein directly indicates a **DMD mutation**, as this mutation prevents normal dystrophin production. This outcome conclusively identifies the mutation, eliminating the need for further testing. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 13352, "observations": [null, {"action": "Enzyme assay", "observation": 95.19151134746268}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Southern blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 95.19 falls within the range (75, 100), which excludes **SERPINA1 mutation** and **G6PD deficiency mutation**. The remaining possibilities are **DMD mutation** and **FMR1 gene expansion**. To differentiate between these, the **Southern blot** assay can detect FMR1 expansions. If the Southern blot shows a normal-sized fragment, FMR1 expansion is excluded, leaving DMD mutation. If an expanded fragment is detected, FMR1 is confirmed. This is the most direct next step. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Enzyme assay ruled out SERPINA1 and G6PD mutations. The Southern blot's normal-sized fragment excluded FMR1 gene expansion. Only **DMD mutation** remains possible. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 6189, "observations": [null, {"action": "Enzyme assay", "observation": 95.19151134746268}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Southern blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result of 95.19 falls within the 75-100 range, excluding **G6PD deficiency mutation** and **SERPINA1 mutation**. This leaves **DMD mutation** and **FMR1 gene expansion** as possibilities. To differentiate between these, the most direct assays are **Southern blot** or **Tandem repeat PCR** (to check for FMR1 expansions) or **Western blot/FISH** (to assess DMD-related protein/deletions). Southern blot is efficient here: a normal fragment would exclude FMR1 (pointing to DMD), while an expanded fragment confirms FMR1. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result of a normal-sized fragment excludes **FMR1 gene expansion**, leaving **DMD mutation** as the only remaining possibility. All other mutations (G6PD, SERPINA1, FMR1) have been ruled out by previous assays. No further testing is needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 10651, "observations": [null, {"action": "Enzyme assay", "observation": 95.19151134746268}, {"action": "Southern blot", "observation": "Normal-sized fragment"}], "successful": true, "parse_error": false}, {"actions": ["Enzyme assay", "Western blot", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Enzyme assay </ANSWER>", "\n\nThe Enzyme assay result (95.19) falls within the 75-100 range, ruling out **G6PD deficiency mutation** and **SERPINA1 mutation**. The remaining possibilities are **DMD mutation** and **FMR1 gene expansion**. To differentiate between these, the **Western blot** can check for the presence of the DMD-associated protein. If the protein is normal, DMD is excluded, leaving FMR1 as the answer. If the protein is absent/truncated, DMD is confirmed. \n\n<ANSWER> Western blot </ANSWER>", "\n\nThe Western blot result (\"Protein absent or truncated\") confirms the **DMD mutation**, as this outcome indicates an abnormal or missing dystrophin protein (associated with DMD). All other mutations (G6PD deficiency, SERPINA1, and FMR1) were previously ruled out. No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 5933, "observations": [null, {"action": "Enzyme assay", "observation": 95.19151134746268}, {"action": "Western blot", "observation": "Protein absent or truncated"}], "successful": true, "parse_error": false}], "seed": 45, "average_actions": 4.0, "average_tokens": 8326.8, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 4.0, "average_successful_tokens": 8326.8}
{"trajectories": [{"actions": ["Southern blot", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing an expanded fragment directly indicates the presence of an HTT gene expansion, as this assay detects large expansions like the one characteristic of Huntington's disease. No further testing is needed. <ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 4335, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing an expanded fragment directly indicates the presence of an HTT gene expansion, as this assay specifically detects large expansions like those in Huntington's Disease. All other mutations can be ruled out based on this observation. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 5369, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot assay detected an expanded fragment, which directly indicates the presence of an HTT gene expansion (as Southern blot identifies large expansions like the HTT mutation). This result rules out all other mutations in the list (APC, MTHFR, HBB), leaving HTT gene expansion as the only possible truth. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 4044, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing an expanded fragment directly indicates the presence of an HTT gene expansion, as this assay detects large expansions like those in Huntington's disease. All other mutations can be ruled out because they are unrelated to Southern blot findings. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 4869, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "HTT gene expansion", {"predicted_truth": "HTT gene expansion"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot assay detected an expanded fragment, which directly indicates the presence of an **HTT gene expansion** (as per the guidebook: Southern blot identifies gene expansions, and a normal-sized fragment would rule it out). Since no other mutations involve expansions detectable by this method, the correct diagnosis is clear. \n\n<ANSWER> HTT gene expansion </ANSWER>"], "consumed_tokens": 5048, "observations": [null, {"action": "Southern blot", "observation": "Expanded fragment detected"}], "successful": true, "parse_error": false}], "seed": 46, "average_actions": 3.0, "average_tokens": 4733.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.0, "average_successful_tokens": 4733.0}
{"trajectories": [{"actions": ["Fluorescence in situ hybridization (FISH)", "PCR amplification", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nThe FISH assay detected a deletion, which according to the guidebook means both **DMD mutation** and **PMP22 duplication** remain possible. To narrow down, the next logical step is to test for **DMD mutation** using **PCR amplification**. If the fragment is amplified, DMD is ruled out; if not, it confirms DMD. This efficiently targets the mutation most aligned with the FISH result.\n\n<ANSWER> PCR amplification </ANSWER>", "\n\nThe **PCR amplification** result of \"No amplification\" confirms the **DMD mutation** (as the absence of amplification indicates a disrupted gene segment). Since FISH already narrowed possibilities to DMD or PMP22 duplication, and PCR directly implicates DMD, no further tests are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 12504, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "PCR amplification", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter the FISH assay detected a deletion, the remaining possible mutations are **DMD mutation** and **PMP22 duplication** (since FISH rules them out only if no deletion is found). However, PMP22 duplication involves a duplication, not a deletion, making **DMD mutation** the more plausible candidate. To confirm, **PCR amplification** is chosen next. If PCR fails to amplify the fragment (due to a deletion in DMD), it would definitively confirm the DMD mutation. \n\n<ANSWER> PCR amplification </ANSWER>", "\n\nThe FISH assay detected a deletion, which kept **DMD mutation** and **PMP22 duplication** as possibilities (since FISH rules them out only if no deletion is found). Subsequent PCR amplification failed to amplify a fragment, which confirms **DMD mutation** (as PCR amplification rules out DMD mutation *only* if a fragment is amplified). No further assays are needed. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 11109, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "PCR amplification", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter performing FISH and detecting a deletion, DMD mutation and PMP22 duplication remain possible since the absence of deletions would have ruled them out. To further narrow down, PCR amplification can confirm or exclude DMD mutation. If the fragment is amplified, DMD is ruled out; if not, DMD is confirmed. This step efficiently targets one of the remaining mutations.\n\n<ANSWER> PCR amplification </ANSWER>", "\n\nThe FISH test detected a deletion, which keeps DMD mutation and PMP22 duplication as possibilities. However, the subsequent PCR amplification failed to amplify a fragment, directly confirming a DMD mutation (as PCR amplification would rule it out if successful). Since PMP22 duplication involves a duplication (not a deletion) and FISH detected a deletion, PMP22 duplication is irrelevant here. The remaining mutation is DMD mutation.\n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 11684, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "PCR amplification", "observation": "No amplification"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter performing FISH and detecting a deletion, the guidebook indicates that this result does **not** rule out DMD mutation or PMP22 duplication. However, PMP22 duplication involves a **duplication** (copy number increase), not a deletion. Therefore, the detected deletion strongly points to the **DMD mutation** (a deletion in the DMD gene). Since no other mutations are associated with deletions in this context, the correct answer is DMD mutation. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 9398, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}], "successful": true, "parse_error": false}, {"actions": ["Fluorescence in situ hybridization (FISH)", "Multiplex ligation-dependent probe amplification (MLPA)", "DMD mutation", {"predicted_truth": "DMD mutation"}], "generated_text": ["\n\n<ANSWER> Fluorescence in situ hybridization (FISH) </ANSWER>", "\n\nAfter the FISH test detected a deletion, PMP22 duplication and DMD mutation remain possible. To narrow down, MLPA can check for PMP22 duplication. If MLPA shows a normal copy number, PMP22 duplication is ruled out. Choosing MLPA here efficiently targets one of the remaining mutations. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter FISH detected a deletion, the remaining possibilities were **DMD mutation** and **PMP22 duplication**. The subsequent MLPA test with a **normal copy number** ruled out PMP22 duplication. This leaves **DMD mutation** as the only remaining possibility. Further tests like PCR amplification or Southern blot are unnecessary since the results already isolate the mutation conclusively. \n\n<ANSWER> DMD mutation </ANSWER>"], "consumed_tokens": 10552, "observations": [null, {"action": "Fluorescence in situ hybridization (FISH)", "observation": "Deletion detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}], "successful": true, "parse_error": false}], "seed": 47, "average_actions": 3.8, "average_tokens": 11049.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.8, "average_successful_tokens": 11049.4}
{"trajectories": [{"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay detected a copy number variation, which directly indicates the presence of SMN1 deletion (a deletion is a copy number loss). Other mutations (LEP, COL1A1, GJB2) are point mutations not affecting copy number. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 8060, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Copy number variation detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Multiplex ligation-dependent probe amplification (MLPA)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing NGS and ruling out COL1A1 and GJB2 mutations, the remaining possibilities are LEP mutation and SMN1 deletion. To distinguish between these, the best next step is to use **Multiplex ligation-dependent probe amplification (MLPA)**. If MLPA shows a normal SMN1 copy number, SMN1 deletion is excluded, leaving LEP mutation as the answer. If a deletion is detected, SMN1 deletion is confirmed. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result showing copy number variation confirms the presence of a deletion in SMN1, ruling out all other remaining possibilities. Thus, the correct answer is **SMN1 deletion**. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 7421, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Copy number variation detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay detected a copy number variation. Since SMN1 deletion involves a copy number loss (deletion), this result directly supports the presence of SMN1 deletion. All other mutations (LEP, COL1A1, GJB2) are point mutations not detectable by MLPA. Thus, SMN1 deletion is confirmed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 4048, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Copy number variation detected"}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "ELISA", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing NGS and detecting no variants, COL1A1 and GJB2 mutations are ruled out. The remaining possibilities are LEP mutation and SMN1 deletion. Using **ELISA** next can test for leptin levels, which would exclude LEP mutation if results are within the normal range (0\u201325). This approach efficiently narrows down to the remaining candidate (SMN1 deletion) if LEP is excluded. \n\n<ANSWER> ELISA </ANSWER>", "\n\nThe ELISA result (19.06) falls within the normal range (0\u201325), ruling out the **LEP mutation**. After NGS and ELISA, only **SMN1 deletion** remains possible. Since all other mutations have been excluded, the correct diagnosis is SMN1 deletion. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 7298, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "ELISA", "observation": 19.05656857632108}], "successful": true, "parse_error": false}, {"actions": ["Next-generation sequencing (NGS)", "Multiplex ligation-dependent probe amplification (MLPA)", "SMN1 deletion", {"predicted_truth": "SMN1 deletion"}], "generated_text": ["\n\n<ANSWER> Next-generation sequencing (NGS) </ANSWER>", "\n\nAfter performing NGS and ruling out COL1A1 and GJB2 mutations, the remaining possibilities are **LEP mutation** and **SMN1 deletion**. To differentiate between these, the most efficient assay is **Multiplex ligation-dependent probe amplification (MLPA)**. If MLPA shows a **normal SMN1 copy number**, SMN1 deletion is excluded, leaving LEP mutation as the answer. If it detects an **abnormal copy number**, SMN1 deletion is confirmed. This approach resolves the remaining options in one step. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA result showing **copy number variation detected** directly confirms an SMN1 deletion (since SMN1 deletion is a copy number loss). This conclusively identifies the mutation as SMN1 deletion. No further assays are needed. \n\n<ANSWER> SMN1 deletion </ANSWER>"], "consumed_tokens": 9445, "observations": [null, {"action": "Next-generation sequencing (NGS)", "observation": "No variants detected"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Copy number variation detected"}], "successful": true, "parse_error": false}], "seed": 48, "average_actions": 3.6, "average_tokens": 7254.4, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 3.6, "average_successful_tokens": 7254.4}
{"trajectories": [{"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "Mass spectrometry genotyping", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result ruled out FMR1 gene expansion. The remaining possibilities are LEP mutation, PMP22 duplication, and MTHFR mutation. Performing MLPA can determine if PMP22 duplication is present. If MLPA shows a normal copy number, PMP22 duplication is excluded, narrowing it to LEP or MTHFR. If duplication is detected, PMP22 duplication is confirmed. This is the most efficient next step. \n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter ruling out FMR1 gene expansion and PMP22 duplication, the remaining possibilities are LEP mutation and MTHFR mutation. The next step is to differentiate between these two. **Mass spectrometry genotyping** can detect MTHFR mutation by identifying mass shifts. If no shifts are observed, MTHFR is excluded, leaving LEP mutation as the diagnosis. This assay directly targets one of the remaining mutations efficiently. \n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nThe remaining possibilities are LEP mutation and MTHFR mutation after ruling out FMR1 and PMP22 duplication. The mass spectrometry detected shifts, which do not exclude MTHFR mutation. To differentiate conclusively, **DNA sequencing** is required. If no mutations are found, MTHFR is ruled out, leaving LEP. If mutations are detected, MTHFR is confirmed. This assay directly addresses the remaining candidates efficiently.\n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, the remaining possibilities are LEP mutation and MTHFR mutation. However, DNA sequencing explicitly detects mutations in the MTHFR gene (as per the guidebook), and since mutations were found, this confirms the MTHFR mutation. LEP mutation would require ELISA results (not performed here) to rule in/out. Since DNA sequencing directly identified mutations in MTHFR, the correct diagnosis is **MTHFR mutation**. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 15543, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Southern blot", "Mass spectrometry genotyping", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter performing MLPA and observing a normal copy number, PMP22 duplication is ruled out. The remaining possibilities are LEP mutation, MTHFR mutation, and FMR1 gene expansion. The next most strategic assay is **Southern blot**, which directly tests for FMR1 gene expansion. If Southern blot detects a normal-sized fragment, FMR1 expansion is eliminated, narrowing the options to LEP and MTHFR. If an expanded fragment is found, FMR1 is confirmed. This approach efficiently reduces the possibilities in the fewest steps. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out PMP22 duplication (via MLPA) and FMR1 gene expansion (via Southern blot), the remaining possibilities are **LEP mutation** and **MTHFR mutation**. The most efficient next step is to use **mass spectrometry genotyping** to test for the MTHFR mutation. If no mass shifts are detected, MTHFR mutation is ruled out, leaving LEP mutation as the only remaining option. If mass shifts are detected, MTHFR mutation is confirmed. This approach resolves the diagnosis in one step.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nAfter detecting mass shifts with mass spectrometry (supporting MTHFR mutation) but needing to confirm definitively, the most efficient step is **DNA sequencing**. If sequencing detects mutations, MTHFR is confirmed. If no mutations are found, MTHFR is ruled out, leaving LEP mutation as the only remaining possibility. This resolves the diagnosis in one step. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result (\"Mutations detected\") confirms the presence of a genetic mutation. Since **MTHFR mutation** was the only remaining candidate after ruling out PMP22 duplication and FMR1 expansion (via MLPA and Southern blot), and mass spectrometry genotyping suggested possible MTHFR involvement, the detection of mutations via DNA sequencing conclusively identifies **MTHFR mutation** as the correct diagnosis. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 19680, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Southern blot", "Mass spectrometry genotyping", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nThe MLPA assay result showing a normal copy number rules out PMP22 duplication. The remaining possible mutations are LEP mutation, MTHFR mutation, and FMR1 gene expansion. The Southern blot assay can directly test for FMR1 gene expansion. If the Southern blot result shows a normal-sized fragment, FMR1 expansion is excluded, leaving only LEP and MTHFR mutations. Selecting this assay next would efficiently narrow down the possibilities. \n\n<ANSWER> Southern blot </ANSWER>", "\n\nThe Southern blot result showing a normal-sized fragment rules out FMR1 gene expansion. The remaining possibilities are LEP mutation and MTHFR mutation. To distinguish between these, the ELISA assay can test for leptin levels (linked to LEP mutation). If the ELISA result is in the range (0, 25), LEP mutation is ruled out, leaving MTHFR mutation as the answer. If the result is outside this range, further testing would be needed. However, using Mass spectrometry genotyping or DNA sequencing could directly confirm or exclude MTHFR mutation, leading to a definitive conclusion in one step. Selecting Mass spectrometry genotyping here would efficiently determine whether MTHFR mutation is present. \n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nThe remaining possibilities are LEP mutation and MTHFR mutation. DNA sequencing can directly confirm or exclude MTHFR mutation. If mutations are detected, MTHFR is confirmed; if not, MTHFR is ruled out, leaving LEP mutation as the answer. This assay provides a definitive conclusion in one step. \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nThe DNA sequencing result showing mutations detected confirms the presence of the MTHFR mutation. Since all other possibilities (PMP22 duplication, FMR1 expansion) were ruled out in prior steps, and the remaining options (LEP mutation vs. MTHFR mutation) are resolved by this assay, the correct diagnosis is MTHFR mutation. \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 13859, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}, {"actions": ["Southern blot", "Multiplex ligation-dependent probe amplification (MLPA)", "Mass spectrometry genotyping", "ELISA", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> Southern blot </ANSWER>", "\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter performing the Southern blot and MLPA assays, the results ruled out **FMR1 gene expansion** (normal-sized fragment) and **PMP22 duplication** (normal copy number). The remaining possibilities are **LEP mutation** and **MTHFR mutation**. \n\nTo distinguish between these two, **Mass spectrometry genotyping** is the most efficient next step. If no mass shifts are detected, the MTHFR mutation is ruled out (leaving LEP mutation). If shifts are detected, the MTHFR mutation is confirmed. This assay directly targets the MTHFR mutation and resolves the remaining ambiguity in one step.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nAfter the Southern blot ruled out FMR1 gene expansion and MLPA ruled out PMP22 duplication, the remaining possibilities were **LEP mutation** and **MTHFR mutation**. The **mass spectrometry genotyping** detected mass shifts, which did not rule out any mutations but left MTHFR as a candidate. To definitively differentiate between LEP and MTHFR, the **ELISA assay** is the most efficient next step. If ELISA results fall in the (0, 25) range, LEP mutation is excluded, confirming MTHFR. If the results are in (75, 100), further testing (e.g., DNA sequencing) would be needed. Since ELISA directly addresses LEP and resolves ambiguity in one step, it is the logical choice here.\n\n<ANSWER> ELISA </ANSWER>", "\n\nThe **ELISA result of ~10** falls within the (0, 25) range, which **rules out the LEP mutation**. The only remaining possibility is **MTHFR mutation**, as all other mutations (FMR1, PMP22, LEP) have been excluded through previous assays. No further testing is required.\n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 12228, "observations": [null, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}, {"action": "ELISA", "observation": 10.001982567918777}], "successful": true, "parse_error": false}, {"actions": ["Multiplex ligation-dependent probe amplification (MLPA)", "Southern blot", "Mass spectrometry genotyping", "DNA sequencing", "MTHFR mutation", {"predicted_truth": "MTHFR mutation"}], "generated_text": ["\n\n<ANSWER> Multiplex ligation-dependent probe amplification (MLPA) </ANSWER>", "\n\nAfter ruling out PMP22 duplication with the MLPA assay's normal copy number result, the next logical step is to address another mutation. The Southern blot assay can determine if the FMR1 gene expansion is present. If the Southern blot shows a normal-sized fragment, FMR1 gene expansion is excluded, narrowing the possibilities to LEP mutation or MTHFR mutation. This approach efficiently reduces the remaining options and brings us closer to identifying the correct mutation in the fewest steps.\n\n<ANSWER> Southern blot </ANSWER>", "\n\nAfter ruling out PMP22 duplication and FMR1 gene expansion, the remaining possibilities are LEP mutation and MTHFR mutation. The Mass spectrometry genotyping assay can directly determine if the MTHFR mutation is present. If no mass shifts are detected, MTHFR is ruled out, leaving LEP mutation as the answer. If mass shifts are detected, MTHFR mutation is confirmed. This assay provides a definitive result in one step, making it the most efficient choice.\n\n<ANSWER> Mass spectrometry genotyping </ANSWER>", "\n\nAfter ruling out PMP22 duplication (via MLPA) and FMR1 gene expansion (via Southern blot), the remaining possibilities are **LEP mutation** and **MTHFR mutation**. The Mass spectrometry genotyping detected mass shifts, which leaves MTHFR mutation as a candidate but does not confirm it. To resolve this, **DNA sequencing** can directly check for mutations in the MTHFR gene. If mutations are detected, MTHFR is confirmed; if not, LEP mutation becomes the answer. This assay provides a definitive result in one step, making it the most efficient choice.  \n\n<ANSWER> DNA sequencing </ANSWER>", "\n\nAfter performing DNA sequencing and detecting mutations, the MTHFR mutation is confirmed as the remaining viable option (LEP mutation would require a different assay like ELISA, but DNA sequencing already identified mutations in MTHFR). All other mutations have been systematically ruled out.  \n\n<ANSWER> MTHFR mutation </ANSWER>"], "consumed_tokens": 18625, "observations": [null, {"action": "Multiplex ligation-dependent probe amplification (MLPA)", "observation": "Normal copy number"}, {"action": "Southern blot", "observation": "Normal-sized fragment"}, {"action": "Mass spectrometry genotyping", "observation": "Mass shifts detected"}, {"action": "DNA sequencing", "observation": "Mutations detected"}], "successful": true, "parse_error": false}], "seed": 49, "average_actions": 6.0, "average_tokens": 15987.0, "average_correct": 1.0, "average_parse_error": 0.0, "average_successful_action_num": 6.0, "average_successful_tokens": 15987.0}
